Cover
Cover | 6 Months Ended |
Apr. 30, 2022 | |
Entity Addresses [Line Items] | |
Document Type | S-1/A |
Amendment Flag | true |
Amendment Description | Amendment No. 1 |
Entity Registrant Name | WESTERN MAGNESIUM CORPORATION |
Entity Central Index Key | 0001801762 |
Entity Tax Identification Number | 61-1934413 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 8180 Greensboro Drive |
Entity Address, Address Line Two | Suite 720 |
Entity Address, City or Town | McLean |
Entity Address, State or Province | VA |
Entity Address, Postal Zip Code | 22102 |
City Area Code | (571) |
Local Phone Number | 378-0762 |
Entity Filer Category | Non-accelerated Filer |
Entity Small Business | true |
Entity Emerging Growth Company | true |
Elected Not To Use the Extended Transition Period | false |
Business Contact [Member] | |
Entity Addresses [Line Items] | |
Entity Address, Address Line One | 1209 Orange Street |
Entity Address, City or Town | Wilmington |
Entity Address, State or Province | DE |
Entity Address, Postal Zip Code | 19801 |
City Area Code | (302) |
Local Phone Number | 658-7581 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) | Apr. 30, 2022 | Oct. 31, 2021 | Oct. 31, 2020 |
Current assets | |||
Cash | $ 774,409 | $ 462,360 | $ 39,571 |
Other receivables | 50,765 | 151,485 | 4,579 |
Subscription receivable | 185,000 | ||
Prepayments | 119,970 | 133,647 | 115,109 |
Deposits held by related parties | 388,757 | 486,462 | |
Total Current assets | 1,518,901 | 1,233,954 | 159,259 |
Non-current assets | |||
Property, plant and equipment, net | 3,977,619 | 2,574,704 | 79,436 |
Right-of-use assets, net | 469,821 | 598,575 | 373,987 |
Mineral property costs | 93,453 | 93,453 | 93,453 |
Reclamation deposits | 2,826 | 2,628 | |
Reclamation and other deposits | 12,736 | 12,826 | |
Deferred costs | 2,973 | ||
Other deposits | 10,000 | ||
TOTAL ASSETS | 6,075,503 | 4,513,512 | 708,763 |
Current liabilities | |||
Accounts payable and accrued liabilities | 2,715,924 | 1,989,316 | 1,169,817 |
Due to related parties | 1,253,280 | 1,026,817 | 843,990 |
Lease obligations – current | 244,592 | 192,045 | 143,709 |
Promissory note | 60,567 | ||
Provision for flow through share issuances | 225,833 | 233,285 | 216,924 |
Convertible debenture | 107 | 96,318 | |
Convertible debenture – derivative liability | 7,449,700 | 20,123 | |
Convertible debenture, net | 1,783,584 | 7,449,807 | |
Warrant liability | 2,468,261 | ||
Total Current liabilities | 8,691,474 | 10,891,270 | 2,551,448 |
Non-current liabilities | |||
Lease obligations – non-current | 254,147 | 392,280 | 237,218 |
Total liabilities | 8,945,621 | 11,283,550 | 2,788,666 |
Commitments and contingencies [note 9] | |||
Shareholders’ deficit | |||
Capital stock Authorized: 1 billion common stock at par value of $0.001 Issued and paid: 434,866,801 (2021 – 392,943,398) | 39,096,950 | 29,842,167 | 21,322,022 |
Additional paid-in-capital | 23,204,066 | 15,186,480 | 4,182,037 |
Obligations to issue shares | 388,701 | 209,827 | 596,872 |
Accumulated other comprehensive income | 335,072 | 121,109 | 399,175 |
Accumulated deficit | (65,894,907) | (52,129,621) | (28,580,009) |
Total shareholders’ deficit | (2,870,118) | (6,770,038) | (2,079,903) |
TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT | $ 6,075,503 | $ 4,513,512 | $ 708,763 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Parenthetical) | Apr. 30, 2022 $ / shares shares | Oct. 31, 2021 $ / shares shares | Oct. 31, 2020 $ / shares shares |
Statement of Financial Position [Abstract] | |||
Common stock, shares authorized | 1,000,000,000 | 1,000,000,000 | 1,000,000,000 |
Common stock, par value | (per share) | $ 0.001 | $ 0.001 | $ 0.001 |
Common stock, shares issued | 434,866,801 | 392,943,398 | 323,419,527 |
Common stock, shares outstanding | 434,866,801 | 392,943,398 | 323,419,527 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Loss and Comprehensive Loss - USD ($) | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Apr. 30, 2022 | Apr. 30, 2021 | Apr. 30, 2022 | Apr. 30, 2021 | Oct. 31, 2021 | Oct. 31, 2020 | |
Operating expenses (recoveries) | ||||||
Bank charges | $ 5,388 | $ 3,591 | $ 8,652 | $ 6,154 | $ 15,287 | $ 10,764 |
Business development | 31,777 | 77,329 | ||||
Computer system and software | 27,703 | 11,697 | 39,354 | 71,785 | 94,426 | 58,230 |
Consulting and management fees | 215,709 | 271,853 | 413,636 | 338,954 | 914,617 | 598,574 |
Depreciation | 132,987 | 45,666 | 242,327 | 96,993 | 229,902 | 86,706 |
Due diligence expenses | 1,964 | 1,964 | 5,565 | 25,776 | ||
Engineering expenses (recoveries) | (1,565) | 119,066 | 116,808 | 55,454 | 105,706 | 569,145 |
Foreign exchange loss (gain) | 58,661 | (152,518) | 226,135 | (86,227) | (109,054) | (10,685) |
Interest and accretion | 326,868 | 17,760 | 649,148 | 36,334 | 74,319 | 60,638 |
Investor relations | 109,456 | 19,060 | 215,834 | 70,936 | 280,249 | 237,874 |
Legal and professional fees | 970,206 | 263,841 | 1,577,054 | 287,586 | 889,175 | 138,916 |
Office and general | 21,278 | 22,158 | 77,358 | 59,611 | 180,348 | 185,553 |
Property maintenance fees | 15,069 | 15,098 | ||||
Facilities and rent | 112,452 | 70,190 | 176,121 | 85,275 | 187,832 | 50,304 |
Salaries and benefits | 1,201,297 | 631,284 | 2,196,839 | 1,366,932 | 3,168,008 | 1,797,783 |
Stock-based compensation | 302,254 | (1,060,085) | 433,829 | 11,051,124 | 666,259 | |
Shareholder communications | 7,500 | 86,234 | 40,701 | 86,234 | 127,747 | 54,554 |
Subsidies and recoveries | (48,117) | (41,247) | (79,219) | (41,247) | (41,735) | |
Transfer agent and regulatory fees | 65,720 | 14,747 | 88,737 | 23,630 | 107,098 | 64,371 |
Travel expenses | 137,827 | 109,839 | 221,943 | 110,676 | 409,528 | 104,880 |
Total operating expenses | 3,677,401 | 435,100 | 6,722,586 | 2,571,044 | 17,705,211 | 4,714,740 |
Other income (expense) | ||||||
Change in fair value of derivative liability | 4,858,644 | 31,190 | (6,701,147) | 16,656 | (5,701,270) | 4,979 |
Loss on recognition of debt host liability | (341,553) | (140,943) | ||||
Gain on sale of assets previously written off | 37,156 | |||||
Write-off of equipment | (2,188) | |||||
Total other income (expense), net | 4,858,644 | 31,190 | (7,042,700) | 16,656 | (5,844,401) | 42,135 |
Net income (loss) | 1,181,243 | (403,910) | (13,765,286) | (2,554,388) | (23,549,612) | (4,672,605) |
Other comprehensive income (loss) | ||||||
Foreign currency translation | 49,183 | (114,645) | 213,963 | (191,049) | (278,066) | (76,806) |
Comprehensive income (loss) | $ 1,230,426 | $ (518,555) | $ (13,551,323) | $ (2,745,438) | $ (23,827,678) | $ (4,749,411) |
Basic and diluted income (loss) per common share | $ 0 | $ 0 | $ (0.03) | $ (0.01) | $ (0.07) | $ (0.01) |
Weighted average number of common shares outstanding – basic and diluted | 425,430,900 | 344,627,567 | 443,272,627 | 330,018,463 | 356,656,854 | 312,450,631 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Shareholders' Deficit - USD ($) | Common Stock [Member] | Additional Paid-in Capital [Member] | Obligation to issue shares [Member] | AOCI Attributable to Parent [Member] | Retained Earnings [Member] | Total |
Beginning balance, value at Oct. 31, 2019 | $ 18,587,118 | $ 3,535,553 | $ 39,722 | $ 475,981 | $ (23,907,404) | $ (1,269,030) |
Beginning balance, shares at Oct. 31, 2019 | 278,939,075 | |||||
Shares issued pursuant to private placements [note 13[b]] | $ 416,719 | (39,722) | 376,997 | |||
Shares issued pursuant to private placements [note 13[b]], shares | 3,643,791 | |||||
Shares issued on warrants exercised [notes 12[f] and 13[b]] | $ 2,313,284 | 2,313,284 | ||||
Shares issued on warrants exercised [notes 12[f] and 13[b]], shares | 40,336,661 | |||||
Shares issued on options exercised [note 13[b]] | $ 46,176 | (19,775) | 26,401 | |||
Shares issued on options exercised [note 13[b]], shares | 500,000 | |||||
Share issue costs [note 13[b]] | $ (41,275) | (41,275) | ||||
Stock-based compensation [note 13[d]] | 666,259 | 666,259 | ||||
Share subscriptions [note 13[f]] | 596,872 | 596,872 | ||||
Foreign currency translation | (76,806) | (76,806) | ||||
Net loss for the period | (4,672,605) | (4,672,605) | ||||
Ending balance, value at Oct. 31, 2020 | $ 21,322,022 | 4,182,037 | 596,872 | 399,175 | (28,580,009) | (2,079,903) |
Ending balance, shares at Oct. 31, 2020 | 323,419,527 | |||||
Shares issued pursuant to private placements [note 13[b]] | $ 2,621,314 | (596,872) | 2,024,442 | |||
Shares issued pursuant to private placements [note 13[b]], shares | 25,724,955 | |||||
Shares issued on warrants exercised [notes 12[f] and 13[b]] | $ 16,113 | 16,113 | ||||
Shares issued on warrants exercised [notes 12[f] and 13[b]], shares | 400,000 | |||||
Shares issued on options exercised [note 13[b]] | $ 4,002 | 4,002 | ||||
Shares issued on options exercised [note 13[b]], shares | 100,000 | |||||
Share issue costs [note 13[b]] | $ (194,584) | (194,584) | ||||
Share subscriptions [note 13[f]] | 45,446 | 45,446 | ||||
Foreign currency translation | (191,049) | (191,049) | ||||
Net loss for the period | (2,554,388) | (2,554,388) | ||||
Ending balance, value at Apr. 30, 2021 | $ 23,768,867 | 4,182,037 | 45,446 | 208,126 | (31,134,397) | (2,929,921) |
Ending balance, shares at Apr. 30, 2021 | 349,644,482 | |||||
Beginning balance, value at Oct. 31, 2020 | $ 21,322,022 | 4,182,037 | 596,872 | 399,175 | (28,580,009) | (2,079,903) |
Beginning balance, shares at Oct. 31, 2020 | 323,419,527 | |||||
Shares issued pursuant to private placements [note 13[b]] | $ 7,438,041 | (596,872) | 6,841,169 | |||
Shares issued pursuant to private placements [note 13[b]], shares | 56,979,482 | |||||
Shares issued on warrants exercised [notes 12[f] and 13[b]] | $ 891,811 | (4,291) | 887,520 | |||
Shares issued on warrants exercised [notes 12[f] and 13[b]], shares | 7,014,969 | |||||
Shares issued on options exercised [note 13[b]] | $ 262,666 | (121,932) | 140,734 | |||
Shares issued on options exercised [note 13[b]], shares | 2,630,000 | |||||
Shares issued upon conversion of convertible debenture [notes 12[b], 12[c] and 13[b]] | $ 162,829 | 162,829 | ||||
Shares issued upon conversion of convertible debenture [notes 12[b], 12[c] and 13[b]], shares | 1,360,959 | |||||
Shares issued for equipment [note 14[b]] | $ 305,832 | 305,832 | ||||
Shares issued for equipment [note 14[b]], shares | 1,538,461 | |||||
Share issue costs [note 13[b]] | $ (541,034) | (541,034) | ||||
Stock-based compensation [note 13[d]] | 11,051,124 | 11,051,124 | ||||
Beneficial conversion feature on convertible debentures [note 12[d]] | 79,542 | 79,542 | ||||
Share subscriptions [note 13[f]] | 209,827 | 209,827 | ||||
Foreign currency translation | (278,066) | (278,066) | ||||
Net loss for the period | (23,549,612) | (23,549,612) | ||||
Ending balance, value at Oct. 31, 2021 | $ 29,842,167 | 15,186,480 | 209,827 | 121,109 | (52,129,621) | (6,770,038) |
Ending balance, shares at Oct. 31, 2021 | 392,943,398 | |||||
Shares issued pursuant to private placements [note 13[b]] | $ 756,524 | (209,827) | 546,697 | |||
Shares issued pursuant to private placements [note 13[b]], shares | 1,375,499 | |||||
Shares issued on warrants exercised [notes 12[f] and 13[b]] | $ 7,794,624 | 7,794,624 | ||||
Shares issued on warrants exercised [notes 12[f] and 13[b]], shares | 23,701,146 | |||||
Shares issued on options exercised [note 13[b]] | $ 51,918 | (22,203) | 29,715 | |||
Shares issued on options exercised [note 13[b]], shares | 750,000 | |||||
Shares issued upon conversion of convertible debenture [notes 12[b], 12[c] and 13[b]] | $ 688,178 | 688,178 | ||||
Shares issued upon conversion of convertible debenture [notes 12[b], 12[c] and 13[b]], shares | 6,933,333 | |||||
Share issue costs [note 13[b]] | $ (36,461) | (36,461) | ||||
Stock-based compensation [note 13[d]] | 433,829 | 433,829 | ||||
Beneficial conversion feature on convertible debentures [note 12[d]] | 240,000 | 240,000 | ||||
Share subscriptions [note 13[f]] | 388,701 | 388,701 | ||||
Foreign currency translation | 213,963 | 213,963 | ||||
Net loss for the period | (13,765,286) | (13,765,286) | ||||
Shares issued for finder’s fees [note 13[b]] | ||||||
Shares issued for finder's fees [note 13[b]], shares | 9,163,425 | |||||
Effects of change in functional currency on convertible debentures [note 12[e]] | 7,370,158 | 7,370,158 | ||||
Effects of change in functional currency on broker warrants [note 12[f]] | (4,198) | (4,198) | ||||
Ending balance, value at Apr. 30, 2022 | $ 39,096,950 | $ 23,204,066 | $ 388,701 | $ 335,072 | $ (65,894,907) | $ (2,870,118) |
Ending balance, shares at Apr. 30, 2022 | 434,866,801 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows - USD ($) | 6 Months Ended | 12 Months Ended | ||
Apr. 30, 2022 | Apr. 30, 2021 | Oct. 31, 2021 | Oct. 31, 2020 | |
OPERATING ACTIVITIES | ||||
Net loss | $ (13,765,286) | $ (2,554,388) | $ (23,549,612) | $ (4,672,605) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||||
Accrued interest and accretion | 50,819 | 21,317 | 25,331 | 53,605 |
Amortization of debt discount | 600,771 | |||
Change in fair value of derivative liability | 6,701,147 | (16,656) | 5,701,270 | (4,979) |
Loss on recognition of debt host liability | 341,553 | 140,943 | ||
Depreciation of property, plant and equipment | 123,961 | 8,645 | 44,148 | 20,871 |
Depreciation of right-of-use assets | 118,366 | 88,348 | 185,754 | 65,835 |
Foreign exchange loss | 204,106 | 73,637 | (198,371) | (55,080) |
Gain on sale of exploration and evaluation assets | (37,156) | |||
Interest expense on lease obligations | 17,897 | 10,821 | 25,319 | 7,033 |
Stock-based compensation | 433,829 | 11,051,124 | 666,259 | |
Cashless warrant exercise | (113,765) | |||
Write-off of equipment | 2,188 | |||
Changes in operating assets and liabilities: | ||||
Amounts receivable | (144,283) | 15,500 | ||
Other receivables | 96,860 | (58,815) | ||
Prepayments | 9,509 | (23,000) | (9,703) | (35,317) |
Deposits held by related parties | 83,022 | (235,682) | (478,902) | |
Accounts payable and accrued liabilities | 798,064 | 1,114,588 | 719,906 | 510,773 |
Due to related parties | 261,840 | 294,115 | 117,321 | 194,727 |
Cash used in operating activities | (4,037,307) | (1,335,724) | (6,367,567) | (3,270,534) |
INVESTING ACTIVITIES | ||||
Purchase of property, plant and equipment | (1,601,999) | (397,869) | (2,056,566) | (18,172) |
Other deposits | (10,000) | |||
Proceeds from sale of exploration and evaluation assets | 37,157 | |||
Cash used in investing activities | (1,601,999) | (397,869) | (2,066,566) | 18,985 |
FINANCING ACTIVITIES | ||||
Proceeds from issuance of shares, net of share issuance costs | 3,851,614 | 1,856,336 | 7,328,389 | 2,715,129 |
Deferred financing costs | (2,973) | (25,179) | ||
Proceeds from share subscriptions | 203,701 | 45,446 | 209,827 | 557,150 |
Proceeds from convertible debenture | 2,000,000 | 78,566 | 1,579,542 | 111,470 |
Payments of promissory note | (64,993) | (65,761) | (56,478) | |
Payments of lease obligations | (93,244) | (99,573) | (201,562) | (69,448) |
Cash provided by financing activities | 5,959,098 | 1,790,603 | 8,850,435 | 3,257,823 |
Change in cash for the period | 319,792 | 57,010 | 416,302 | 6,274 |
Cash, beginning of the period | 462,360 | 39,571 | 39,571 | 33,649 |
Effect of foreign exchange on cash | (7,743) | (26,216) | 6,487 | (352) |
Cash, end of the period | 774,409 | 70,365 | 462,360 | 39,571 |
Other non-cash transactions: | ||||
Shares issued for conversion of debt and interest | 688,178 | 468,661 | ||
Shares issued for payment of finder’s fees | 4,796,832 | |||
ROU asset addition by way of lease obligation | 351,886 | 437,812 | ||
Other cash flow disclosures: | ||||
Cash paid during the period for interest | $ 5,549 | $ 13,204 | $ 28,199 |
NATURE OF OPERATIONS AND GOING
NATURE OF OPERATIONS AND GOING CONCERN | 6 Months Ended | 12 Months Ended |
Apr. 30, 2022 | Oct. 31, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
NATURE OF OPERATIONS AND GOING CONCERN | 1. NATURE OF OPERATIONS AND GOING CONCERN Western Magnesium Corporation (the “Company”, or “WMC”) was incorporated under the laws of British Columbia on March 24, 1966. On May 14, 2019, the Company discontinued from the jurisdiction of the Business Corporations Act (British Columbia) and domesticated under the General Corporation Law of the State of Delaware under the name “Western Magnesium Corporation”. The Company is a reporting issuer in Canada and in the United States, listed for trading in Canada on the TSX Venture Exchange (the “TSX-V”) under the symbol “WMG.V”, in the United States on the OTCQB tier of the OTC Markets (the “OTCQB”) under the symbol “MLYF”, and in Germany on the Frankfurt Stock Exchange under the symbol “3WM”. The Company has developed proprietary magnesium production technology with the aim of becoming a premier low-cost producer of green primary magnesium metal. As at April 30, 2022, the Company had an accumulated deficit of $ 65,894,907 (October 31, 2021 – $ 52,129,621 ) and working capital deficiency of $ 7,172,573 (October 31, 2021 – $ 9,657,316 ). For the six months ended April 30, 2022, the Company reported a comprehensive loss of $ 13,551,323 (2021 – $ 2,745,438 ). The Company has not yet achieved profitable operations and expects to incur further losses from operations. The Company has financed its activities and operations through equity issuances and debt financing and expects to continue to do so to the extent such financing is available. There can be no assurance that such financing will be available under terms acceptable to the Company or at all. These unaudited condensed consolidated financial statements (the “Financial Statements”) have been prepared under the assumption that the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will be able to meet its obligations and continue its operations for the foreseeable future and be able to realize its assets and discharge its liabilities and commitments in the normal course of business. Management believes that the going concern assumption is appropriate for these Financial Statements based on its continuing ability to raise financings through share and debt issuances. If future financing is unavailable or if for any reason the Company is unable to continue as a going concern, it could impact the Company’s ability to realize its assets at their recognized values and to meet its obligations in the ordinary course of business at the amounts stated in these Financial Statements. These Financial Statements do not give effect to adjustments that would be necessary to the carrying values and classifications of assets and liabilities should the Company be unable to continue as a going concern. If the going concern assumption is not used, the adjustments required to report the Company’s assets and liabilities on a liquidation basis could be material to these Financial Statements. The Company’s management has evaluated whether there is substantial doubt about the Company’s ability to continue as a going concern and has determined that substantial doubt existed as of April 30, 2022. This determination was based on the following factors: (i) the Company used cash of approximately $ 4.0 million in operations during the six months ended April 30, 2022; (ii) the Company’s available cash as of April 30, 2022 will not be sufficient to fund its anticipated level of operations for the next 12 months; (iii) the Company will require additional financing for the fiscal year ending October 31, 2022 to continue at its expected level of operations; and (iv) if the Company fails to obtain the needed capital, it will be forced to delay, scale back, or eliminate some or all of its development activities or perhaps cease operations. In the opinion of management, these factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern for at least one year from the date of these Financial Statements are issued. In March 2020, the World Health Organization declared COVID-19 a global pandemic. In order to combat the spread of COVID-19, governments worldwide, including the Unites States and Canada, have enacted emergency measures including travel bans, legally enforced or self-imposed quarantine periods, social distancing and business and organization closures. These measures have adversely affected workforces, economies, and financial markets globally, leading to an economic downturn. The impact on the Company has not been significant but could affect the Company’s ability to raise financings in the future and restrict travel. Management continues to monitor the situation. | 1. NATURE OF OPERATIONS AND GOING CONCERN Western Magnesium Corporation (the “Company”, or “WMC”) was incorporated under the laws of British Columbia on March 24, 1966. On May 14, 2019, the Company discontinued from the jurisdiction of the Business Corporations Act (British Columbia) and domesticated under the General Corporation Law of the State of Delaware under the name “Western Magnesium Corporation”. The Company is a reporting issuer in Canada and in the United States, listed for trading in Canada on the TSX Venture Exchange (the “TSX-V”) under the symbol “WMG.V”, in the United States on the OTCQB tier of the OTC Markets (the “OTCQB”) under the symbol “MLYF”, and in Germany on the Frankfurt Stock Exchange under the symbol “3WM”. The Company has developed proprietary magnesium production technology with the aim of becoming a premier low-cost producer of green primary magnesium metal. As at October 31, 2021, the Company had an accumulated deficit of $ 52,129,621 28,580,009 9,657,316 2,392,189 23,827,678 4,749,411 These consolidated financial statements (the “Financial Statements”) have been prepared under the assumption that the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will be able to meet its obligations and continue its operations for the foreseeable future and be able to realize its assets and discharge its liabilities and commitments in the normal course of business. Management believes that the going concern assumption is appropriate for these Financial Statements based on its continuing ability to raise financings through share and debt issuances. If future financing is unavailable or if for any reason the Company is unable to continue as a going concern, it could impact the Company’s ability to realize its assets at their recognized values and to meet its obligations in the ordinary course of business at the amounts stated in these Financial Statements. These Financial Statements do not give effect to adjustments that would be necessary to the carrying values and classifications of assets and liabilities should the Company be unable to continue as a going concern. If the going concern assumption is not used, the adjustments required to report the Company’s assets and liabilities on a liquidation basis could be material to these Financial Statements. These factors indicate the existence of a material uncertainty that cast substantial doubt on the Company’s ability to continue as a going concern. In March 2020, the World Health Organization declared COVID-19 a global pandemic. In order to combat the spread of COVID-19, governments worldwide, including the Unites States and Canada, have enacted emergency measures including travel bans, legally enforced or self-imposed quarantine periods, social distancing and business and organization closures. These measures have adversely affected workforces, economies, and financial markets globally, leading to an economic downturn. The impact on the Company has not been significant but could affect the Company’s ability to raise financings in the future and restrict travel. Management continues to monitor the situation. WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated |
BASIS OF PRESENTATION
BASIS OF PRESENTATION | 6 Months Ended | 12 Months Ended |
Apr. 30, 2022 | Oct. 31, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
BASIS OF PRESENTATION | 2. BASIS OF PRESENTATION These Financial Statements comprise the financial statements of Western Magnesium Corporation and its wholly owned subsidiaries, Western Magnesium Corp., incorporated in Nevada, United States and Western Magnesium Canada Corporation, incorporated in British Columbia, Canada. [a] Accounting standards The accompanying Financial Statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and the rules and regulations of the United States Securities and Exchange Commission (the “SEC”) on the basis that the Company will continue as a going concern, which assumes that the Company will be able to meet its obligations as they become due and continue its operations for at least one year from the date these Financial Statements are issued. Realization values may be substantially different from carrying values as shown and these Financial Statements do not give effect to adjustments that would be necessary to the carrying values and classification of assets and liabilities should the Company be unable to continue as a going concern. These Financial Statements have been prepared on a historical cost basis except for financial instruments that have been measured at fair value. In addition, these Financial Statements have been prepared using the accrual basis of accounting, except for cash flow information. They do not include all the information required for complete annual financial statements and should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended October 31, 2021 (the “Fiscal 2021 Financial Statements”). [b] Functional and presentation currency These Financial Statements are presented in United States dollars (“US dollars” or “US$”), except where otherwise indicated. The functional currency of each entity of the Company is as follows: Entity Functional Currency Western Magnesium Corporation United States dollars Western Magnesium Corp. United States dollars Western Magnesium Canada Corporation Canadian dollars (“CA$”) During the three months ended January 31, 2022, significant changes in economic facts and circumstances have occurred in Western Magnesium Corporation’s operations which resulted in the change of its functional currency to the United States dollars from the Canadian dollar effective November 1, 2021. For both monetary and non-monetary assets and liabilities, translated balances at the end of the prior period become the new accounting basis. The rate on the date of change becomes the historical rate at which non-monetary assets and liabilities are translated in subsequent years. There is no effect on the cumulative translation adjustment on the consolidated basis. Previously recorded cumulative translation adjustments are not reversed. Effects of change in functional currency included the reclassifications of convertible debentures and warrants and broker warrants [notes 12[d] and [e]] The accounts of the Company’s subsidiary Western Magnesium Canada Corporation have been translated to United States dollars with the exchange translation adjustments recorded in other comprehensive income (loss). [c] Critical accounting estimates and judgments Significant Estimates and Assumptions The preparation of these Financial Statements in accordance with US GAAP requires the Company to make estimates and assumptions concerning the future that affect the amounts reported in the Financial Statements and accompanying notes. Management reviews these estimates and underlying assumptions on an ongoing basis, based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Revisions to estimates are adjusted for prospectively in the period in which the estimates are revised. Estimates and assumptions where there is potential risk of material adjustments to assets and liabilities in future accounting periods include the useful lives of property, plant and equipment, recoverability of the carrying value of exploration and evaluation assets, fair value measurements for financial instruments, discount rates for leases, recoverability and measurement of deferred tax assets and liabilities, and contingent liabilities. Significant Judgments The preparation of these Financial Statements in accordance with US GAAP requires the Company to make judgments, apart from those involving estimates, in applying accounting policies. The most significant judgments in applying the Company’s Financial Statements include: - the assessment of the Company’s ability to continue as a going concern and whether there are events or conditions that may give rise to substantial doubt; - whether there are indicators of impairment of the Company’s exploration and evaluation assets and other non-current assets; - the classification of financial instruments; and - determination of functional currency. | 2. BASIS OF PRESENTATION These Financial Statements comprise the financial statements of Western Magnesium Corporation and its wholly owned subsidiaries, Western Magnesium Canada Corporation, incorporated in British Columbia, Canada and Western Magnesium Corp., incorporated in the State of Nevada in the United States. [a] Accounting standards The accompanying Financial Statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) on the basis that the Company will continue as a going concern, which assumes that the Company will be able to meet its obligations and continue its operations for the next year. Realization values may be substantially different from carrying values as shown and these Financial Statements do not give effect to adjustments that would be necessary to the carrying values and classification of assets and liabilities should the Company be unable to continue as a going concern. These Financial Statements have been prepared on a historical cost basis except for financial instruments that have been measured at fair value. In addition, these Financial Statements have been prepared using the accrual basis of accounting, except for cash flow information. [b] Functional and presentation currency These Financial Statements are presented in United States dollars (“US dollars” or “USD”), except where otherwise indicated. The functional currency of each entity of the Company is as follows: Entity Functional Currency Western Magnesium Corporation Canadian dollars (“CA$”) Western Magnesium Canada Corporation Canadian dollars Western Magnesium Corp. United States dollars The accounts of the Company, and those of its subsidiary Western Magnesium Canada Corporation, have been translated to US dollars. [c] Critical accounting estimates and judgments Significant Estimates and Assumptions The preparation of these Financial Statements in accordance with US GAAP requires the Company to make estimates and assumptions concerning the future. Management reviews these estimates and underlying assumptions on an ongoing basis, based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Revisions to estimates are adjusted for prospectively in the period in which the estimates are revised. Estimates and assumptions where there is potential risk of material adjustments to assets and liabilities in future accounting periods include the useful lives of property, plant and equipment, the recoverability of the carrying value of exploration and evaluation assets, fair value measurements for financial instruments, discount rates for leases, the recoverability and measurement of deferred tax assets and liabilities and contingent liabilities. Significant Judgments The preparation of these Financial Statements in accordance with US GAAP requires the Company to make judgments, apart from those involving estimates, in applying accounting policies. The most significant judgments in applying the Company’s Financial Statements include: - the assessment of the Company’s ability to continue as a going concern and whether there are events or conditions that may give rise to substantial doubt; - whether there are indicators of impairment of the Company’s exploration and evaluation assets and other non-current assets; - the classification of financial instruments; and - determination of functional currency. WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated |
SIGNIFICANT ACCOUNTING POLICIES
SIGNIFICANT ACCOUNTING POLICIES | 12 Months Ended |
Oct. 31, 2021 | |
Accounting Policies [Abstract] | |
SIGNIFICANT ACCOUNTING POLICIES | 3. SIGNIFICANT ACCOUNTING POLICIES The accounting policies set out below have been applied consistently to all periods presented in these Financial Statements by the Company and its subsidiaries. [a] Principles of consolidation These Financial Statements include the accounts of the Company and its wholly owned and controlled subsidiaries as described in note 2 [b] Foreign currency Items included in the financial statements of each consolidated entity are measured using the currency of the primary economic environment in which the entity operates (the “functional currency”). Foreign currency transactions are translated into the functional currency using the prevailing exchange rates on the dates of transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities not denominated in the functional currency of an entity are recognized in the statements of loss and comprehensive loss. Assets and liabilities of the Company and its subsidiary with a functional currency in Canadian dollars are translated at the period end rates of exchange, and the results of its operations are translated at average rates of exchange for the period. Equity transactions have been translated using historical rates in effect on the date that each transaction occurred. The resulting translation adjustments are included in accumulated other comprehensive income or loss as shareholders’ equity or deficit. Additionally, foreign exchange gains and losses related to certain intercompany loans that are permanent in nature are included in accumulated other comprehensive income or loss. [c] Cash and cash equivalents Cash and cash equivalents include highly liquid financial instruments that are readily convertible into cash with original maturities of three months or less. [d] Property, plant and equipment Property, plant and equipment (“PP&E”) is carried at cost, less accumulated depreciation and accumulated impairment losses. The cost of an item of PP&E consists of the purchase price, any costs directly attributable to bringing the asset to the location and condition necessary for its intended use and an initial estimate of the costs of dismantling and removing the item and restoring the site on which it is located. Depreciation is provided at rates calculated to write off the cost of PP&E, less their estimated residual value. The depreciation rates and method applicable to each category of property, plant and equipment are as follows: SCHEDULE OF DEPRECIATION RATE Class Rate Computer equipment 55% declining balance Furniture 20% declining balance Plant equipment 20% declining balance Furnace To be determined Leasehold improvement Term of lease Right-of-use assets Term of lease WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated An item of PP&E is derecognized upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on disposal of the asset, determined as the difference between the net disposal proceeds and the carrying amount of the asset, is recognized in profit or loss in the consolidated statements of loss and comprehensive loss. Where an item of PP&E comprises major components with different useful lives, the components are accounted for as separate items. Expenditures incurred to replace a component of an item of PP&E that is accounted for separately, including major inspection and overhaul expenditures, are capitalized. [e] Reclamation deposits The Company maintains cash deposits, as required by regulatory bodies, as assurance for the funding of decommissioning costs. These funds are restricted to that purpose and are not available to the Company until the reclamation obligations have been fulfilled and are therefore classified as long-term assets. [f] Research and development Expenditures on research activities taken to develop a pyro metallurgical process to extract and recover magnesium metal from dolomite are expensed as incurred. Development expenditures are expensed in the period incurred. [g] Mineral property acquisition and exploration assets Mineral property acquisition costs are capitalized when incurred. Acquisition costs include cash consideration and the fair market value of shares issued on the acquisition of mineral property claims. Costs related to the development of mineral reserves are capitalized when it has been determined an ore body can be economically developed. The development stage begins when an ore body is determined to be economically recoverable based on proven and probable reserves and appropriate permits are in place, and ends when the production stage or exploitation of reserves begins. Major mine development expenditures are capitalized, including primary development costs such as costs of building access ways, tailings impoundment, development of water supply and infrastructure developments. Exploration costs include those relating to activities carried out (a) in search of previously unidentified mineral deposits, or (b) at undeveloped concessions. Pre-development activities involve costs incurred in the exploration stage that may ultimately benefit production that are expensed due to the lack of evidence of economic development, which is necessary to demonstrate future recoverability of these expenses. Secondary development costs are incurred for preparation of an ore body for production in a specific ore block or work area, providing a relatively short-lived benefit only to the mine area they relate to, and not to the ore body as a whole. All exploration costs have been expensed. Once production has commenced, capitalized costs will be depleted using the units-of-production method over the estimated life of the proven and probable reserves. If mineral properties are subsequently abandoned or impaired, any capitalized costs will be charged to the consolidated statements of loss and comprehensive loss in that period. The carrying cost of mineral properties is assessed for impairment whenever information or circumstances indicate the potential for impairment. Such evaluations compare estimated future net cash flows with carrying costs and future obligations on an undiscounted basis. If it is determined that the future undiscounted cash flows are less than the carrying value of the property, a write down to the estimated fair value is charged to the consolidated statements of loss and comprehensive loss for the period. Where estimates of future net cash flows are not available and where other conditions suggest impairment, management assesses if the carrying value can be recovered. WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated Management conducted an impairment test on its mineral properties for recoverability and impairment loss during the years ended October 31, 2021 and 2020 and determined that its mineral properties were not impaired. For significant development projects, interest is capitalized as part of the historical cost of developing and constructing assets in accordance with ASC 835-20. Interest is capitalized until the asset is ready for service. Capitalized interest is determined by multiplying the Company’s weighted-average borrowing cost on general debt by the average amount of qualifying costs incurred. Once an asset subject to interest capitalization is completed and placed in service, the associated capitalized interest is expensed through depletion or impairment. [h] Impairment of non-financial assets Non-financial assets are evaluated at the end of each reporting period by management for indicators that carrying value is impaired and may not be recoverable. When indicators of impairment are present, non-financial assets are tested for impairment as an individual asset, as part of an asset group or at the reporting unit (“RU”) level. An asset group is the lowest level for which there are identifiable cash flows (i.e. both cash inflows and cash outflows) that are largely independent of the net cash flows of other groups of assets. An RU is an operating segment or one level below an operating segment if certain conditions are met. Impairment tests for non-financial assets subject to depreciation or amortization are applied to individual assets if possible. If this is not possible, then these assets are tested for impairment at the asset group level. An impairment loss is triggered for non-financial assets only if the asset’s, or asset group’s, carrying amount exceeds its recoverable amount (i.e. the carrying amount is greater than the undiscounted cash flows of the asset or asset group). If the carrying amount is not recoverable, then the impairment loss is the difference between the carrying amount of the asset (asset group) and the fair value of the asset (asset group). An impairment loss for an asset group is allocated pro rata to the non-financial assets in the asset group. Impairment losses are recognized in the consolidated statements of loss and comprehensive loss and are not reversed. [i] Income taxes The Company accounts for income taxes using the asset and liability method. The asset and liability method provides that deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates. The Company records a valuation allowance to reduce deferred tax assets to the amount that is believed more likely than not to be realized. The Company has adopted the provisions of FASB ASC 740 “Income Taxes” regarding accounting for uncertainty in income taxes. The Company initially recognizes tax positions in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are initially and subsequently measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the tax authority, assuming full knowledge of the position and all relevant facts. Application requires numerous estimates based on available information. The Company considers many factors when evaluating and estimating its tax positions and tax benefits, and its recognized tax positions and tax benefits may not accurately anticipate actual outcomes. As additional information is obtained, there may be a need to periodically adjust the recognized tax positions and tax benefits. These periodic adjustments may have a material impact on the consolidated statements of loss and comprehensive loss. When applicable, the Company classifies penalties and interest associated with uncertain tax positions as a component of income tax expense in its consolidated statements of loss and comprehensive loss. WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated [j] Loss per share Basic earnings (loss) per share (“EPS”) is calculated by dividing profit or loss attributable to ordinary equity holders (numerator) by the weighted average number of ordinary shares outstanding (denominator) during the period. The denominator is calculated by adjusting the shares issued at the beginning of the period by the number of shares bought back during the period, multiplied by a time-weighting factor. Diluted EPS is calculated by adjusting the earnings and number of shares for the effects of dilutive options and other dilutive potential units. The effects of anti-dilutive options and potential units are ignored in calculating diluted EPS. All options and potential units are considered anti-dilutive when the Company is in a loss position. [k] Share-based payments The Company has an equity-settled share purchase stock option plan that is described in note 14 The fair value of stock-based payments to non-employees is periodically re-measured until the counterparty performance is complete, and any change therein is recognized over the vesting period of the award and in the same manner as if the Company had paid cash instead of paying with or using equity-based instruments. The cost of the stock-based payments to non-employees that are fully vested and non-forfeitable as at the grant date is measured and recognized at that date, unless there is a contractual term for services in which case such compensation would be amortized over the contractual term. The Company accounts for the granting of stock options to employees using the fair value method whereby all awards to employees will be recorded at fair value on the date of the grant. The fair value of all stock options is expensed over their vesting period with a corresponding increase to additional paid-in capital. Compensation costs for stock-based payments that do not include performance conditions are recognized on a straight-line basis. Compensation cost associated with a share-based award having a performance condition is only recognized over the requisite service period if it is probable. Share-based awards with a performance condition are accrued on an award by award basis. The share-based compensation fair value is determined using an estimated forfeiture rate. Compensation ultimately recognized is revised in subsequent periods to reflect final grant amounts. For employees and consultants who are working on specific capital projects, the share-based compensation is allocated to projects under development. For the remainder of employees and consultants, the compensation is expensed. [l] Decommissioning liabilities The Company records a liability for the reclamation of its exploration and evaluation interests based on the best estimate of costs for site closure and reclamation activities that the Company is legally or constructively required to remediate, and the liability is recognized at the time the environmental disturbance occurs. The resulting costs are capitalized to the corresponding asset. The fair value of the provision for closure and reclamation liabilities is estimated using expected cash flows, based on engineering and environmental reports prepared by third party industry specialists, discounted at a pre-tax rate specific to the liability. The capitalized amount is amortized on the same basis as the related asset. The liability is adjusted for accretion of the discounted obligation and any changes in the amount or timing of the underlying future cash flows. Significant judgments and estimates are involved in forming expectations of the amount and timing of future site closure and reclamation cash flows. Future restoration costs are reviewed annually and any changes in the estimate are reflected in the present value of the provision at the reporting date. WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated [m] Share capital The Company records proceeds from share issuances net of issuance costs. Shares issued for consideration other than cash are valued at the quoted price on the date the shares are issued. [n] Financial instruments The Company’s classification of its financial instruments is as follows: Asset or Liability Classification Cash Held-for-trading Amounts receivable Amortized cost Accounts payable Amortized cost Due to related parties Amortized cost Promissory note and convertible debenture Amortized cost Derivative liability Fair value through profit and loss (“FVTPL”) The fair value hierarchy under US GAAP is based on the following three levels of inputs, of which the first two are considered observable and the last unobservable: Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2: Observable inputs other than Level I, quoted prices for similar assets or liabilities in active prices whose inputs are observable or whose significant value drivers are observable; and Level 3: Assets and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s derivative liability is based on Level 3 inputs in the ASC 820 fair value hierarchy. . Derivative Liabilities The Company evaluates its financial instruments and other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815. The result of this accounting treatment is that the fair value of the embedded derivative is marked-to-market at each balance sheet date and recorded as a liability and the change in fair value is recorded in the consolidated statements of loss and comprehensive loss. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instruments that become subject to reclassification are reclassified at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not settlement of the derivative instrument is expected within 12 months of the balance sheet date. The Company uses the Black-Scholes Option Pricing Model to value derivative liabilities. This model uses Level 3 inputs in the fair value hierarchy established by ASC 820 Fair Value Measurement. WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated |
RECENT ACCOUNTING PRONOUNCEMENT
RECENT ACCOUNTING PRONOUNCEMENTS | 6 Months Ended | 12 Months Ended |
Apr. 30, 2022 | Oct. 31, 2021 | |
Accounting Changes and Error Corrections [Abstract] | ||
RECENT ACCOUNTING PRONOUNCEMENTS | 3. RECENT ACCOUNTING PRONOUNCEMENTS New Accounting Standards Adopted During the Periods In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years, with early adoption permitted. Effective November 1, 2021, the Company adopted the new standard. There was no material impact or adjustment to these Financial Statements. In January 2020, the FASB issued ASU 2020-01, Investments – Equity Securities (Topic 321), Investments – Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) (“ASU 2020-01”), which is intended to clarify the interactions of the accounting for equity securities under Topic 321 and investments accounted for under the equity method of accounting in Topic 323 and the accounting for certain forward contracts and purchased options accounted for under Topic 815. ASU 2020-01 is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years, with early adoption permitted. Effective November 1, 2021, the Company adopted the new standard. There was no material impact or adjustment to these Financial Statements. New Accounting Standards Not Yet Adopted In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”). ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments and supersedes the respective guidance within ASC 470-20 and ASC 740-10-55-51, which will result in more instruments to be accounted for as a single instrument rather than having their proceeds allocated between liability and equity accounting units. As smaller reporting companies as defined by the United States Securities and Exchange Commission (the “SEC”), ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the effect this standard will have on its Financial Statements. | 4. RECENT ACCOUNTING PRONOUNCEMENTS New Accounting Standards Adopted During the Year Fair Value Measurements In August 2018, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2018-13, “Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement” which adds the disclosure of the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. Certain alternatives apply. Effective November 1, 2020, the Company adopted the new standard. There was no material impact or adjustment to these Financial Statements. New Accounting Standards Not Yet Adopted There are no new accounting standards not yet adopted by the Company that are expected to have a significant impact on its Financial Statements. |
PROPERTY, PLANT AND EQUIPMENT
PROPERTY, PLANT AND EQUIPMENT | 6 Months Ended | 12 Months Ended |
Apr. 30, 2022 | Oct. 31, 2021 | |
Property, Plant and Equipment [Abstract] | ||
PROPERTY, PLANT AND EQUIPMENT | 4. PROPERTY, PLANT AND EQUIPMENT SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT Computer Equipment Furniture Leasehold Improvement Furnace & Plant Equipment Vehicle Total $ $ $ $ $ $ Cost Balance, October 31, 2020 32,318 38,916 7,610 28,413 – 107,257 Additions 77,955 11,510 129,257 2,278,205 – 2,496,927 Write-off of equipment (4,245 ) – – – – (4,245 ) Foreign exchange effect 3,601 3,116 2,614 38,108 – 47,439 Balance, October 31, 2021 109,629 53,542 139,481 2,344,726 – 2,647,378 Cost, Beginning Balance 109,629 53,542 139,481 2,344,726 – 2,647,378 Additions 7,008 2,171 107,014 1,456,591 29,215 1,601,999 Foreign exchange effect – (288 ) (5,306 ) (70,509 ) (302 ) (76,405 ) Balance, April 30, 2022 116,637 55,425 241,189 3,730,808 28,913 4,172,972 Cost, Ending Balance 116,637 55,425 241,189 3,730,808 28,913 4,172,972 Accumulated Depreciation Balance, October 31, 2020 14,677 8,326 4,818 – – 27,821 Depreciation expense 13,907 7,443 8,827 13,971 – 44,148 Write-off of equipment (2,057 ) – – – – (2,057 ) Foreign exchange effect 1,294 745 502 221 – 2,762 Balance, October 31, 2021 27,821 16,514 14,147 14,192 – 72,674 Accumulated Depreciation, Beginning Balance 27,821 16,514 14,147 14,192 – 72,674 Depreciation expense 18,236 3,833 15,217 83,755 2,920 123,961 Foreign exchange effect – (48 ) (404 ) (801 ) (29 ) (1,282 ) Balance, April 30, 2022 46,057 20,299 28,960 97,146 2,891 195,353 Accumulated Depreciation, Ending Balance 46,057 20,299 28,960 97,146 2,891 195,353 Net Book Value Balance, October 31, 2020 17,641 30,590 2,792 28,413 – 79,436 Balance, October 31, 2021 81,808 37,028 125,334 2,330,534 – 2,574,704 Balance, April 30, 2022 70,580 35,126 212,229 3,633,662 26,022 3,977,619 | 5. PROPERTY, PLANT AND EQUIPMENT SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT Computer Equipment Furniture Leasehold Improvement Furnace & Plant Equipment Total $ $ $ $ $ Cost Balance, October 31, 2019 22,632 33,584 5,850 27,897 89,963 Additions 9,852 5,672 1,810 838 18,172 Foreign exchange effect (166 ) (340 ) (50 ) (322 ) (878 ) Balance, October 31, 2020 32,318 38,916 7,610 28,413 107,257 Cost, Beginning Balance 32,318 38,916 7,610 28,413 107,257 Additions 77,955 11,510 129,257 2,278,205 2,496,927 Write-off of equipment (4,245 ) – – – (4,245 ) Foreign exchange effect 3,601 3,116 2,614 38,108 47,439 Balance, October 31, 2021 109,629 53,542 139,481 2,344,726 2,647,378 Cost, Ending Balance 109,629 53,542 139,481 2,344,726 2,647,378 Accumulated Depreciation Balance, October 31, 2019 3,184 1,679 1,950 – 6,813 Depreciation expense 11,412 6,598 2,861 – 20,871 Foreign exchange effect 81 49 7 – 137 Balance, October 31, 2020 14,677 8,326 4,818 – 27,821 Accumulated Depreciation, Beginning Balance 14,677 8,326 4,818 – 27,821 Depreciation expense 13,907 7,443 8,827 13,971 44,148 Write-off of equipment (2,057 ) – – – (2,057 ) Foreign exchange effect 1,294 745 502 221 2,762 Balance, October 31, 2021 27,821 16,514 14,147 14,192 72,674 Accumulated Depreciation, Ending Balance 27,821 16,514 14,147 14,192 72,674 Net Book Value Balance, October 31, 2020 17,641 30,590 2,792 28,413 79,436 Balance, October 31, 2021 81,808 37,028 125,334 2,330,534 2,574,704 Net Book Value 81,808 37,028 125,334 2,330,534 2,574,704 WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated |
RIGHT-OF-USE ASSETS
RIGHT-OF-USE ASSETS | 6 Months Ended | 12 Months Ended |
Apr. 30, 2022 | Oct. 31, 2021 | |
Right-of-use Assets | ||
RIGHT-OF-USE ASSETS | 5. RIGHT-OF-USE ASSETS As at April 30, 2022, the right-of-use assets are leases for the Company’s offices in Vancouver, British Columbia and McLean, Virginia, and its research and development pilot plant located in Burnaby, British Columbia. These leases terminate on March 31, 2023, February 28, 2025 and September 30, 2023, respectively. The lease for the Company’s office in Las Vegas, Nevada ended on May 31, 2021. SCHEDULE OF RIGHT-OF-USE ASSETS Vancouver Office Virginia Office Nevada Office Pilot Plant Total $ $ $ $ $ Cost Balance, October 31, 2020 59,701 – 22,856 357,949 440,506 Additions 91,237 287,847 – – 379,084 Foreign exchange effect 5,943 4,544 1,724 26,997 39,208 Balance, October 31, 2021 156,881 292,391 24,580 384,946 858,798 Operating lease right-of-use asset, cost, beginning balance 156,881 292,391 24,580 384,946 858,798 Foreign exchange effect – (3,038 ) – (12,278 ) (15,316 ) Balance, April 30, 2022 156,881 289,353 24,580 372,668 843,482 Operating lease right-of-use asset, cost, ending balance 156,881 289,353 24,580 372,668 843,482 Accumulated Depreciation Balance, October 31, 2020 42,142 – 14,434 9,943 66,519 Depreciation expense 44,259 15,288 8,915 117,292 185,754 Foreign exchange effect 3,876 241 1,231 2,602 7,950 Balance, October 31, 2021 90,277 15,529 24,580 129,837 260,223 Operating lease right-of-use asset, accumulated depreciation, beginning balance 90,277 15,529 24,580 129,837 260,223 Depreciation expense 22,229 33,790 – 62,347 118,366 Foreign exchange effect – (162 ) – (4,766 ) (4,928 ) Balance, April 30, 2022 112,506 49,157 24,580 187,418 373,661 Operating lease right-of-use asset, accumulated depreciation, ending balance 112,506 49,157 24,580 187,418 373,661 Net Book Value Balance, October 31, 2020 17,559 – 8,422 348,006 373,987 Balance, October 31, 2021 66,604 276,862 – 255,109 598,575 Balance, April 30, 2022 44,375 240,196 – 185,250 469,821 | 6. RIGHT-OF-USE ASSETS As at October 31, 2021, the right-of-use assets are leases for the Company’s corporate offices in Vancouver, British Columbia and McLean, Virginia, and its research and development pilot plant located in Burnaby, British Columbia. These leases terminate on March 31, 2023, February 28, 2025 and September 30, 2023, respectively. The lease for the Company’s office in Las Vegas, Nevada ended on May 31, 2021. SCHEDULE OF RIGHT-OF-USE ASSETS Vancouver Office Virginia Office Nevada Office Pilot Plant Total $ $ $ $ $ Cost Balance, October 31, 2019 – – – – – Initial adoption of ASU 2016-02 60,418 – 23,131 – 83,549 Additions – – – 354,263 354,263 Foreign exchange effect (717 ) – (275 ) 3,686 2,694 Balance, October 31, 2020 59,701 – 22,856 357,949 440,506 Operating lease right-of-use asset, cost, beginning balance 59,701 – 22,856 357,949 440,506 Additions 91,237 287,847 – – 379,084 Foreign exchange effect 5,943 4,544 1,724 26,997 39,208 Balance, October 31, 2021 156,881 292,391 24,580 384,946 858,798 Operating lease right-of-use asset, cost, ending balance 156,881 292,391 24,580 384,946 858,798 Accumulated Depreciation Balance, October 31, 2019 – – – – – Depreciation expense 41,708 – 14,286 9,841 65,835 Foreign exchange effect 434 – 148 102 684 Balance, October 31, 2020 42,142 – 14,434 9,943 66,519 Operating lease right-of-use asset, accumulated depreciation, beginning balance 42,142 – 14,434 9,943 66,519 Depreciation expense 44,259 15,288 8,915 117,292 185,754 Foreign exchange effect 3,876 241 1,231 2,602 7,950 Balance, October 31, 2021 90,277 15,529 24,580 129,837 260,223 Operating lease right-of-use asset, accumulated depreciation, ending balance 90,277 15,529 24,580 129,837 260,223 Net Book Value Balance, October 31, 2020 17,559 – 8,422 348,006 373,987 Balance, October 31, 2021 66,604 276,862 – 255,109 598,575 Operating lease right-of-use asset 66,604 276,862 – 255,109 598,575 WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated |
LEASE OBLIGATIONS
LEASE OBLIGATIONS | 6 Months Ended | 12 Months Ended |
Apr. 30, 2022 | Oct. 31, 2021 | |
Lease Obligations | ||
LEASE OBLIGATIONS | 6. LEASE OBLIGATIONS On adoption of ASU 2016-02 on November 1, 2019, the Company recognized lease liabilities of $ 83,549 7% During the year ended October 31, 2020, the Company entered into a new operating lease with respect to its research and development pilot plant located in Burnaby, British Columbia and recognized a lease liability of $ 354,263 6% During the year ended October 31, 2021, the Company renewed its operating lease with respect to its office in Vancouver, British Columbia and recognized a lease liability of $ 91,237 7% During the year ended October 31, 2021, the Company entered into a new operating lease with respect to its corporate head office in McLean, Virginia and recognized a lease liability of $ 260,649 7% SCHEDULE OF OPERATING LEASE Vancouver Office Virginia Office Nevada Office Pilot Plant Total $ $ $ $ $ Balance, October 31, 2020 18,123 – 12,211 350,593 380,927 Additions 91,237 260,649 – – 351,886 Lease payments (47,931 ) (5,137 ) (9,457 ) (139,037 ) (201,562 ) Interest expense 3,076 3,019 219 19,005 25,319 Prior period adjustment – – (3,065 ) – (3,065 ) Foreign exchange effect 2,099 4,081 92 24,548 30,820 Balance, October 31, 2021 66,604 262,612 – 255,109 584,325 Operating lease liability, beginning 66,604 262,612 – 255,109 584,325 Lease payments (24,187 ) – – (69,057 ) (93,244 ) Interest expense 1,958 9,230 – 6,711 17,899 Foreign exchange effect – (2,728 ) – (7,513 ) (10,241 ) Balance, April 30, 2022 44,375 269,114 – 185,250 498,739 Operating lease liability, ending 44,375 269,114 – 185,250 498,739 Which consist of: Current lease obligation 44,375 71,092 – 129,125 244,592 Non-current lease obligation – 198,022 – 56,125 254,147 Balance, April 30, 2022 44,375 269,114 – 185,250 498,739 | 7. LEASE OBLIGATIONS On adoption of ASU 2016-02 on November 1, 2019, the Company recognized lease liabilities of $ 83,549 7 During the year ended October 31, 2020, the Company entered into a new operating lease with respect to its research and development pilot plant located in Burnaby, British Columbia and recognized a lease liability of $ 354,263 6 During the year ended October 31, 2021, the Company renewed its operating lease with respect to its corporate office in Vancouver, British Columbia and recognized a lease liability of $ 91,237 7 During the year ended October 31, 2021, the Company entered into a new operating lease with respect to its office in McLean,Virginia and recognized a lease liability of $ 260,649 7 SCHEDULE OF OPERATING LEASE Vancouver Office Virginia Office Nevada Office Pilot Plant Total $ $ $ $ $ Balance, October 31, 2019 – – – – – Initial adoption of ASU 2016-02 60,418 – 23,131 – 83,549 Additions – – – 354,263 354,263 Lease payments (43,627 ) – (14,990 ) (10,831 ) (69,448 ) Interest expenses 2,477 – 1,005 3,551 7,033 Foreign exchange effect (1,145 ) – 3,065 3,610 5,530 Balance, October 31, 2020 18,123 – 12,211 350,593 380,927 Additions 91,237 260,649 – – 351,886 Lease payments (47,931 ) (5,137 ) (9,457 ) (139,037 ) (201,562 ) Interest expenses 3,076 3,019 219 19,005 25,319 Prior period adjustment – – (3,065 ) – (3,065 ) Foreign exchange effect 2,099 4,081 92 24,548 30,820 Balance, October 31, 2021 66,604 262,612 – 255,109 584,325 Which consist of: Current lease obligation 46,270 16,328 – 129,447 192,045 Non-current lease obligation 20,334 246,284 – 125,662 392,280 Balance, October 31, 2021 66,604 262,612 – 255,109 584,325 WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated |
MINERAL PROPERTY COSTS
MINERAL PROPERTY COSTS | 6 Months Ended | 12 Months Ended |
Apr. 30, 2022 | Oct. 31, 2021 | |
Extractive Industries [Abstract] | ||
MINERAL PROPERTY COSTS | 7. MINERAL PROPERTY COSTS As at April 30, 2022, the Company had the following mining claims: [a] Silverado Property Nevada, United States The Silverado property is located in the Pinto mining district of Nevada, consists of 3 patented mining claims totaling approximately 120 100 1 [b] Tami Mosi Property, Nevada, United States The Company holds a 100 1,637 10 2 93,452 | 8. MINERAL PROPERTY COSTS SCHEDULE OF MINERAL PROPERTY COSTS Beaverdell Property Silverado Property Tami Mosi Total $ $ $ $ Balance, October 31, 2019 1 1 93,452 93,454 Sale of mineral property (1 ) – – (1 ) Balance, October 31, 2020 and 2021 – 1 93,452 93,453 Sale of mineral property - – – - Balance, October 31, 2020 and 2021 – 1 93,452 93,453 [a] Beaverdell Property, Greenwood Mining Division, British Columbia, Canada The Beaverdell property is located in British Columbia, and was 100 100 50,000 37,157 37,156 1 [b] Silverado Property , The Silverado property is located in the Pinto mining district of Nevada, consists of 3 patented mining claims totaling approximately 120 hectares, and is 100 1 [c] Tami Mosi Property, Nevada, United States The Company holds a 100 1,637 2 WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated |
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS | 6 Months Ended | 12 Months Ended |
Apr. 30, 2022 | Oct. 31, 2021 | |
Related Party Transactions [Abstract] | ||
RELATED PARTY TRANSACTIONS | 8. RELATED PARTY TRANSACTIONS [a] Deposits held by related parties The Company provided related parties with advances that were held as deposits for anticipated future costs related to the Company’s planned magnesium research and development pilot plant and other administrative expenses (the “Pilot Plant Advances”). As at April 30, 2022, the Company had the following deposits held by related parties: SCHEDULE OF DEPOSITS HELD BY RELATED PARTY Related Party A [i] Related Party B [ii] Total $ $ $ Balance, October 31, 2020 – – – Advances 987,912 2,292,912 3,280,824 Costs and expenses (696,431 ) (2,097,931 ) (2,794,362 ) Balance, October 31, 2021 291,481 194,981 486,462 Deposits held by related parties, beginning 291,481 194,981 486,462 Advances 330,930 1,225,118 1,556,048 Costs and expenses (249,872 ) (1,420,829 ) (1,670,701 ) Foreign exchange effect 16,218 730 16,948 Balance, April 30, 2022 388,757 – 388,757 Deposits held by related parties, beginning 388,757 – 388,757 [i] Related Party A is a company controlled by a director and officer. [ii] Related Party B is a company controlled by an officer. [b] Due to related parties As at April 30, 2022, balances due to related parties totaled $ 1,253,280 1,026,817 SCHEDULE OF DUE TO RELATED PARTIES April 30, 2022 October 31, $ $ Wages payable to directors and officers 357,500 357,500 Benefits payable to directors and officers 730,810 539,209 Fees and expenses payable to directors and officers 164,970 127,878 Interest due to a shareholder – 2,230 Total 1,253,280 1,026,817 [c] Key management compensation As at April 30, 2022, the Company had twelve executives including seven key senior management members. Their aggregate annualized compensation is approximately $ 3.1 1,626,279 160,700 [d] Transactions with related parties [i] During the six months ended April 30, 2022, the Company incurred consulting fees of $ 27,630 35,000 [ii] During the six months ended April 30, 2022, the Company incurred consulting fees of $ 30,000 [iii] In June 2021, the Company renewed its sublease agreement with a company controlled by a director and officer for its office in Vancouver, British Columbia with a lease term from April 1, 2021 to March 31, 2023 7,656 9,794 [iv] Pursuant to an agreement entered on August 29, 2018 and which was approved by the TSX-V on September 12, 2018, a company controlled by a director and officer is eligible to receive up to 5 5 9,163,425 0.65 4,796,832 5,956,226 | 9. RELATED PARTY TRANSACTIONS [a] Deposits held by related parties During the year ended October 31, 2021, the Company provided related parties with advances that were held as deposits for anticipated future costs related to the Company’s planned magnesium research and development pilot plant and other administrative expenses (the “Pilot Plant Advances”). During the year ended October 31, 2021, the Company provided Pilot Plant Advances to a company controlled by a director and officer in the aggregate amount of $ 987,912 696,431 291,481 2,292,912 2,097,931 194,981 486,462 SCHEDULE OF DEPOSITS HELD BY RELATED PARTY Related Party A [i] Related Party B [ii] Total $ $ $ Balance, October 31, 2020 – – – Advances 987,912 2,292,912 3,280,824 Costs and expenses (696,431 ) (2,097,931 ) (2,794,362 ) Balance, October 31, 2021 291,481 194,981 486,462 Advances 330,930 1,225,118 1,556,048 Costs and expenses (249,872 ) (1,420,829 ) (1,670,701 ) Foreign exchange effect 16,218 730 16,948 Balance, April 30, 2022 388,757 – 388,757 [i] Related Party A is a company controlled by a director and officer. [ii] Related Party B is a company controlled by an officer. [b] Due to related parties As at October 31, 2021, balances due to related parties totaled $ 1,026,817 843,990 SCHEDULE OF DUE TO RELATED PARTIES October 31, 2021 October 31, 2020 $ $ Wages payable to directors and officers 357,500 161,922 Benefits payable to directors and officers 539,209 – Fees and expenses payable to directors and officers 127,878 682,068 Interests due to a shareholder 2,230 – Total 1,026,817 843,990 [c] Key management compensation As at October 31, 2021, the Company had twelve executives including eight in senior management. Their aggregate annualized compensation is approximately $ 2.9 3,020,102 1,785,032 10,248,013 300,211 [d] Transactions with related parties During the year ended October 31, 2021, the Company incurred consulting fees of CA$ 120,000 95,390 45,000 35,771 20,000 WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated |
CONTINGENT LIABILITIES AND COMM
CONTINGENT LIABILITIES AND COMMITMENTS | 6 Months Ended | 12 Months Ended |
Apr. 30, 2022 | Oct. 31, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | ||
CONTINGENT LIABILITIES AND COMMITMENTS | 9. CONTINGENT LIABILITIES AND COMMITMENTS [a] Contingent liabilities [i] On September 29, 2020, James Sever filed a Notice of Civil Claim against the Company in the Supreme Court of British Columbia (the “Sever Claim”). The Sever Claim alleges that Mr. Sever had an employment and/or other similar contractual relationship with the Company, and that the Company breached such contractual relationship by way of constructive dismissal or similar conduct. The Sever Claim seeks damages in excess of $ 2.5 million, certain equity compensation, prejudgment garnishment, costs, interest and other non-monetary relief. On July 27, 2021, the Company filed a response to the Sever Claim. On April 5, 2022, the Company filed an amended response to the Sever Claim, which included the following pleadings: (a) British Columbia is an inappropriate and inconvenient forum for the Sever Claim; (b) to the extent that British Columbia is the appropriate forum for the Sever Claim, nonetheless: (i) the Sever Claim is barred in whole or in part by applicable doctrines of delay / statute of limitations, (ii) the Company did not constructively dismiss Mr. Sever and, instead, it was Mr. Sever that abandoned, quit or resigned from his obligations to the Company, (iii) the Company has no debts, liabilities or obligations to Mr. Sever. The Company intends to vigorously defend against the Sever Claim, and believes that the Sever Claim is without merit. As the Company cannot predict the outcome of the Sever Claim, no provision has been recognized as there is no present obligation and the probability of an outcome cannot be determined. [ii] On December 31, 2020, GEM Yield Bahamas Limited (“GEM”) served the Company with a Notice of Intention to Arbitrate (the “New York Arbitration Notice”) before the American Arbitration Association in New York (the “GEM New York Arbitration”). The New York Arbitration Notice alleges the Company breached a Share Subscription Agreement dated November 15, 2019 entered into between the Company and GEM (the “GEM Agreement”), among other things, claiming damages of approximately $ 3.4 million (CA$ 4.2 million). On January 19, 2021, the Company filed a petition in the New York Supreme Court to stay the GEM New York Arbitration claiming the GEM Agreement was not valid. On March 19, 2021, the Court in the New York State Action ruled that there was an arbitration clause in the GEM Agreement but it was up to the arbitrator to determine if the arbitration clause was valid. Following this ruling, the New York State Action was closed. In June 2021, GEM filed a Statement of Claim in the GEM New York Arbitration, and the Company filed a Statement of Answer denying the existence of any binding agreement between the Company and GEM, among other defenses. In January 2022, the Company filed a Modified Statement of Defense and Counterclaims. On April 8, 2022, the parties agreed to consolidate this arbitration with the GEM Montreal Arbitration. The parties then filed consolidated pleadings, and both matters will be decided via arbitration in Montreal. The Company intends to vigorously defend itself in the GEM New York Arbitration and believes the allegations lack merit. As the Company cannot predict the outcome of this arbitration proceeding, no provision has been recognized in respect to the GEM New York Arbitration as there is no present obligation and the probability of an outcome cannot be determined. [iii] On February 8, 2021, GEM instituted another arbitration against the Company before the International Centre for Dispute Resolution in Montreal Canada (the “GEM Montreal Arbitration”) and joined GEM’s affiliate, GEM Global Yield LLC SCS (“GEM Global Yield” together with GEM, the “GEM Parties”). The Statement of Claim filed by the GEM Parties alleges the Company breached a Share Subscription Agreement dated November 15, 2019 and promissory note, among other things, claiming damages of approximately $ 3.9 million (CA$ 4.9 million), in addition to costs and expenses, stemming from the Company’s alleged failure to issue to GEM Global Yield warrants to purchase up to 33 million shares of the Company’s common stock. The Company filed a Statement of Defense denying the existence of any binding agreement between the Company and GEM, among other defenses. In January 2022, the Company filed an Amended Statement of Defense and Cross-claim. On April 8, 2022, the parties agreed to consolidate this arbitration with the GEM New York Arbitration. The parties then filed consolidated pleadings, and both matters will be decided via arbitration in Montreal. The Company intends to vigorously defend itself in the GEM Montreal Arbitration and believes the allegations lack merit. As the Company cannot predict the outcome of this arbitration proceeding, no provision has been recognized in respect to the GEM Montreal Arbitration as there is no present obligation and the probability of an outcome cannot be determined. [iv] On April 19, 2021, Lampert Advisors, LLC (“Lampert”) filed a Verified Complaint against the Company’s wholly owned subsidiary Western Magnesium Corp., a Nevada corporation (“Western Magnesium – Nevada”) in the Supreme Court of the State of New York, County of New York (the “Lampert Lawsuit”). The complaint filed in the Lampert Lawsuit alleges that Lampert entered into an agreement with Western Magnesium – Nevada to provide various financial advisory services including acquisition advisory services and act as an exclusive placement agent for a combination of debt and equity securities (the “Lampert Agreement”), that it performed all services required under that agreement and that it is owed $ 367,227 plus interest at the rate of 9 % from February 3, 2021 and that it has a right of first refusal to act as financial advisor in connection with any debt, equity or debt restructuring assignments on terms, conditions and compensation customary for Lampert for a transaction of the type contemplated. Although Lampert claims to have personally served Western Magnesium – Nevada, the Company never received the Summons and Complaint and therefore, never submitted a response. On September 9, 2021, Lampert filed a Motion seeking the entry of a default judgment (the “Motion”). The Company opposed the Motion and filed a cross-motion to compel Lampert to accept the Company’s answer. The Court granted the Company’s cross-motion and denied Lampert’s Motion as moot. On March 4, 2022, the Company filed a Verified Amended Answer, Affirmative Defenses, and Counterclaims. The counterclaims seek at least $ 120,000 [b] Commitments [i] On November 1, 2016, the Company signed a contract services agreement with Lodestar Management Group, LLC (“Lodestar”), a US corporate logistics company. Lodestar provides advisory, consulting, negotiation and other management services relating to corporate management, administrative and/or operational activities of the Company. The term of the contract was for one year and has been renewed under the same terms on January 1, 2018 and 2019. The Company has agreed to compensate Lodestar in the amount of $ 1,800 2,500 0.05 1,800 2,500 30,624 nil nil 32,716 53,491 [ii] During the year ended October 31, 2020, the Company has entered into a lease agreement for its research and development pilot plant in Burnaby, British Columbia with a lease term from October 1, 2020 to September 30, 2023 at a monthly rent of $ 16,194 (CA$ 20,715 ). In June 2021, the Company renewed its sublease agreement with a company controlled by a director and officer for its office in Vancouver, British Columbia with a lease term from April 1, 2021 to March 31, 2023 at a monthly rent of $ 7,656 (CA$ 9,794 ). In September 2021, the Company entered into a lease agreement for its corporate head office in McLean, Virginia with a lease term from September 14, 2021 to February 28, 2025 at a monthly rent of $ 9,113 . The Company will be abated for the first five months and is entitled to a tenant allowance of $ 41,010 [notes 5 and 6] | 10. CONTINGENT LIABILITIES AND COMMITMENTS [a] Contingent liabilities [i] On September 29, 2020, James Sever filed a Notice of Civil Claim against the Company in the Supreme Court of British Columbia (the “Sever Claim”). The Sever Claim alleges that Mr. Sever had an employment and/or other similar contractual relationship with the Company, and that the Company breached such contractual relationship by way of constructive dismissal or similar conduct. The Sever Claim seeks damages in excess of $ 2.5 [ii] On December 30, 2020, the Company entered into a settlement agreement with Frank Halliday, a former director and officer of the Company, whereby the Company has agreed to pay Mr. Halliday termination pay in the amount of CA$ 102,001 76,588 [iii] On December 31, 2020, GEM Yield Bahamas Limited (“GEM”) served the Company with a Notice of Intention to Arbitrate (the “New York Arbitration Notice”) before the American Arbitration Association in New York (the “GEM New York Arbitration”). The New York Arbitration Notice alleges the Company breached a Share Subscription Agreement dated November 15, 2019 entered into between the Company and GEM (the “GEM Agreement”), among other things, claiming damages of CA$ 4.2 3.4 [iv] On February 8, 2021, GEM instituted another arbitration against the Company before the International Centre for Dispute Resolution in Montreal Canada (the “GEM Montreal Arbitration”) and joined GEM’s affiliate, GEM Global Yield LLC SCS (“GEM Global Yield” together with GEM, the “GEM Parties”). The Statement of Claim filed by the GEM Parties alleges the Company breached a Share Subscription Agreement dated November 15, 2019 and promissory note, among other things, claiming damages of approximately CA$ 4.9 3.9 33 WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated [v] On April 19, 2021, Lampert Advisors, LLC (“Lampert”) filed a Verified Complaint against the Company’s wholly owned subsidiary Western Magnesium Corp., a Nevada corporation (“Western Magnesium – Nevada”) in the Supreme Court of the State of New York, County of New York (the “Lampert Lawsuit”). The complaint filed in the Lampert Lawsuit alleges that Lampert entered into an agreement with Western Magnesium – Nevada to provide various financial advisory services including acquisition advisory services and act as an exclusive placement agent for a combination of debt and equity securities (the “Lampert Agreement”), that it performed all services required under that agreement and that it is owed $ 367,227 9 [b] Commitments [i] On November 1, 2016, the Company signed a contract services agreement with Lodestar Management Group, LLC (“Lodestar”), a US corporate logistics company. Lodestar provides advisory, consulting, negotiation and other management services relating to corporate management, administrative and/or operational activities of the Company. The term of the contract was for one year and has been renewed under the same terms on January 1, 2018 and 2019. The Company has agreed to compensate Lodestar in the amount of $ 1,800 2,500 0.05 1,800 2,500 21,600 nil 53,491 [ii] During the year ended October 31, 2020, the Company has entered into a lease agreement for its research and development pilot plant in Burnaby, British Columbia with a lease term from October 1, 2020 to September 30, 2023 at a monthly rent of CA$ 20,715 (USD equivalent $ 16,727 ). In June 2021, the Company renewed its sublease agreement with a company controlled by a director and officer for its corporate office in Vancouver, British Columbia with a lease term from April 1, 2021 to March 31, 2023 at a monthly rent of CA$ 9,794 (USD equivalent $ 7,909 ). In September 2021, the Company entered into a lease agreement for its office in McLean, Virginia with a lease term from September 14, 2021 to February 28, 2025 at a monthly rent of $ 9,113 . The Company will be abated for the beginning five months and is entitled to a tenant allowance of $ 41,010 [notes 6 and 7] [iii] Pursuant to an agreement entered on August 29, 2018 and which was approved by the TSX-V on September 12, 2018, a company controlled by a director and officer is eligible to receive up to 5 5 9,163,425 0.65 5,956,226 4,796,832 |
PROMISSORY NOTE
PROMISSORY NOTE | 6 Months Ended | 12 Months Ended |
Apr. 30, 2022 | Oct. 31, 2021 | |
Promissory Note | ||
PROMISSORY NOTE | 10. PROMISSORY NOTE During the year ended October 31, 2019, the Company received a loan of $ 112,895 150,000 18 44,588 60,000 157,483 210,000 September 24, 2021 1,639 16,655 65,761 101,066 | 11. PROMISSORY NOTE During the year ended October 31, 2019, the Company received a loan of CA$ 150,000 112,895 18 60,000 44,588 210,000 157,483 1,639 16,655 65,761 101,066 nil 60,567 |
PROVISION FOR FLOW THROUGH SHAR
PROVISION FOR FLOW THROUGH SHARE ISSUANCES | 6 Months Ended | 12 Months Ended |
Apr. 30, 2022 | Oct. 31, 2021 | |
Provision For Flow Through Share Issuances | ||
PROVISION FOR FLOW THROUGH SHARE ISSUANCES | 11. PROVISION FOR FLOW THROUGH SHARE ISSUANCES The Company has recorded a provision in the amount of $ 225,833 233,285 | 12. PROVISION FOR FLOW THROUGH SHARE ISSUANCES The Company has recorded a provision in the amount of $ 233,285 216,924 WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated |
CONVERTIBLE DEBENTURE AND DERIV
CONVERTIBLE DEBENTURE AND DERIVATIVE LIABILITY | 6 Months Ended | 12 Months Ended |
Apr. 30, 2022 | Oct. 31, 2021 | |
Debt Disclosure [Abstract] | ||
CONVERTIBLE DEBENTURE AND DERIVATIVE LIABILITY | 12. CONVERTIBLE DEBENTURE AND DERIVATIVE LIABILITY [a] July 2020 Convertible Debenture On July 27, 2020, the Company closed a non-brokered private placement of an unsecured convertible note in the principal amount of $ 112,124 150,000 12 0.15 1,360,959 263,973 26,286 37 [b] July 2021 Convertible Debenture On July 15, 2021, the Company closed a non-brokered private placement of an unsecured convertible note in the principal amount of $ 79,542 100,000 12 0.12 0.20 933,333 594% [c] June 2021 Convertible Debenture On June 15, 2021, the Company closed a non-brokered private placement of an unsecured convertible note in the principal amount of $ 1,500,000 12 December 10, 2022 15,000,000 (i) one share of the Company’ common stock, (ii) one-half of one Class A common stock purchase warrant, with each whole warrant being exercisable at a price of $0.13 until June 10, 2026, and (iii) one-half of one Class B common stock purchase warrant, with each whole warrant being exercisable at a price of $0.19 until June 10, 2026 (collectively, the “Class A and B Warrants”). In addition, the conversion price for accrued interest is the greater of (i) $0.10 and (ii) the minimum conversion price permitted by the TSX-V at the time of conversion As part of the offering of the June 2021 Convertible Debenture, the Company also entered into a securities purchase agreement dated June 10, 2021 (the “2021 Securities Purchase Agreement”), whereby the Company agreed to use commercially reasonable efforts to file a registration statement with the United States Securities and Exchange Commission (the “SEC”) by August 14, 2021, covering the public resale of the shares of common stock underlying such debenture and, upon its conversion, the Class A and B Warrants issuable upon such conversion (the “Underlying Shares”), and to use its best efforts to cause the registration statement to be declared effective on October 13, 2021. On December 13, 2021, the Company’s Form 10 Registration Statement filed with the SEC was declared effective. In addition to certain covenants contained in the 2021 Securities Purchase Agreement, the terms of the June 2021 Convertible Debenture contain certain negative covenants by the Company, including, among others, sell or offer to sell any securities with non-fixed or floating price features, issue any common stock or common stock equivalents at a price lower than the conversion price herein then in effect, or issue any equity or debt instruments with anti-dilution provisions. In the event the Company issues or sells any common stock or common stock equivalents with terms that the purchaser holding the outstanding June 2021 Convertible Debenture or the Class A and B Warrants reasonably believes are more favorable to such holder than the terms of the June 2021 Convertible Debenture or the Class A and B Warrants, then upon notice to the Company by such holder within five trading days after notice to such holder by the Company, the Company will use commercially reasonable efforts to obtain the approval of the TSX-V and any additional required regulatory approval to amend the terms of the June 2021 Convertible Debenture or the Class A and B Warrants as required, as the case may be, so as to give such holder the benefit of such more favorable terms or conditions. The conversion price of the June 2021 Convertible Debenture and the exercise price of the Class A and B Warrants are subject to proportional adjustment in the event of stock splits, stock dividends and similar corporate events, including merger or consolidation of the Company or in a “Fundamental Transaction” as defined in the June 2021 Convertible Debenture. The Company has granted the holders certain rights of first refusal on its future offerings for as long as the June 2021 Convertible Debenture or the Class A and B Warrants are outstanding. The Company may prepay and satisfy the June 2021 Convertible Debenture so long as an event of default has not occurred, upon 20 days’ prior written notice received by the Company to the holder, by paying 125% of the amounts owed on the June 2021 Convertible Debenture, including all principal, interest and other fees. The holder of this debenture may, however, convert all or a portion of the debenture during the 20-day notice period. During the six months ended April 30, 2022, the Company issued an aggregate 6,000,000 6,000,000 3,000,000 0.13 3,000,000 0.19 [note 13[b]] 140,942 70,521 effective interest rate of 1,240 [d] April 2022 Convertible Debenture On April 14, 2022, the Company entered into a securities purchase agreement (the “2022 Securities Purchase Agreement”) and closed a non-brokered private placement of an unsecured convertible note in the principal amount of $ 2,000,000 15 October 14, 2023 6,666,667 0.40 The April 2022 Convertible Debenture may not be prepaid prior to maturity and contains customary events of default relating to, among other things, payment defaults, breach of representations and warranties, and breach of provisions of the 2022 Securities Purchase Agreement or the April 2022 Convertible Debenture. In the event of default under the April 2022 Convertible Debenture, the interest rate shall increase to the lesser of 20% per annum or the maximum rate permitted under applicable law until paid and the following “Mandatory Default Amount” shall be paid, if demanded by the purchaser: the sum of (a) the greater of (i) the outstanding principal amount of the April 2022 Convertible Debenture divided by the conversion price on the date the Mandatory Default Amount is either (A) demanded (if demand or notice is required to create an event of default) or otherwise due or (B) paid in full, whichever has a lower conversion price, multiplied by the VWAP on the date the Mandatory Default Amount is either (x) demanded, (y) due, or (z) paid in full, whichever is highest, or (ii) 125% of the outstanding principal amount of the April 2022 Convertible Debenture plus (b) all other amounts, costs, expenses and liquidated damages due in respect of the April 2022 Convertible Debenture. Pursuant to the terms of the 2022 Securities Purchase Agreement, the Company also entered into a registration rights agreement dated April 14, 2022 (the “2022 Registration Rights Agreement”). Pursuant to the terms of the 2022 Registration Rights Agreement, the Company agreed to prepare and file with the SEC a registration statement covering the resale of all shares issued or issuable upon conversion of the April 2022 Convertible Debenture, upon exercise of the respective warrants of the April 2022 Convertible Debenture, upon conversion of the June 2021 Debenture, and upon exercise of the respective warrants of the June 2021 Convertible Debenture. The Company agreed to file the registration statement with the SEC within 30 days following April 14, 2022 and to use best efforts to have the registration statement declared effective by the SEC within 60 days following April 14, 2022 if the SEC does not review it or by August 12, 2022 if the SEC reviews it. In the event the Company fails to file the registration statement or such registration statement is not declared effective within the time periods noted above or such registration statement is not kept effective while any of the securities registered pursuant to such registration statement, the Company will be obligated to pay the holder of the debentures a penalty in cash, in the amount of $ 20,000 As at April 30, 2022, the Company incurred contractual interest of $ 13,151 nil 22% [e] Debt Host Liability and Embedded Derivative Liability Certain of the Company’s convertible debentures were determined to be hybrid financial instruments comprised of a debt host liability and an embedded derivative liability, as under the conversion feature the number of shares that will or may be issued to settle the notes may vary. The Company uses the Black-Scholes Option Pricing Model based on different default risks and assumptions. The debt host liability of the convertible note will be measured at amortized cost, with the embedded derivative liability measured at fair value. On issuance date of the July 2020 Convertible Debenture, the fair value of its debt host liability was determined to be $ 87,083 and the respective embedded derivative liability was valued at $ 25,041 . Fair value adjustments were made to the embedded derivative liability of the July 2020 Convertible Debenture on conversion date of May 18, 2021, resulting in a fair value of $nil. On issuance date of the July 2021 Convertible Debenture, it was determined to be a convertible debt instrument with a beneficial conversion feature accounted for in accordance with ASU 470-20. The Company allocated the intrinsic value of the beneficial conversion feature of the July 2021 Convertible Debenture capped at the face value of $ 79,542 (CA$ 100,000 ) to additional paid-in capital. On November 1, 2021, the Company’s functional currency change resulted in the reclassification of the July 2021 Convertible Debenture to a hybrid financial instrument accounted for in accordance with ASU 815-15. The embedded derivative liability was valued at $ 421,095 (CA$ 529,400 ), the previous beneficial conversion feature was reversed out of additional paid-in capital, and a loss of $ 341,553 (CA$ 429,400 ) was recognized in the statements of loss and comprehensive loss. Fair value adjustments were made to the embedded derivative liability of the July 2021 Convertible Debenture on conversion date of April 22, 2022, resulting in a fair value of $nil. On issuance date of the June 2021 Convertible Debenture, it was determined to be a hybrid financial instrument comprised of a debt host liability and an embedded derivative liability. The embedded derivative liability was valued at $ 1,646,600 1,500,000 1 146,601 7,449,744 600,769 899,231 On issuance date of the April 2022 Convertible Debenture, it was determined to be a convertible debt instrument with a beneficial conversion feature accounted for in accordance with ASU 470-20. The Company allocated the intrinsic value of the beneficial conversion feature of the April 2022 Convertible Debenture of $ 240,000 2 239,998 SCHEDULE OF DERIVATIVE INSTRUMENTS July 2020 Convertible Debenture July 2021 Convertible Debenture June 2021 Convertible Debenture April 2022 Convertible Debenture Total $ $ $ $ $ Debt Host Liability Balance, October 31, 2020 96,318 – – – 96,318 Fair value of debt host liability recognized – – 1 – 1 Accretion and interest expense 23,587 63 43 – 23,693 Conversion (125,560 ) – – – (125,560 ) Foreign currency translation 5,655 – – – 5,655 Balance, October 31, 2021 – 63 44 – 107 Effects of functional currency change – – 1,500,000 – 1,500,000 Fair value at inception – – – 2,000,000 2,000,000 Accretion and interest expense – 28,050 5,610 17,159 50,819 Conversion – (28,031 ) (600,000 ) – (628,031 ) Foreign currency translation – (82 ) – – (82 ) Balance, April 30, 2022 – – 905,654 2,017,159 2,922,813 Embedded Derivative Liability Balance, October 31, 2020 20,123 – – – 20,123 Fair value of embedded derivative liability recognized – – 1,646,600 – 1,646,600 Fair value adjustment (16,058 ) – 5,717,328 – 5,701,270 Conversion (5,247 ) – – – (5,247 ) Foreign currency translation 1,182 – 85,772 – 86,954 Balance, October 31, 2021 – – 7,449,700 – 7,449,700 Effects of functional currency change – 421,094 (7,449,700 ) – (7,028,606 ) Fair value adjustment – (259,447 ) – – (259,447 ) Conversion – (158,169 ) – – (158,169 ) Foreign currency translation – (3,478 ) – – (3,478 ) Balance, April 30, 2022 – – – – – Debt Discount Balance, October 31, 2021 – – – – – Effects of functional currency change – – (1,500,000 ) – (1,500,000 ) Inception – – – (240,000 ) (240,000 ) Amortization – – 600,769 2 600,771 Balance, April 30, 2022 – – (899,231 ) (239,998 ) (1,139,229 ) Combined Value of Convertible Debenture Balance, October 31, 2020 116,441 – – – 116,441 Balance, October 31, 2021 – 63 7,449,744 7,449,744 7,449,807 Balance, April 30, 2022 – – 6,423 1,777,161 1,783,584 The inputs used in the Black-Scholes Option Pricing Model are as follows: SCHEDULE OF OPTION PRICING MODEL April 22, November 1, October 31, June 15, July 27, 2022 2021 2021 2021 2020 Risk free rate of interest 2.65 % 1.07 % 1.08 % 0.31 % 0.26 % Expected life in years 0.23 0.70 1.11 1.50 0.74 Conversion exercise price CA$ 0.12 CA$ 0.12 $ 0.10 $ 0.10 CA$ 0.15 Underlying share price of the Company CA$ 0.36 CA$ 0.75 $ 0.59 $ 0.19 CA$ 0.13 Expected volatility 99.90 % 124.34 % 107.62 % 87.17 % 82.54 % Expected dividend rate Nil Nil Nil Nil Nil [f] Derivative Liability – Warrants and Broker Warrants On November 1, 2021, the Company’s functional currency change resulted in the reclassification of its outstanding warrants and broker warrants denominated in Canadian dollars as derivative liabilities measured at fair value. The previous value of outstanding broker warrants was reversed out of additional paid-in capital, and the derivative liability of warrants and broker warrants were valued at $ 26,956,177 and $ 76,811 , respectively. During the six months ended April 30, 2022, upon exercise of common share purchase warrants, $ 4,482,962 was reclassified from derivative liability to stockholders’ deficit. The Company recognized a loss of $ 7,060,790 in the change in fair value of the derivative liability. As at April 30, 2022, the derivative liability of warrants and broker warrants were valued at $ 2,465,603 and $ 2,658 , respectively. The Company uses the Black-Scholes Option Pricing Model based on default risks and assumptions as appropriate to value its warrants. | 13. CONVERTIBLE DEBENTURE CONVERTIBLE DEBENTURE AND DERIVATIVE LIABILITY [a] July 2020 Convertible Debenture On July 27, 2020, the Company closed a non-brokered private placement of an unsecured convertible note in the principal amount of CA$ 150,000 (USD equivalent $ 112,124 , the “July 2020 Convertible Debenture”). The note bears interest at 12 % per annum and is due on the date that is one year following the closing date. The note is convertible into common shares of the Company at the price which is the greater of CA$ 0.15 per common share and the market price on the date of the conversion notice. Any accrued but unpaid interest will be payable on the earlier of the maturity date and the date of conversion in cash or common shares. No finder’s fees were paid in connection with this private placement. On May 18, 2021, the Company issued a total of 1,360,959 common shares on the conversion of the July 2020 Convertible Debenture including conversion of accrued interest and 263,973 common shares valued at $ 26,286 in transaction costs. [b] July 2021 Convertible Debenture On July 15, 2021, the Company closed a non-brokered private placement of an unsecured convertible note in the principal amount of CA$ 100,000 79,542 12 0.12 0.20 7,299 5,802 effective interest rate of 1,878% 100,000 79,542 [c] June 2021 Convertible Debenture On June 15, 2021, the Company closed a non-brokered private placement of an unsecured convertible note in the principal amount of $ 1,500,000 12 December 10, 2022 15,000,000 one-half of one Class A common stock purchase warrant, with each whole warrant being exercisable at a price of $0.13 until June 10, 2026, and (iii) one-half of one Class B common stock purchase warrant, with each whole warrant being exercisable at a price of $0.19 until June 10, 2026 (collectively, the “Class A and B Warrants”). In addition, the conversion price for accrued interest is the greater of (i) $0.10 and (ii) the minimum conversion price permitted by the TSX-V at the time of conversion. As part of the offering of the June 2021 Convertible Debenture, the Company also entered into the June 10, 2021 Securities Purchase Agreement (the “Securities Purchase Agreement”), whereby the Company agreed to use commercially reasonable efforts to file a registration statement with the United States Securities and Exchange Commission (the “SEC”) by August 14, 2021, covering the public resale of the shares of common stock underlying such debenture and, upon its conversion, the Class A and B Warrants issuable upon such conversion (the “Underlying Shares”), and to use its best efforts to cause the registration statement to be declared effective on October 13, 2021 [note 19[vi]] In addition to certain covenants contained in the Securities Purchase Agreement, the terms of the June 2021 Convertible Debenture contain certain negative covenants by the Company, including, among others, sell or offer to sell any securities with non-fixed or floating price features, issue any common stock or common stock equivalents at a price lower than the Conversion Price herein then in effect, or issue any equity or debt instruments with anti-dilution provisions. WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated In the event the Company issues or sells any common stock or common stock equivalents with terms that the purchaser holding the outstanding June 2021 Convertible Debenture (the “Convertible Debenture Holder”) or the Class A and B Warrants reasonably believes are more favorable to such holder than the terms of the June 2021 Convertible Debenture or the Class A and B Warrants, then upon notice to the Company by such holder within five trading days after notice to such holder by the Company, the Company will use commercially reasonable efforts to obtain the approval of the TSX-V and any additional required regulatory approval to amend the terms of the June 2021 Convertible Debenture or the Class A and B Warrants as required, as the case may be, so as to give such holder the benefit of such more favorable terms or conditions. The conversion price of the June 2021 Convertible Debenture and the exercise price of the Class A and B Warrants are subject to proportional adjustment in the event of stock splits, stock dividends and similar corporate events, including merger or consolidation of the Company or in a “Fundamental Transaction” as defined in the June 2021 Convertible Debenture. The Company has granted the holders certain rights of first refusal on its future offerings for as long as the June 2021 Convertible Debenture or the Class A and B Warrants are outstanding. The Company may prepay and satisfy the June 2021 Convertible Debenture so long as an event of default has not occurred, upon 20 days’ prior written notice received by the Company to the holder, by paying 125% of the amounts owed on the June 2021 Convertible Debenture, including all principal, interest and other fees. The holder of this debenture may, however, convert all or a portion of the debenture during the 20-day notice period. As at October 31, 2021, the Company incurred contractual interest of $ 70,521 Subsequent to October 31, 2021, the Company issued an aggregate 3,000,000 3,000,000 1,500,000 0.13 1,500,000 0.19 [note 19[iii]] [d] Debt Host Liability and Embedded Derivative Liability The July 2020 Convertible Debenture and the June 2021 Convertible Debenture were determined to be hybrid financial instruments comprised of a debt host liability and an embedded derivative liability, as under the conversion feature the number of shares that will or may be issued to settle the notes may vary. The Company uses the Black-Scholes Option Pricing Model based on different default risks and assumptions. The debt host liability of the convertible note will be measured at amortized cost, with the embedded derivative liability measured at fair value through profit and loss. On issuance date of the July 2020 Convertible Debenture, the fair value of its debt host liability was determined to be $ 87,083 25,041 nil 96,318 nil 20,123 nil 116,441 37 On issuance date of the June 2021 Convertible Debenture, the embedded derivative liability was valued at $ 1,646,600 1,500,000 1 146,601 44 nil 7,449,700 nil 7,449,744 nil 1,448 WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated The inputs used in the Black-Scholes Option Pricing Model are as follows: SCHEDULE OF OPTION PRICING MODEL October 31, June 15, July 27, 2021 2021 2020 Risk free rate of interest 1.08 % 0.31 % 0.26 % Expected life in years 1.11 1.50 0.74 Conversion exercise price $ 0.10 $ 0.10 CA$ 0.15 Underlying share price of the Company CA$ 0.73 CA$ 0.23 CA$ 0.13 Expected volatility 107.62 % 87.17 % 82.54 % Expected dividend rate Nil Nil Nil SCHEDULE OF DERIVATIVE INSTRUMENTS July 2020 Convertible Debenture June 2021 Convertible Debenture July 2021 Convertible Debenture Total $ $ $ $ Debt Host Liability Balance, October 31, 2019 – – – – Value of debt host liability recognized 87,083 – – 87,083 Accretion and interest expense 8,751 – – 8,751 Foreign currency translation 484 – – 484 Fair value of embedded derivative liability recognized Fair value adjustment Conversion Effects of change in functional currency Balance, October 31, 2020 96,318 – – 96,318 Value of debt host liability recognized – 1 – 1 Accretion and interest expense 23,587 43 63 23,693 Conversion (125,560 ) – – (125,560 ) Foreign currency translation 5,655 – – 5,655 Balance, October 31, 2021 – 44 63 107 Embedded Derivative Liability Balance, October 31, 2019 – – – – Fair value of embedded derivative liability recognized 25,041 – – 25,041 Fair value adjustment (4,979 ) – – (4,979 ) Foreign currency translation 61 – – 61 Balance, October 31, 2020 20,123 – – 20,123 Fair value of embedded derivative liability recognized – 1,646,600 – 1,646,600 Fair value adjustment (16,058 ) 5,717,328 – 5,701,270 Conversion (5,247 ) – – (5,247 ) Foreign currency translation 1,182 85,772 – 86,954 Balance, October 31, 2021 – 7,449,700 – 7,449,700 Combined Value of Convertible Debenture Balance, October 31, 2019 – – – – Conversion – – – – Amortization Balance, October 31, 2020 116,441 – – 116,441 Conversion – – – – Balance, October 31, 2021 – 7,449,744 63 7,449,807 WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated |
SHARE CAPITAL
SHARE CAPITAL | 6 Months Ended | 12 Months Ended |
Apr. 30, 2022 | Oct. 31, 2021 | |
Equity [Abstract] | ||
SHARE CAPITAL | 13. SHARE CAPITAL [a] Authorized capital The authorized share capital consists of 1,000,000,000 0.001 [b] Common shares issued Fiscal 2021 [i] In connection with the non-brokered private placement announced on September 10, 2020: On November 20, 2020, the Company closed the first tranche of the non-brokered private placement, issuing 5,599,171 0.13 556,876 727,892 On January 15, 2021, the Company closed the second tranche of the non-brokered private placement, consisting of 7,337,914 0.13 749,435 953,930 39,996 On January 29, 2021, the Company closed the third tranche of the non-brokered private placement consisting of 5,382,303 0.13 547,496 699,699 On March 24, 2021, the Company closed the fourth tranche of the non-brokered private placement consisting of 6,554,172 0.13 678,270 852,042 On April 27, 2021, the Company closed the fifth and final tranche of the non-brokered private placement consisting of 851,395 0.13 89,237 110,681 In total, the Company issued an aggregate 25,724,955 0.13 2,621,314 3,344,244 Each unit issued consists of one common share and one common share purchase warrant entitling the holder to acquire a further common share at a price of CA$0.19 for a period of one year from the closing date of the respective financing tranche 195,614 [ii] On May 5, 2021, the Company announced a non-brokered private placement priced at CA$ 0.13 3,000,000 5,223,420 0.13 561,844 679,044 17,853,506 0.13 1,880,687 2,320,956 23,076,926 0.13 2,442,531 3,000,000 Each unit issued consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.19 for a period of one year from the date of closing of the respective financing tranche 154,336 [iii] On May 18, 2021, the Company issued a total of 1,360,959 263,973 26,286 [iv] On June 7, 2021, the Company issued 1,538,461 0.24 305,832 369,231 [v] On July 16, 2021, the Company closed a non-brokered private placement and issued 4,350,000 0.20 690,860 870,000 Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.30 for a period of one year from the date of closing 48,319 [vi] On August 11, 2021, the Company closed a non-brokered private placement and issued 3,827,601 0.55 1,683,336 2,105,180 Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$ 0.65 124,923 [vii] During the year ended October 31, 2021, the Company issued a total of 7,014,969 0.05 0.21 887,520 1,120,130 525,173 [viii] During the year ended October 31, 2021, the Company issued a total of 2,630,000 0.05 0.16 140,734 175,800 [ix] With respect to the exercises of common share purchase warrants and options, the Company reclassified $ 4,291 121,932 Fiscal 2022 [i] Pursuant to an agreement entered on August 29, 2018 and which was approved by the TSX-V on September 12, 2018, a company controlled by a director and officer was eligible to receive up to 5% of the issued and outstanding common shares of the Company as at August 28, 2018 for up to $ 5 9,163,425 0.65 4,796,832 5,956,226 [ii] On November 4, 2021, the Company issued 1,000,000 1,000,000 500,000 0.13 500,000 0.19 1,000,000 1,000,000 500,000 0.13 500,000 0.19 1,000,000 1,000,000 500,000 0.13 500,000 0.19 1,361 [iii] On November 26, 2021, the Company closed a non-brokered private placement and issued 1,375,499 0.55 756,524 0.75 26,656 [iv] During the three months ended January 31, 2022, upon exercise of common share purchase warrants, the Company issued an aggregate 15,159,448 0.19 2,279,136 2,880,295 200,000 0.05 7,830 10,000 30,000 0.30 6,981 9,000 15,389,448 2,293,946 2,899,295 2,428,363 [v] On March 10, 2022, the Company issued 1,000,000 units on partial conversion of the June 2021 Convertible Debenture, for a total of 1,000,000 common shares, 500,000 Class A Warrants exercisable at a price of $ 0.13 until June 10, 2026, and 500,000 Class B Warrants exercisable at a price of $ 0.19 until June 10, 2026. On April 27, 2022, the Company issued a further 2,000,000 units on partial conversion of the June 2021 Convertible Debenture, for a total of 2,000,000 common shares, 1,000,000 Class A Warrants exercisable at a price of $ 0.13 until June 10, 2026, and 1,000,000 Class B Warrants exercisable at a price of $ 0.19 until June 10, 2026. [vi] On April 22, 2022, the Company issued a total of 933,333 933,333 0.20 100,000 12,000 [vii] During the three months ended April 30, 2022, upon the exercise of common share purchase warrants, the Company issued an aggregate 929,005 0.19 929,005 1,177,755 2,082,025 0.05 81,354 104,101 30,960 0.30 7,357 9,288 3,191,933 40,000 [viii] During the three months ended April 30, 2022, the Company issued a total of 750,000 0.05 29,715 37,500 22,203 [c] Common share purchase warrants A summary of the changes in the Company’s common share purchase warrants during the six months ended April 30, 2022 are as follows: SUMMARY OF CHANGES IN COMMON SHARE PURCHASE WARRANTS Expiry Date Exercise Price Weighted Average Life (Years) October 31, 2021 Granted Exercised Expired/ Cancelled April 30, 2022 Expiry Date Exercise Price Weighted Average Life (Years) October 31, 2021 Granted Exercised Expired/ Cancelled April 30, 2022 November 22, 2021 CA$ 0.19 – 4,160,021 – (4,080,573 ) (79,448 ) – January 17, 2022 CA$ 0.19 – 7,267,914 – (5,959,396 ) (1,308,518 ) – January 31, 2022 CA$ 0.19 – 5,382,303 – (4,341,906 ) (1,040,397 ) – February 21, 2022 CA$ 0.05 – 1,505,200 – (200,000 ) (1,305,200 ) – March 24, 2022 CA$ 0.19 – 6,341,872 – (4,515,139 ) (1,826,733 ) – March 27, 2022 CA$ 0.05 – 982,025 – (882,025 ) (100,000 ) – April 27, 2022 CA$ 0.19 – 791,395 – (791,395 ) – – May 9, 2022 CA$ 0.05 0.02 1,813,725 – (1,000,000 ) – 813,725 May 30, 2022 CA$ 0.19 0.08 5,223,420 – (276,675 ) – 4,946,745 June 17, 2022 CA$ 0.19 0.13 17,703,506 – (1,393,077 ) – 16,310,429 July 18, 2022 CA$ 0.30 0.22 4,350,000 – (60,960 ) – 4,289,040 August 14, 2022 CA$ 0.05 0.29 200,000 – (200,000 ) – – February 13, 2023 CA$ 0.65 0.79 3,827,601 – – – 3,827,601 April 22, 2024 CA$ 0.20 1.98 – 933,333 – – 933,333 Subtotal 59,548,982 933,333 (23,701,146 ) (5,660,296 ) 31,120,873 Weighted average exercise price CA$ 0.22 CA$ 0.20 CA$ 0.18 CA$ 0.16 CA$ 0.26 November 27, 2022 US$ 0.75 0.58 – 1,375,499 – – 1,375,499 June 10, 2026 US$ 0.13 4.12 – 3,000,000 – – 1,500,000 June 10, 2026 US$ 0.19 4.12 – 3,000,000 – – 1,500,000 Subtotal – 7,375,499 – – 4,375,499 Weighted average exercise price – US$ 0.27 – – US$ 0.27 Total 59,548,982 8,308,832 (23,701,146 ) (5,660,296 ) 38,496,372 A summary of the changes in the Company’s common share purchase warrants during the six months ended April 30, 2021 are as follows: Expiry Date Exercise Price Weighted Average Life (Years) October 31, 2020 Granted Exercised Expired/ Cancelled April 30, 2021 August 31, 2021 * CA$ 0.21 0.34 3,643,791 – – – 3,643,791 November 22, 2021 CA$ 0.19 0.56 – 5,599,171 – – 5,599,171 January 17, 2022 CA$ 0.19 0.71 – 7,337,914 – – 7,337,914 January 31, 2022 CA$ 0.19 0.75 – 5,382,303 – – 5,382,303 February 21, 2022 CA$ 0.05 0.81 1,505,200 – – – 1,505,200 March 24, 2022 CA$ 0.19 0.90 – 6,554,172 – – 6,554,172 March 27, 2022 CA$ 0.05 0.91 1,482,025 – – – 1,482,025 April 27, 2022 CA$ 0.19 0.99 – 851,395 – – 851,395 May 9, 2022 CA$ 0.05 1.02 2,368,626 – – – 2,368,626 August 14, 2022 CA$ 0.05 1.29 1,110,000 – (400,000 ) – 710,000 Total 10,109,642 25,724,955 (400,000 ) – 35,434,597 Weighted average exercise price CA$ 0.11 CA$ 0.19 CA$ 0.05 – CA$ 0.17 * The Company received approval of the TSX-V on January 13, 2021 and amended the expiry date of 3,643,791 extending the expiry date from January 17, 2021 to August 31, 2021 0.30 [d] Stock options The Company has adopted an incentive stock option plan, effective on August 8, 2017 and as amended on August 8, 2018, under the rules of the TSX-V pursuant to which it is authorized to grant stock options to executive officers, directors, employees and consultants, enabling them to acquire up to 20 Stock options granted are subject to a maximum term of 5 years. All options granted shall vest immediately, except for those options granted to persons performing investor relations activities for the Company On June 11, 2021, the Company adopted the 2021 Equity Incentive Plan which replaces the 2017 Stock Option for providing stock-based compensation to directors, officers, employees, consultants, and advisors of the Company and no further options will be granted under the 2017 Stock Option Plan. Under the 2021 Equity Incentive Plan, the Company is authorized to issue up 27,312,368 5,980,000 1,730,000 33,292,368 2,9,042,368 On December 30, 2020, the Company granted 15,650,000 0.13 9,500,000 6,150,000 On August 30, 2021, the Company granted 21,700,000 0.70 five years On October 1, 2021, the Company granted 1,450,000 0.50 five years On December 3, 2021, the Company granted 250,000 0.58 five years On March 7, 2022, the Company granted 500,000 0.40 five years On April 8, 2022, the Company granted 500,000 0.40 five years As at April 30, 2022, 9,092,368 During the six months April 30, 2022, the Company recognized a stock-based compensation totaling $ 433,829 nil The weighted average grant date fair value of the stock options granted during the six months ended April 30, 2022 was CA$ 0.37 0.09 SCHEDULE OF ASSUMPTIONS USED 2022 2021 Risk free rate of interest 1.34 2.59 0.20 1.07 Expected life of options 5 2 5 Exercise price of options CA$ 0.40 0.58 CA$ 0.13 0.70 Expected annualized volatility 134.93 136.08 130.88 140.05 Expected dividend rate Nil Nil A summary of the changes in the Company’s stock options during the six months ended April 30, 2022 are as follows: SCHEDULE OF STOCK OPTIONS ACTIVITY Expiry Date Exercise Price Weighted Average Life (Years) Outstanding as at October 31, 2021 Granted Exercised Expired/ Cancelled Outstanding as at April 30, 2022 Vested as at April 30, 2022 March 27, 2022 0.05 – 1,500,000 – (750,000 ) (750,000 ) – – December 30, 2022 0.13 0.67 6,000,000 – – (150,000 ) 5,850,000 5,850,000 August 12, 2023 0.05 1.28 2,290,000 – – (750,000 ) 1,540,000 1,540,000 December 3, 2023 0.05 1.59 6,450,000 – – (1,000,000 ) 5,450,000 5,450,000 May 22, 2024 0.12 2.06 7,900,000 – – (850,000 ) 7,050,000 7,050,000 November 3, 2024 0.15 2.52 700,000 – – – 700,000 700,000 November 24, 2024 0.16 2.57 320,000 – – (300,000 ) 20,000 20,000 March 26, 2025 0.11 2.91 100,000 – – – 100,000 100,000 April 23, 2025 0.12 2.98 3,350,000 – – (250,000 ) 3,100,000 3,100,000 December 30, 2025 0.13 3.67 9,500,000 – – – 9,500,000 9,500,000 August 30, 2026 0.70 4.34 21,700,000 – – (200,000 ) 21,500,000 21,350,000 October 1, 2026 0.50 4.42 1,450,000 – – – 1,450,000 1,450,000 December 3, 2026 0.58 4.60 – 250,000 – – 250,000 250,000 March 7, 2027 0.40 4.85 – 500,000 – – 500,000 500,000 April 8, 2027 0.40 4.94 – 500,000 – – 500,000 500,000 Total 61,260,000 1,250,000 (750,000 ) (4,250,000 ) 57,510,000 57,360,000 Weighted average exercise price CA$ 0.33 CA$ 0.44 CA$ 0.05 CA$ 0.11 CA$ 0.34 CA$ 0.33 Aggregate intrinsic value $ 19,994,025 $ (2,149,050 ) $ (2,102,148 ) Weighted average remaining life 3.46 3.15 3.15 A summary of the changes in the Company’s nonvested stock options during the six months ended April 30, 2022 are as follows: SCHEDULE OF NONVESTED STOCK OPTIONS Expiry Date Fair Value Per Share Weighted Average Life (Years) Nonvested as at October 31, 2021 Granted Vested Expired/ Cancelled Nonvested as at April 30, 2022 December 30, 2022 0.07 1.16 162,500 – (162,500 ) – – August 30, 2026 0.56 4.83 300,000 – (150,000 ) – 150,000 Total 462,500 – (312,500 ) – 150,000 Weighted average grant date fair value – per option CA$ 0.39 – CA$ 0.30 – CA$ 0.56 Weighted average grant date fair value – total $ 144,131 – $ 74,063 – $ 65,463 A summary of the changes in the Company’s stock options during the six months ended April 30, 2021 are as follows: Expiry Date Exercise Price Weighted Average Life (Years) Outstanding as at October 31, 2020 Granted Exercised Expired/ Cancelled Outstanding as at April 30, 2021 Vested as at April 30, 2021 February 11, 2021 0.05 0.03 800,000 – – (800,000 ) – – August 16, 2021 0.05 0.54 600,000 – – – 600,000 600,000 March 27, 2022 0.05 1.15 1,750,000 – – – 1,750,000 1,750,000 August 26, 2022 0.13 – 500,000 – – (500,000 ) – – December 30, 2022 0.13 1.91 – 6,150,000 – (6,150,000 ) – – April 19, 2023 0.05 2.21 800,000 – – – 800,000 800,000 August 12, 2023 0.05 2.53 3,120,000 – (100,000 ) – 3,020,000 3,020,000 December 3, 2023 0.05 2.84 7,000,000 – – – 7,000,000 7,000,000 May 22, 2024 0.12 3.31 7,950,000 – – – 7,950,000 7,950,000 November 3, 2024 0.15 3.76 700,000 – – – 700,000 700,000 November 24, 2024 0.16 3.82 900,000 – – – 900,000 900,000 March 26, 2025 0.11 4.15 300,000 – – – 300,000 300,000 April 23, 2025 0.12 4.23 4,000,000 – – (300,000 ) 3,700,000 3,700,000 December 30, 2025 0.13 4.92 – 9,500,000 – (9,500,000 ) – – Total 28,420,000 15,650,000 (100,000 ) (17,250,000 ) 26,720,000 26,720,000 Weighted average exercise price CA$ 0.09 CA$ 0.13 CA$ 0.05 CA$ 0.13 CA$ 0.09 CA$ 0.09 Aggregate intrinsic value $ 801,922 $ 597,721 $ 597,721 Weighted average remaining life 3.18 2.78 2.78 [e] Share-based payments and other reserves The share-based payments and other reserves are used to recognize the fair value of stock options granted to directors, officers, employees and consultants as part of their remuneration, as well as those of broker warrants issued in relation to the Company’s financings. When stock options and broker warrants are subsequently exercised, the fair value of such stock options and broker warrants in additional paid-in capital is credited to share capital. Common share purchase warrants attached to units as part of a unit placement were assigned a $ nil On November 1, 2021, the Company’s functional currency change resulted in the reclassification of its outstanding warrants and broker warrants denominated in Canadian dollars as a derivative liability. The fair value of outstanding broker warrants was reversed out of additional paid-in capital. On November 1, 2021, the Company’s functional currency change resulted in the reclassification of the June 2021 Convertible Debenture from a hybrid financial instrument to a convertible debt instrument with a beneficial conversion feature. The value of the embedded derivative liability was reclassified to additional paid-in capital. [f] Obligations to issue shares As at April 30, 2022, the Company received advance share subscriptions in the amount of $ 388,701 209,827 [g] Dilutive common shares As at April 30, 2022, potentially dilutive common shares relating to common share purchase warrants and options outstanding totaling 96,006,372 120,808,982 | 14. SHARE CAPITAL [a] Authorized capital The authorized share capital consists of 1,000,000,000 0.001 [b] Common shares issued Fiscal 2020 [i] On December 20, 2019, the Company exercised its right to call, subject to acceleration provisions, all outstanding common share purchase warrants set to expire between May 7, 2020 and May 13, 2021. The expiry was amended to January 19, 2020. This expiry date was then extended to February 19, 2020 35,472,661 0.08 24,794,484 4,864,000 0.05 [ii] On January 17, 2020, the Company closed a non-brokered private placement consisting of 3,643,792 0.15 546,569 416,719 52,922 39,722 Each unit consists of one common share and one common share purchase warrant exercisable at a price of CA$ 0.21 41,275 [iii] On May 26, 2020, the Company issued a total of 500,000 37,000 26,401 19,775 [iv] On September 10, 2020, the Company announced a non-brokered private placement of up to 53,846,154 0.13 7,000,000 Each unit is comprised of one common share and one common share purchase warrant exercisable at CA$0.19 per common share for a period of one year. 747,392 596,872 [note 14[f]] Fiscal 2021 [i] In connection with the non-brokered private placement announced on September 10, 2020: On November 20, 2020, the Company closed the first tranche of the non-brokered private placement, issuing 5,599,171 0.13 727,892 556,876 On January 15, 2021, the Company closed the second tranche of the non-brokered private placement, consisting of 7,337,914 0.13 953,930 749,435 39,996 On January 29, 2021, the Company closed the third tranche of the non-brokered private placement consisting of 5,382,303 0.13 699,699 547,496 WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated On March 24, 2021, the Company closed the fourth tranche of the non-brokered private placement consisting of 6,554,172 0.13 852,042 678,270 On April 27, 2021, the Company closed the fifth and final tranche of the non-brokered private placement consisting of 851,395 0.13 110,681 89,237 In total, the Company issued an aggregate 25,724,955 0.13 3,344,244 2,621,314 Each unit issued consists of one common share and one common share purchase warrant entitling the holder to acquire a further common share at a price of CA$0.19 for a period of one year from the closing date of the respective financing tranche. 195,614 [ii] On May 5, 2021, the Company announced a non-brokered private placement priced at CA$ 0.13 3,000,000 5,223,420 0.13 679,044 561,844 17,853,506 0.13 2,320,956 1,880,687 23,076,926 0.13 3,000,000 2,442,531 Each unit issued consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.19 for a period of one year from the date of closing of the respective financing tranche. 154,336 [iii] On May 18, 2021, the Company issued a total of 1,360,959 263,973 26,286 [iv] On June 7, 2021, the Company issued 1,538,461 0.24 369,231 305,832 [v] On July 16, 2021, the Company closed a non-brokered private placement and issued 4,350,000 0.20 870,000 690,860 Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.30 for a period of one year from the date of closing. 48,319 [vi] On August 11, 2021, the Company closed a non-brokered private placement and issued 3,827,601 0.55 0.44 2,105,180 1,683,336 Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.65 (US$0.52) for a period of eighteen months from the date of closing. 116,479 [vii] During the year ended October 31, 2021, the Company issued a total of 7,014,969 0.05 0.21 1,120,130 887,520 525,173 [viii] During the year ended October 31, 2021, the Company issued a total of 2,630,000 0.05 0.16 175,800 140,734 [ix] With respect to the exercises of common share purchase warrants and options, the Company reclassified $ 4,291 121,932 WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated [x] Pursuant to an agreement entered on August 29, 2018 and which was approved by the TSX-V on September 12, 2018, a company controlled by a director and officer is eligible to receive up to 5 5 9,163,425 0.65 5,956,226 4,796,832 [c] Common share purchase warrants A summary of the changes in the Company’s common share purchase warrants during the year ended October 31, 2021 are as follows: SUMMARY OF CHANGES IN COMMON SHARE PURCHASE WARRANTS Expiry Date Exercise Price (CA$) Weighted Average Life (Years) October 31, Granted Exercised Expired/ Cancelled October 31, 2021 August 31, 2021* 0.21 – 3,643,791 - (3,118,618 ) (525,173 ) – November 22, 2021 0.19 0.14 – 5,599,171 (1,439,150 ) – 4,160,021 January 17, 2022 0.19 0.29 – 7,337,914 (70,000 ) – 7,267,914 January 31, 2022 0.19 0.33 – 5,382,303 – – 5,382,303 February 21, 2022 0.05 0.39 1,505,200 – – – 1,505,200 March 24, 2022 0.19 0.48 – 6,554,172 (212,300 ) – 6,341,872 March 27, 2022 0.05 0.49 1,482,025 – (500,000 ) – 982,025 April 27, 2022 0.19 0.57 – 851,395 (60,000 ) – 791,395 May 9, 2022 0.05 0.61 2,368,626 – (554,901 ) – 1,813,725 May 30, 2022 0.19 0.66 – 5,223,420 – – 5,223,420 June 17, 2022 0.19 0.71 – 17,853,506 (150,000 ) – 17,703,506 July 18, 2022 0.30 0.79 – 4,350,000 – – 4,350,000 August 14, 2022 0.05 0.87 1,110,000 – (910,000 ) – 200,000 February 13, 2023 0.65 1.37 – 3,827,601 – – 3,827,601 Total 10,109,642 56,979,482 (7,014,969 ) (525,173 ) 59,548,982 Weighted average exercise price CA$ 0.11 CA$ 0.23 CA$ 0.16 CA$ 0.21 CA$ 0.22 * The Company received approval of the TSX-V on January 13, 2021 and amended the expiry date of 3,643,791 warrants, extending the expiry date from January 17, 2021 to August 31, 2021, subject to acceleration if the closing price of the Company’s shares exceeds CA$ 0.30 per common share for at least 10 consecutive trading days. A summary of the changes in the Company’s common share purchase warrants during the year ended October 31, 2020 are as follows: Expiry Date Exercise Price Weighted Average Life (Years) October 31, 2019 Granted Exercised Expired/ Cancelled October 31, 2020 January 17, 2021 0.21 – – 3,643,791 – – 3,643,791 February 21, 2022 0.05 2.31 1,505,200 – – – 1,505,200 March 27, 2022 0.05 2.41 3,426,025 – (1,944,000 ) – 1,482,025 May 9, 2022 0.05 2.52 5,088,626 – (2,720,000 ) – 2,368,626 August 14, 2022 0.05 2.79 1,310,000 – (200,000 ) – 1,110,000 May 7, 2020* 0.07 – 3,100,000 – (3,000,000 ) (100,000 ) – October 4, 2020* 0.08 – 5,016,000 – (3,425,000 ) (1,591,000 ) – November 30, 2020* 0.08 – 6,169,926 – (3,091,383 ) (3,078,543 ) – January 23, 2021* 0.08 – 6,388,435 – (3,409,160 ) (2,979,275 ) – March 29, 2021* 0.08 – 8,188,046 – (4,496,710 ) (3,691,336 ) – May 13, 2021* 0.08 – 31,404,738 – (18,050,408 ) (13,354,330 ) – Total 71,596,996 3,643,791 (40,336,661 ) (24,794,484 ) 10,109,642 Weighted average exercise price CA$ 0.07 CA$ 0.21 CA$ 0.08 CA$ 0.08 CA$ 0.11 * On December 20, 2019, the Company exercised its right to call, subject to acceleration provisions, all outstanding warrants set to expire between May 7, 2020 and May 13, 2021. The expiry was amended to January 19, 2020. This expiry date was then extended to February 19, 2020. Any unexercised warrants were voided and of no value after February 19, 2020. WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated [d] Stock options The Company has adopted an incentive stock option plan, effective on August 8, 2017 and as amended on August 8, 2018, under the rules of the TSX-V pursuant to which it is authorized to grant stock options to executive officers, directors, employees and consultants, enabling them to acquire up to 20% Stock options granted are subject to a maximum term of 5 years. All options granted shall vest immediately, except for those options granted to persons performing investor relations activities for the Company. On June 11, 2021, the Company adopted the 2021 Equity Incentive Plan which replaces the 2017 Stock Option for providing stock-based compensation to directors, officers, employees, consultants, and advisors of the Company and no further options will be granted under the 2017 Stock Option Plan. Under the 2021 Equity Incentive Plan, the Company is authorized to issue up 27,312,368 1,730,000 During the year ended October 31, 2020, the Company granted 6,600,000 0.11 0.16 two five years On December 30, 2020, the Company granted 15,650,000 0.13 9,500,000 6,150,000 On August 30, 2021, the Company granted 21,700,000 0.70 five years On October 1, 2021, the Company granted 1,450,000 0.50 five years WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated As at October 31, 2021, the maximum number of common shares available under the 2021 Equity Incentive Plan was 29,042,368 5,892,368 During the year ended October 31, 2021, the Company recognized a net stock-based compensation totaling $ 11,051,124 666,259 The weighted average grant date fair value of the stock options granted during the year ended October 31, 2021 was CA$ 0.36 0.14 SCHEDULE OF ASSUMPTIONS USED 2021 2020 Risk free rate of interest 0.20 1.07 % 0.43 1.51 % Expected life of options 2 5 5 Exercise price of options CA$ 0.13 0.70 CA$ 0.11 0.16 Expected annualized volatility 130.88 140.05 % 120.13 188.46 % Expected dividend rate Nil Nil A summary of the changes in the Company’s stock options during the year ended October 31, 2021 are as follows: SCHEDULE OF STOCK OPTIONS ACTIVITY Expiry Date Exercise Price Weighted Average Life (Years) Outstanding as at October 31, 2020 Granted Exercised Expired/ Cancelled Outstanding as at October 31, 2021 Vested as at October 31, 2021 February 11, 2021 0.05 – 800,000 – – (800,000 ) – – August 16, 2021 0.05 – 600,000 – (600,000 ) – – – March 27, 2022 0.05 0.40 1,750,000 – (250,000 ) – 1,500,000 1,500,000 August 26, 2022 0.13 – 500,000 – – (500,000 ) – – December 30, 2022 0.13 1.16 – 6,150,000 (100,000 ) (50,000 ) 6,000,000 5,837,500 April 19, 2023 0.05 – 800,000 – – (800,000 ) – – August 12, 2023 0.05 1.78 3,120,000 – (600,000 ) (230,000 ) 2,290,000 2,290,000 December 3, 2023 0.05 2.09 7,000,000 – (550,000 ) – 6,450,000 6,450,000 May 22, 2024 0.12 2.56 7,950,000 – – (50,000 ) 7,900,000 7,900,000 November 3, 2024 0.15 3.01 700,000 – – – 700,000 700,000 November 24, 2024 0.16 3.07 900,000 – (30,000 ) (550,000 ) 320,000 320,000 March 26, 2025 0.11 3.40 300,000 – (200,000 ) – 100,000 100,000 April 23, 2025 0.12 3.48 4,000,000 – (300,000 ) (350,000 ) 3,350,000 3,350,000 December 30, 2025 0.13 4.17 – 9,500,000 – – 9,500,000 9,500,000 August 30, 2026 0.70 4.83 – 21,700,000 – – 21,700,000 21,400,000 October 1, 2026 0.50 4.92 – 1,450,000 – – 1,450,000 1,450,000 Total 28,420,000 38,800,000 (2,630,000 ) (3,330,000 ) 61,260,000 60,797,500 Weighted average exercise price CA$0.09 CA$0.46 CA$0.07 CA$0.09 CA$0.33 CA$0.32 Aggregate intrinsic value $ 19,994,025 $ 19,908,026 Weighted average remaining life 3.46 3.46 WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated A summary of the changes in the Company’s nonvested stock options during the year ended October 31, 2021 are as follows: SCHEDULE OF NONVESTED STOCK OPTIONS Expiry Date Fair Value Per Share Weighted Average Life (Years) Nonvested as at October 31, 2020 Granted Vested Expired/ Cancelled Nonvested as at October 31, 2021 December 30, 2022 0.07 1.16 – 650,000 487,500 – 162,500 August 30, 2026 0.56 4.83 – 300,000 – – 300,000 Total – 950,000 487,500 – 462,500 Weighted average grant date fair value – per option – CA$0.22 CA$0.07 – CA$0.39 Weighted average grant date fair value – total – $ 170,781 $ 26,650 – $ 144,131 A summary of the changes in the Company’s stock options during the year ended October 31, 2020 are as follows: Expiry Date Exercise Price Weighted Average Life (Years) Outstanding as at October 31, 2019 Granted Exercised Expired/ Cancelled Outstanding as at October 31, 2020 Vested as at October 31, 2020 May 31, 2020 0.08 – 400,000 – (400,000 ) – – – June 3, 2020 0.05 – 550,000 – – (550,000 ) – – February 11, 2021 0.05 0.53 1,300,000 – – (500,000 ) 800,000 800,000 August 16, 2021 0.05 1.04 1,200,000 – – (600,000 ) 600,000 600,000 March 27, 2022 0.05 1.65 2,000,000 – – (250,000 ) 1,750,000 1,750,000 August 26, 2022 0.13 – – 500,000 – – 500,000 – April 19, 2023 0.05 2.72 800,000 – – – 800,000 800,000 August 12, 2023 0.05 3.03 3,780,000 – (100,000 ) (560,000 ) 3,120,000 3,120,000 December 3, 2023 0.05 3.35 9,600,000 – – (2,600,000 ) 7,000,000 7,000,000 May 22, 2024 0.12 3.81 10,000,000 – – (2,050,000 ) 7,950,000 7,950,000 November 3, 2024 0.15 4.27 – 700,000 – – 700,000 700,000 November 24, 2024 0.16 4.32 – 900,000 – – 900,000 775,000 March 26, 2025 0.11 4.66 – 300,000 – – 300,000 300,000 April 23, 2025 0.12 4.73 – 4,200,000 – (200,000 ) 4,000,000 3,625,000 Total 29,630,000 6,600,000 (500,000 ) (7,310,000 ) 28,420,000 27,420,000 Weighted average exercise price CA$0.07 CA$0.13 CA$0.07 CA$0.07 CA$0.09 CA$0.09 Aggregate intrinsic value $ 801,922 $ 866,441 Weighted average remaining life 3.18 3.18 The intrinsic value of options exercised during the year ended October 31, 2021 was $ 962,936 28,533 [e] Share-based payments and other reserves The share-based payments and other reserves are used to recognize the fair value of stock options granted to executive officers, directors, employees and consultants as part of their remuneration, as well as those of broker warrants issued in relation to the Company’s financings. When stock options and broker warrants are subsequently exercised, the fair value of such stock options and broker warrants in reserves is credited to share capital. Common share purchase warrants attached to units as part of a unit placement are assigned a $nil value. The residual method is used to calculate the fair value of the warrant component of units issued, whereby the residual of the private placement proceeds less the fair value of the share component is assigned as the fair value of the warrants. WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated In addition, the Company has allocated the intrinsic value of the beneficial conversion feature of the July 2021 Convertible Debenture capped at the face value of CA$ 100,000 79,542 [f] Obligations to issue shares As at October 31, 2021, the Company received advance share subscriptions in the amount of $ 209,827 596,872 [note 19[iv]] [g] Dilutive common shares For the year ended October 31, 2021, potentially dilutive common shares relating to common share purchase warrants and options outstanding totaling 120,808,982 38,529,642 |
CAPITAL MANAGEMENT
CAPITAL MANAGEMENT | 12 Months Ended |
Oct. 31, 2021 | |
Capital Management | |
CAPITAL MANAGEMENT | 15. CAPITAL MANAGEMENT The Company classifies the components of shareholders’ equity as capital, which at October 31, 2021, was a deficiency of $ 6,770,038 2,079,903 WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated |
FINANCIAL INSTRUMENTS AND FINAN
FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT | 6 Months Ended | 12 Months Ended |
Apr. 30, 2022 | Oct. 31, 2021 | |
Fair Value Disclosures [Abstract] | ||
FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT | 14. FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT The Company’s classification of its financial instruments is as follows: SCHEDULE OF CLASSIFICATION OF FINANCIAL INSTRUMENTS Financial Instruments Measurement Method Associated Risk Fair Value at April 30, 2022 ($) Cash FVTPL Credit and currency 774,409 Other receivables Amortized cost Credit and currency 50,765 Subscription receivable Amortized cost Credit and currency 185,000 Deposits held by related parties Amortized cost Credit and currency 388,757 Accounts payable and accrued liabilities Amortized cost Currency 2,715,924 Due to related parties Amortized cost Currency 1,253,280 Convertible debenture, net Amortized cost Currency 1,783,584 Warrant liability FVTPL Currency 2,468,261 [a] Fair value The fair value of financial instruments is the amount of consideration that would be agreed upon in an arm’s length transaction between knowledgeable, willing parties who are under no compulsion to act. The fair value of current financial instruments except derivative liability approximates their carrying values as long as they are short-term in nature or bear interest at market rates. [b] Fair value hierarchy Financial instruments that are held at fair value are categorized based on a valuation hierarchy which is determined by the valuation methodology utilized. The fair value hierarchy under US GAAP is based on the following three levels of inputs, of which the first two are considered observable and the last unobservable: Level 1 Level 2 Level 3 The Company evaluates its financial instruments and other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815. The result of this accounting treatment is that the fair value of the embedded derivative is marked-to-market at each balance sheet date and recorded as a liability and the change in fair value is recorded in the consolidated statements of loss and comprehensive loss. Upon conversion or exercise of a derivative instrument, the instrument is marked to market at the conversion date and then that fair value is reclassified to equity. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instruments that become subject to reclassification are reclassified at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified on the consolidated balance sheets as current or non-current based on whether or not settlement of the derivative instrument is expected within 12 months of the balance sheet date. The Company uses the Black-Scholes Option Pricing Model to value derivative liabilities. This model uses Level 3 inputs in the fair value hierarchy established by ASC 820 Fair Value Measurement. The inputs used in determining the fair value of the embedded derivative are disclosed in note 12[e] [c] Financial risk management The Company’s board of directors has the overall responsibility for the establishment and oversight of the Company’s risk management framework. The Company’s risk management policies are established to identify and analyze the risks faced by the Company, to set appropriate risk limits and controls, and to monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and in response to the Company’s activities. Management regularly monitors compliance with the Company’s risk management policies and procedures and reviews the adequacy of the risk management framework in relation to the risks faced by the Company. In the normal course of operations, the Company is exposed to various risks such interest rate, foreign exchange, commodity, credit, and liquidity. To manage these risks, management determines what activities must be undertaken to minimize potential exposure to risks. The objectives of the Company in managing risks are as follows: ● Maintaining sound financial condition: ● Financing operations; and ● Ensuring liquidity to all operations. In order to satisfy these objectives, the Company has adopted the following policies: ● Prepare budget documents at prevailing market rates to ensure clear corporate alignment to performance management and achievement of targets; ● Recognize and observe the extent of operating risk within the business; and ● Identify the magnitude of the impact of market risk factors on the overall risk of the business and take advantage of natural risk reductions that arise from these relationships. [i] Interest rate risk Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in the market interest rates. The Company is exposed to interest rate risk on its cash on deposits with banks and, from time to time, on its holdings of short-term investments. As of April 30, 2022, the Company had $ 774,409 462,360 no [ii] Foreign currency risk The Company is exposed to foreign currency risk on fluctuations related to cash, other receivables, accounts payable, due to related parties and convertible debenture that are denominated in Canadian dollars. The Company has not entered into foreign exchange derivative contracts. A significant change in the currency exchange rates between the US dollar relative to the Canadian dollar could have a material effect on the Company’s financial position, results of operations, or cash flows. Based on the Company net exposures as at April 30, 2022, assuming that all other variables remain constant, a 5 78,312 The Company had the following assets and liabilities denominated in Canadian dollars: SCHEDULE OF FOREIGN CURRENCY RISK April 30, 2022 CA$ Cash 208,683 Other receivables 64,930 Accounts payable and accrued liabilities (1,511,845 ) Due to related parties (765,409 ) Total (2,003,641 ) [iii] Commodity price risk The value of the Company’s magnesium production business and its exploration and evaluation assets are dependent on the price of magnesium and the outlook for this mineral. Market prices for these metals historically have fluctuated widely and are affected by numerous factors outside the Company’s control, including but not limited to, levels of worldwide production, short-term changes in supply and demand, industrial and retail demand, as well as certain other factors related specifically to magnesium. If magnesium prices decline for a prolonged period below the cost of production, it may not be economically feasible to continue towards production. [iv] Credit risk Credit risk is the risk of loss if counterparties do not fulfill their contractual obligations and arises principally from trade receivables. The Company’s credit risk is primarily attributable to cash, and deposits held by related parties. The Company limits its exposure to credit risk on cash as these financial instruments are held with major Canadian and international banks. Other receivables consist primarily of GST due from the Federal Government of Canada. Management believes the credit risk concentration with respect to other receivables is remote. The carrying amount of financial assets recorded in the financial statements, net of any allowances, represents the Company’s maximum exposure to credit risk. [v] Liquidity risk Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they come due. The Company’s exposure to liquidity risk is dependent on its purchasing commitments and obligations and its ability to raise funds to meet commitments and sustain operations. The Company manages liquidity risk by continuously monitoring its actual and forecasted working capital requirements to ensure there is capital to meet short-term and long-term obligations. As of April 30, 2022 and October 31, 2021, the Company had working capital deficiency of $ 7,172,573 and $ 9,657,316 , respectively. As disclosed in note 1 | 16. FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT The Company’s classification of its financial instruments is as follows: SCHEDULE OF CLASSIFICATION OF FINANCIAL INSTRUMENTS Financial Instruments Measurement Method Associated Risk Fair Value at October 31, 2021 ($) Cash FVTPL Credit and currency 462,360 Amounts receivable Amortized cost Credit and currency 151,485 Deposits held by related parties Amortized cost Credit and currency 486,462 Accounts payable and accrued liabilities Amortized cost Currency 1,989,316 Due to related parties Amortized cost Currency 1,026,817 Convertible debenture Amortized cost Currency 107 Convertible debenture - derivative liability FVTPL Currency 7,449,700 [a] Fair value The fair value of financial instruments is the amount of consideration that would be agreed upon in an arm’s length transaction between knowledgeable, willing parties who are under no compulsion to act. The fair value of current financial instruments except derivative liability approximates their carrying values as long as they are short-term in nature or bear interest at market rates. [b] Fair value hierarchy Financial instruments that are held at fair value are categorized based on a valuation hierarchy which is determined by the valuation methodology utilized. The fair value hierarchy under US GAAP is based on the following three levels of inputs, of which the first two are considered observable and the last unobservable: Level 1 Level 2 Level 3 Cash and cash equivalents are valued using a market approach based upon unadjusted quoted prices for identical assets in an active market obtained from securities exchanges. As at October 31, 2021, the fair value of cash and cash equivalents held by the Company was based on Level 1 of the fair value hierarchy. There were no transfers between Levels 1 and 2 during the period. The Company evaluates its financial instruments and other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815. The result of this accounting treatment is that the fair value of the embedded derivative is marked-to-market at each balance sheet date and recorded as a liability and the change in fair value is recorded in the consolidated statements of loss and comprehensive loss. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instruments that become subject to reclassification are reclassified at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not settlement of the derivative instrument is expected within 12 months of the balance sheet date. WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated The Company uses the Black-Scholes Option Pricing Model to value derivative liabilities. This model uses Level 3 inputs in the fair value hierarchy established by ASC 820 Fair Value Measurement. The inputs used in determining the fair value of the embedded derivative are disclosed in note 13[d] [c] Financial risk management The Company’s board of directors has the overall responsibility for the establishment and oversight of the Company’s risk management framework. The Company’s risk management policies are established to identify and analyze the risks faced by the Company, to set appropriate risk limits and controls, and to monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and in response to the Company’s activities. Management regularly monitors compliance with the Company’s risk management policies and procedures and reviews the adequacy of the risk management framework in relation to the risks faced by the Company. In the normal course of operations, the Company is exposed to various risks such interest rate, foreign exchange, commodity, credit, and liquidity. To manage these risks, management determines what activities must be undertaken to minimize potential exposure to risks. The objectives of the Company in managing risks are as follows: ● Maintaining sound financial condition: ● Financing operations; and ● Ensuring liquidity to all operations. In order to satisfy these objectives, the Company has adopted the following policies: ● Prepare budget documents at prevailing market rates to ensure clear corporate alignment to performance management and achievement of targets; ● Recognize and observe the extent of operating risk within the business; and ● Identify the magnitude of the impact of market risk factors on the overall risk of the business and take advantage of natural risk reductions that arise from these relationships. [i] Interest rate risk Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in the market interest rates. The Company is exposed to interest rate risk on its cash on deposits with banks and, from time to time, on its holdings of short-term investments. As of October 31, 2021, the Company had $ 462,360 39,571 no [ii] Foreign currency risk The Company is exposed to foreign currency risk on fluctuations related to cash, deposits held by related parties, accounts payable, due to related parties and convertible debenture that are denominated in US dollars. The Company has not entered into foreign exchange derivative contracts. A significant change in the currency exchange rates between the Canadian dollar relative to the US dollar could have a material effect on the Company’s financial position, results of operations, or cash flows. WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated Based on the Company net exposures as at October 31, 2021, assuming that all other variables remain constant, a 5% 262,941 SCHEDULE OF FOREIGN CURRENCY RISK October 31, 2021 $ Cash 186,627 Deposits held by related parties 486,462 Accounts payable and accrued liabilities (773,011 ) Due to related parties (467,500 ) Convertible debenture (1,500,000 ) Total (2,067,422 ) [iii] Commodity price risk The value of the Company’s magnesium production business and its exploration and evaluation assets are dependent on the price of magnesium and the outlook for this mineral. Market prices for these metals historically have fluctuated widely and are affected by numerous factors outside the Company’s control, including but not limited to, levels of worldwide production, short-term changes in supply and demand, industrial and retail demand, as well as certain other factors related specifically to magnesium. If magnesium prices decline for a prolonged period below the cost of production, it may not be economically feasible to continue towards production. [iv] Credit risk Credit risk is the risk of loss if counterparties do not fulfill their contractual obligations and arises principally from trade receivables. The Company’s credit risk is primarily attributable to cash, and deposits held by related parties. The Company limits its exposure to credit risk on cash as these financial instruments are held with major Canadian and international banks. Amounts receivable consist primarily of GST due from the Federal Government of Canada. Management believes the credit risk concentration with respect to amounts receivable is remote. The carrying amount of financial assets recorded in the financial statements, net of any allowances, represents the Company’s maximum exposure to credit risk. [v] Liquidity risk Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they come due. The Company’s exposure to liquidity risk is dependent on its purchasing commitments and obligations and its ability to raise funds to meet commitments and sustain operations. The Company manages liquidity risk by continuously monitoring its actual and forecasted working capital requirements to ensure there is capital to meet short-term and long-term obligations. As of October 31, 2021 and October 31, 2020, the Company had working capital deficiency of $ 9,657,316 2,392,189 note 1 WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated |
SEGMENTED INFORMATION
SEGMENTED INFORMATION | 6 Months Ended | 12 Months Ended |
Apr. 30, 2022 | Oct. 31, 2021 | |
Segment Reporting [Abstract] | ||
SEGMENTED INFORMATION | 15. SEGMENTED INFORMATION The Company focuses on plant operations and magnesium production and continues to move towards the buildout of its pilot plant facility and the development of a full-scale commercial magnesium production facility. The Company also owns mining claims for the exploration and development of mineral property interests. Geographic information for the Company’s assets is as follows: SCHEDULE OF ASSETS INFORMATION April 30, 2022 October 31, 2021 $ $ Canada – property, plant and equipment 3,946,315 2,546,383 United States – property, plant and equipment 31,304 28,321 United States – mineral property costs 93,453 93,453 Property, plant and equipment net 4,071,072 2,668,157 Canada – other assets 392,853 1,554,827 United States – other assets 1,611,578 290,528 Other assets 2,004,431 1,845,355 Total Assets 6,075,503 4,513,512 | 17. SEGMENTED INFORMATION The Company focuses on plant operations and magnesium production and continues to move towards the buildout of its pilot plant facility and the development of a full-scale commercial magnesium production facility. The Company also owns mining claims for the exploration and development of mineral property interests. Geographic information for the Company’s assets is as follows: SCHEDULE OF ASSETS INFORMATION October 31, 2021 October 31, 2020 $ $ Canada – property, plant and equipment 2,546,383 79,436 United States – property, plant and equipment 28,321 – United States – mineral property costs 93,453 93,453 Asset 2,668,157 172,889 Canada – other assets 1,554,827 533,815 United States – other assets 290,528 2,059 1,845,355 535,874 Total Assets 4,513,512 708,763 |
INCOME TAX
INCOME TAX | 12 Months Ended |
Oct. 31, 2021 | |
Income Tax Disclosure [Abstract] | |
INCOME TAX | 18. INCOME TAX Significant items resulting in the difference between the Company’s income tax rate and the federal statutory rate are as follows: SCHEDULE OF EFFECTIVE TAX RATES RECONCILIATION 2021 2020 $ $ Loss for the year (23,549,612 ) (4,672,605 ) Effective statutory rate 33.02 % 31.21 % Expected income tax recovery at statutory rate (7,778,880 ) (1,458,320 ) Net adjustment for deductible and non-deductible amounts 2,636,262 250,196 Foreign exchange effect (9,867 ) (175,597 ) Valuation allowance 5,152,485 1,383,721 Deferred income tax provision (recovery) – – The Company’s deferred tax assets and liabilities are as follows: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITY 2021 2020 $ $ Non-capital loss carry-forwards 5,340,578 2,600,561 Property and equipment (159,673 ) (123,561 ) Lease liability 180,812 103,789 Convertible debenture (509,985 ) – Convertible debenture – derivative liability 2,532,898 – Exploration and evaluation asset 359,700 - Share issue costs - 11,056 Valuation allowance (7,744,330 ) (2,591,845 ) Deferred income tax asset (liability) – – The Company has approximately $ 13,439,000 3,515,000 WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 6 Months Ended | 12 Months Ended |
Apr. 30, 2022 | Oct. 31, 2021 | |
Subsequent Events [Abstract] | ||
SUBSEQUENT EVENTS | 16. SUBSEQUENT EVENTS Subsequent to April 30 2022, upon exercise of common share purchase warrants, the Company issued an aggregate 3,793,331 0.19 720,733 800,000 0.05 40,000 1,153,414 13,725 Subsequent to April 30, 2022, upon exercise of stock options, the Company issued 300,000 0.05 15,000 250,000 0.13 32,500 On May 9, 2022, the Company closed the first tranche of a non-brokered private placement and issued 1,727,000 units at a price of $ 0.25 per unit for gross proceeds of $ 431,750 . On June 3, 2022, the Company closed the second and final tranche of the non-brokered private placement and issued 740,000 0.25 185,000 2,467,000 616,750 Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of $0.45 for a period of one year from the date of closing . On June 8, 2022, the Company issued 1,000,000 1,000,000 500,000 0.13 500,000 0.19 | 19. SUBSEQUENT EVENTS [i] Subsequent to October 31, 2021, upon exercise of common share purchase warrants, the Company issued an aggregate 15,159,448 0.19 2,880,295 200,000 0.05 10,000 30,000 0.30 9,000 2,428,363 [ii] Pursuant to an agreement entered on August 29, 2018 and which was approved by the TSX-V on September 12, 2018, a company controlled by a director and officer is eligible to receive up to 5% 5 9,163,425 0.65 5,956,226 4,796,832 [iii] On November 4, 2021, the Company issued 1,000,000 1,000,000 500,000 0.13 500,000 0.19 1,000,000 1,000,000 500,000 0.13 500,000 0.19 1,000,000 1,000,000 500,000 0.13 500,000 0.19 [iv] On November 26, 2021, the Company closed a non-brokered private placement and issued 1,375,499 0.55 756,524 0.75 [v] On December 3, 2021, the Company granted 250,000 0.58 five years [vi] On December 13, 2021, the Company’s Form 10 Registration Statement filed with the US SEC was declared effective, and the Company will be subject to the reporting requirements of the Securities Exchange Act of 1934 (the “Exchange Act”). |
SIGNIFICANT ACCOUNTING POLICI_2
SIGNIFICANT ACCOUNTING POLICIES (Policies) | 12 Months Ended |
Oct. 31, 2021 | |
Accounting Policies [Abstract] | |
Principles of consolidation | [a] Principles of consolidation These Financial Statements include the accounts of the Company and its wholly owned and controlled subsidiaries as described in note 2 |
Foreign currency | [b] Foreign currency Items included in the financial statements of each consolidated entity are measured using the currency of the primary economic environment in which the entity operates (the “functional currency”). Foreign currency transactions are translated into the functional currency using the prevailing exchange rates on the dates of transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities not denominated in the functional currency of an entity are recognized in the statements of loss and comprehensive loss. Assets and liabilities of the Company and its subsidiary with a functional currency in Canadian dollars are translated at the period end rates of exchange, and the results of its operations are translated at average rates of exchange for the period. Equity transactions have been translated using historical rates in effect on the date that each transaction occurred. The resulting translation adjustments are included in accumulated other comprehensive income or loss as shareholders’ equity or deficit. Additionally, foreign exchange gains and losses related to certain intercompany loans that are permanent in nature are included in accumulated other comprehensive income or loss. |
Cash and cash equivalents | [c] Cash and cash equivalents Cash and cash equivalents include highly liquid financial instruments that are readily convertible into cash with original maturities of three months or less. |
Property, plant and equipment | [d] Property, plant and equipment Property, plant and equipment (“PP&E”) is carried at cost, less accumulated depreciation and accumulated impairment losses. The cost of an item of PP&E consists of the purchase price, any costs directly attributable to bringing the asset to the location and condition necessary for its intended use and an initial estimate of the costs of dismantling and removing the item and restoring the site on which it is located. Depreciation is provided at rates calculated to write off the cost of PP&E, less their estimated residual value. The depreciation rates and method applicable to each category of property, plant and equipment are as follows: SCHEDULE OF DEPRECIATION RATE Class Rate Computer equipment 55% declining balance Furniture 20% declining balance Plant equipment 20% declining balance Furnace To be determined Leasehold improvement Term of lease Right-of-use assets Term of lease WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated An item of PP&E is derecognized upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on disposal of the asset, determined as the difference between the net disposal proceeds and the carrying amount of the asset, is recognized in profit or loss in the consolidated statements of loss and comprehensive loss. Where an item of PP&E comprises major components with different useful lives, the components are accounted for as separate items. Expenditures incurred to replace a component of an item of PP&E that is accounted for separately, including major inspection and overhaul expenditures, are capitalized. |
Reclamation deposits | [e] Reclamation deposits The Company maintains cash deposits, as required by regulatory bodies, as assurance for the funding of decommissioning costs. These funds are restricted to that purpose and are not available to the Company until the reclamation obligations have been fulfilled and are therefore classified as long-term assets. |
Research and development | [f] Research and development Expenditures on research activities taken to develop a pyro metallurgical process to extract and recover magnesium metal from dolomite are expensed as incurred. Development expenditures are expensed in the period incurred. |
Mineral property acquisition and exploration assets | [g] Mineral property acquisition and exploration assets Mineral property acquisition costs are capitalized when incurred. Acquisition costs include cash consideration and the fair market value of shares issued on the acquisition of mineral property claims. Costs related to the development of mineral reserves are capitalized when it has been determined an ore body can be economically developed. The development stage begins when an ore body is determined to be economically recoverable based on proven and probable reserves and appropriate permits are in place, and ends when the production stage or exploitation of reserves begins. Major mine development expenditures are capitalized, including primary development costs such as costs of building access ways, tailings impoundment, development of water supply and infrastructure developments. Exploration costs include those relating to activities carried out (a) in search of previously unidentified mineral deposits, or (b) at undeveloped concessions. Pre-development activities involve costs incurred in the exploration stage that may ultimately benefit production that are expensed due to the lack of evidence of economic development, which is necessary to demonstrate future recoverability of these expenses. Secondary development costs are incurred for preparation of an ore body for production in a specific ore block or work area, providing a relatively short-lived benefit only to the mine area they relate to, and not to the ore body as a whole. All exploration costs have been expensed. Once production has commenced, capitalized costs will be depleted using the units-of-production method over the estimated life of the proven and probable reserves. If mineral properties are subsequently abandoned or impaired, any capitalized costs will be charged to the consolidated statements of loss and comprehensive loss in that period. The carrying cost of mineral properties is assessed for impairment whenever information or circumstances indicate the potential for impairment. Such evaluations compare estimated future net cash flows with carrying costs and future obligations on an undiscounted basis. If it is determined that the future undiscounted cash flows are less than the carrying value of the property, a write down to the estimated fair value is charged to the consolidated statements of loss and comprehensive loss for the period. Where estimates of future net cash flows are not available and where other conditions suggest impairment, management assesses if the carrying value can be recovered. WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated Management conducted an impairment test on its mineral properties for recoverability and impairment loss during the years ended October 31, 2021 and 2020 and determined that its mineral properties were not impaired. For significant development projects, interest is capitalized as part of the historical cost of developing and constructing assets in accordance with ASC 835-20. Interest is capitalized until the asset is ready for service. Capitalized interest is determined by multiplying the Company’s weighted-average borrowing cost on general debt by the average amount of qualifying costs incurred. Once an asset subject to interest capitalization is completed and placed in service, the associated capitalized interest is expensed through depletion or impairment. |
Impairment of non-financial assets | [h] Impairment of non-financial assets Non-financial assets are evaluated at the end of each reporting period by management for indicators that carrying value is impaired and may not be recoverable. When indicators of impairment are present, non-financial assets are tested for impairment as an individual asset, as part of an asset group or at the reporting unit (“RU”) level. An asset group is the lowest level for which there are identifiable cash flows (i.e. both cash inflows and cash outflows) that are largely independent of the net cash flows of other groups of assets. An RU is an operating segment or one level below an operating segment if certain conditions are met. Impairment tests for non-financial assets subject to depreciation or amortization are applied to individual assets if possible. If this is not possible, then these assets are tested for impairment at the asset group level. An impairment loss is triggered for non-financial assets only if the asset’s, or asset group’s, carrying amount exceeds its recoverable amount (i.e. the carrying amount is greater than the undiscounted cash flows of the asset or asset group). If the carrying amount is not recoverable, then the impairment loss is the difference between the carrying amount of the asset (asset group) and the fair value of the asset (asset group). An impairment loss for an asset group is allocated pro rata to the non-financial assets in the asset group. Impairment losses are recognized in the consolidated statements of loss and comprehensive loss and are not reversed. |
Income taxes | [i] Income taxes The Company accounts for income taxes using the asset and liability method. The asset and liability method provides that deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates. The Company records a valuation allowance to reduce deferred tax assets to the amount that is believed more likely than not to be realized. The Company has adopted the provisions of FASB ASC 740 “Income Taxes” regarding accounting for uncertainty in income taxes. The Company initially recognizes tax positions in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are initially and subsequently measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the tax authority, assuming full knowledge of the position and all relevant facts. Application requires numerous estimates based on available information. The Company considers many factors when evaluating and estimating its tax positions and tax benefits, and its recognized tax positions and tax benefits may not accurately anticipate actual outcomes. As additional information is obtained, there may be a need to periodically adjust the recognized tax positions and tax benefits. These periodic adjustments may have a material impact on the consolidated statements of loss and comprehensive loss. When applicable, the Company classifies penalties and interest associated with uncertain tax positions as a component of income tax expense in its consolidated statements of loss and comprehensive loss. WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated |
Loss per share | [j] Loss per share Basic earnings (loss) per share (“EPS”) is calculated by dividing profit or loss attributable to ordinary equity holders (numerator) by the weighted average number of ordinary shares outstanding (denominator) during the period. The denominator is calculated by adjusting the shares issued at the beginning of the period by the number of shares bought back during the period, multiplied by a time-weighting factor. Diluted EPS is calculated by adjusting the earnings and number of shares for the effects of dilutive options and other dilutive potential units. The effects of anti-dilutive options and potential units are ignored in calculating diluted EPS. All options and potential units are considered anti-dilutive when the Company is in a loss position. |
Share-based payments | [k] Share-based payments The Company has an equity-settled share purchase stock option plan that is described in note 14 The fair value of stock-based payments to non-employees is periodically re-measured until the counterparty performance is complete, and any change therein is recognized over the vesting period of the award and in the same manner as if the Company had paid cash instead of paying with or using equity-based instruments. The cost of the stock-based payments to non-employees that are fully vested and non-forfeitable as at the grant date is measured and recognized at that date, unless there is a contractual term for services in which case such compensation would be amortized over the contractual term. The Company accounts for the granting of stock options to employees using the fair value method whereby all awards to employees will be recorded at fair value on the date of the grant. The fair value of all stock options is expensed over their vesting period with a corresponding increase to additional paid-in capital. Compensation costs for stock-based payments that do not include performance conditions are recognized on a straight-line basis. Compensation cost associated with a share-based award having a performance condition is only recognized over the requisite service period if it is probable. Share-based awards with a performance condition are accrued on an award by award basis. The share-based compensation fair value is determined using an estimated forfeiture rate. Compensation ultimately recognized is revised in subsequent periods to reflect final grant amounts. For employees and consultants who are working on specific capital projects, the share-based compensation is allocated to projects under development. For the remainder of employees and consultants, the compensation is expensed. |
Decommissioning liabilities | [l] Decommissioning liabilities The Company records a liability for the reclamation of its exploration and evaluation interests based on the best estimate of costs for site closure and reclamation activities that the Company is legally or constructively required to remediate, and the liability is recognized at the time the environmental disturbance occurs. The resulting costs are capitalized to the corresponding asset. The fair value of the provision for closure and reclamation liabilities is estimated using expected cash flows, based on engineering and environmental reports prepared by third party industry specialists, discounted at a pre-tax rate specific to the liability. The capitalized amount is amortized on the same basis as the related asset. The liability is adjusted for accretion of the discounted obligation and any changes in the amount or timing of the underlying future cash flows. Significant judgments and estimates are involved in forming expectations of the amount and timing of future site closure and reclamation cash flows. Future restoration costs are reviewed annually and any changes in the estimate are reflected in the present value of the provision at the reporting date. WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated |
Share capital | [m] Share capital The Company records proceeds from share issuances net of issuance costs. Shares issued for consideration other than cash are valued at the quoted price on the date the shares are issued. |
Financial instruments | [n] Financial instruments The Company’s classification of its financial instruments is as follows: Asset or Liability Classification Cash Held-for-trading Amounts receivable Amortized cost Accounts payable Amortized cost Due to related parties Amortized cost Promissory note and convertible debenture Amortized cost Derivative liability Fair value through profit and loss (“FVTPL”) The fair value hierarchy under US GAAP is based on the following three levels of inputs, of which the first two are considered observable and the last unobservable: Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2: Observable inputs other than Level I, quoted prices for similar assets or liabilities in active prices whose inputs are observable or whose significant value drivers are observable; and Level 3: Assets and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s derivative liability is based on Level 3 inputs in the ASC 820 fair value hierarchy. . Derivative Liabilities The Company evaluates its financial instruments and other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815. The result of this accounting treatment is that the fair value of the embedded derivative is marked-to-market at each balance sheet date and recorded as a liability and the change in fair value is recorded in the consolidated statements of loss and comprehensive loss. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instruments that become subject to reclassification are reclassified at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not settlement of the derivative instrument is expected within 12 months of the balance sheet date. The Company uses the Black-Scholes Option Pricing Model to value derivative liabilities. This model uses Level 3 inputs in the fair value hierarchy established by ASC 820 Fair Value Measurement. |
SIGNIFICANT ACCOUNTING POLICI_3
SIGNIFICANT ACCOUNTING POLICIES (Tables) | 12 Months Ended |
Oct. 31, 2021 | |
Accounting Policies [Abstract] | |
SCHEDULE OF DEPRECIATION RATE | Depreciation is provided at rates calculated to write off the cost of PP&E, less their estimated residual value. The depreciation rates and method applicable to each category of property, plant and equipment are as follows: SCHEDULE OF DEPRECIATION RATE Class Rate Computer equipment 55% declining balance Furniture 20% declining balance Plant equipment 20% declining balance Furnace To be determined Leasehold improvement Term of lease Right-of-use assets Term of lease |
PROPERTY, PLANT AND EQUIPMENT (
PROPERTY, PLANT AND EQUIPMENT (Tables) | 6 Months Ended | 12 Months Ended |
Apr. 30, 2022 | Oct. 31, 2021 | |
Property, Plant and Equipment [Abstract] | ||
SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT | SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT Computer Equipment Furniture Leasehold Improvement Furnace & Plant Equipment Vehicle Total $ $ $ $ $ $ Cost Balance, October 31, 2020 32,318 38,916 7,610 28,413 – 107,257 Additions 77,955 11,510 129,257 2,278,205 – 2,496,927 Write-off of equipment (4,245 ) – – – – (4,245 ) Foreign exchange effect 3,601 3,116 2,614 38,108 – 47,439 Balance, October 31, 2021 109,629 53,542 139,481 2,344,726 – 2,647,378 Cost, Beginning Balance 109,629 53,542 139,481 2,344,726 – 2,647,378 Additions 7,008 2,171 107,014 1,456,591 29,215 1,601,999 Foreign exchange effect – (288 ) (5,306 ) (70,509 ) (302 ) (76,405 ) Balance, April 30, 2022 116,637 55,425 241,189 3,730,808 28,913 4,172,972 Cost, Ending Balance 116,637 55,425 241,189 3,730,808 28,913 4,172,972 Accumulated Depreciation Balance, October 31, 2020 14,677 8,326 4,818 – – 27,821 Depreciation expense 13,907 7,443 8,827 13,971 – 44,148 Write-off of equipment (2,057 ) – – – – (2,057 ) Foreign exchange effect 1,294 745 502 221 – 2,762 Balance, October 31, 2021 27,821 16,514 14,147 14,192 – 72,674 Accumulated Depreciation, Beginning Balance 27,821 16,514 14,147 14,192 – 72,674 Depreciation expense 18,236 3,833 15,217 83,755 2,920 123,961 Foreign exchange effect – (48 ) (404 ) (801 ) (29 ) (1,282 ) Balance, April 30, 2022 46,057 20,299 28,960 97,146 2,891 195,353 Accumulated Depreciation, Ending Balance 46,057 20,299 28,960 97,146 2,891 195,353 Net Book Value Balance, October 31, 2020 17,641 30,590 2,792 28,413 – 79,436 Balance, October 31, 2021 81,808 37,028 125,334 2,330,534 – 2,574,704 Balance, April 30, 2022 70,580 35,126 212,229 3,633,662 26,022 3,977,619 | SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT Computer Equipment Furniture Leasehold Improvement Furnace & Plant Equipment Total $ $ $ $ $ Cost Balance, October 31, 2019 22,632 33,584 5,850 27,897 89,963 Additions 9,852 5,672 1,810 838 18,172 Foreign exchange effect (166 ) (340 ) (50 ) (322 ) (878 ) Balance, October 31, 2020 32,318 38,916 7,610 28,413 107,257 Cost, Beginning Balance 32,318 38,916 7,610 28,413 107,257 Additions 77,955 11,510 129,257 2,278,205 2,496,927 Write-off of equipment (4,245 ) – – – (4,245 ) Foreign exchange effect 3,601 3,116 2,614 38,108 47,439 Balance, October 31, 2021 109,629 53,542 139,481 2,344,726 2,647,378 Cost, Ending Balance 109,629 53,542 139,481 2,344,726 2,647,378 Accumulated Depreciation Balance, October 31, 2019 3,184 1,679 1,950 – 6,813 Depreciation expense 11,412 6,598 2,861 – 20,871 Foreign exchange effect 81 49 7 – 137 Balance, October 31, 2020 14,677 8,326 4,818 – 27,821 Accumulated Depreciation, Beginning Balance 14,677 8,326 4,818 – 27,821 Depreciation expense 13,907 7,443 8,827 13,971 44,148 Write-off of equipment (2,057 ) – – – (2,057 ) Foreign exchange effect 1,294 745 502 221 2,762 Balance, October 31, 2021 27,821 16,514 14,147 14,192 72,674 Accumulated Depreciation, Ending Balance 27,821 16,514 14,147 14,192 72,674 Net Book Value Balance, October 31, 2020 17,641 30,590 2,792 28,413 79,436 Balance, October 31, 2021 81,808 37,028 125,334 2,330,534 2,574,704 Net Book Value 81,808 37,028 125,334 2,330,534 2,574,704 |
RIGHT-OF-USE ASSETS (Tables)
RIGHT-OF-USE ASSETS (Tables) | 6 Months Ended | 12 Months Ended |
Apr. 30, 2022 | Oct. 31, 2021 | |
Right-of-use Assets | ||
SCHEDULE OF RIGHT-OF-USE ASSETS | SCHEDULE OF RIGHT-OF-USE ASSETS Vancouver Office Virginia Office Nevada Office Pilot Plant Total $ $ $ $ $ Cost Balance, October 31, 2020 59,701 – 22,856 357,949 440,506 Additions 91,237 287,847 – – 379,084 Foreign exchange effect 5,943 4,544 1,724 26,997 39,208 Balance, October 31, 2021 156,881 292,391 24,580 384,946 858,798 Operating lease right-of-use asset, cost, beginning balance 156,881 292,391 24,580 384,946 858,798 Foreign exchange effect – (3,038 ) – (12,278 ) (15,316 ) Balance, April 30, 2022 156,881 289,353 24,580 372,668 843,482 Operating lease right-of-use asset, cost, ending balance 156,881 289,353 24,580 372,668 843,482 Accumulated Depreciation Balance, October 31, 2020 42,142 – 14,434 9,943 66,519 Depreciation expense 44,259 15,288 8,915 117,292 185,754 Foreign exchange effect 3,876 241 1,231 2,602 7,950 Balance, October 31, 2021 90,277 15,529 24,580 129,837 260,223 Operating lease right-of-use asset, accumulated depreciation, beginning balance 90,277 15,529 24,580 129,837 260,223 Depreciation expense 22,229 33,790 – 62,347 118,366 Foreign exchange effect – (162 ) – (4,766 ) (4,928 ) Balance, April 30, 2022 112,506 49,157 24,580 187,418 373,661 Operating lease right-of-use asset, accumulated depreciation, ending balance 112,506 49,157 24,580 187,418 373,661 Net Book Value Balance, October 31, 2020 17,559 – 8,422 348,006 373,987 Balance, October 31, 2021 66,604 276,862 – 255,109 598,575 Balance, April 30, 2022 44,375 240,196 – 185,250 469,821 | SCHEDULE OF RIGHT-OF-USE ASSETS Vancouver Office Virginia Office Nevada Office Pilot Plant Total $ $ $ $ $ Cost Balance, October 31, 2019 – – – – – Initial adoption of ASU 2016-02 60,418 – 23,131 – 83,549 Additions – – – 354,263 354,263 Foreign exchange effect (717 ) – (275 ) 3,686 2,694 Balance, October 31, 2020 59,701 – 22,856 357,949 440,506 Operating lease right-of-use asset, cost, beginning balance 59,701 – 22,856 357,949 440,506 Additions 91,237 287,847 – – 379,084 Foreign exchange effect 5,943 4,544 1,724 26,997 39,208 Balance, October 31, 2021 156,881 292,391 24,580 384,946 858,798 Operating lease right-of-use asset, cost, ending balance 156,881 292,391 24,580 384,946 858,798 Accumulated Depreciation Balance, October 31, 2019 – – – – – Depreciation expense 41,708 – 14,286 9,841 65,835 Foreign exchange effect 434 – 148 102 684 Balance, October 31, 2020 42,142 – 14,434 9,943 66,519 Operating lease right-of-use asset, accumulated depreciation, beginning balance 42,142 – 14,434 9,943 66,519 Depreciation expense 44,259 15,288 8,915 117,292 185,754 Foreign exchange effect 3,876 241 1,231 2,602 7,950 Balance, October 31, 2021 90,277 15,529 24,580 129,837 260,223 Operating lease right-of-use asset, accumulated depreciation, ending balance 90,277 15,529 24,580 129,837 260,223 Net Book Value Balance, October 31, 2020 17,559 – 8,422 348,006 373,987 Balance, October 31, 2021 66,604 276,862 – 255,109 598,575 Operating lease right-of-use asset 66,604 276,862 – 255,109 598,575 |
LEASE OBLIGATIONS (Tables)
LEASE OBLIGATIONS (Tables) | 6 Months Ended | 12 Months Ended |
Apr. 30, 2022 | Oct. 31, 2021 | |
Lease Obligations | ||
SCHEDULE OF OPERATING LEASE | SCHEDULE OF OPERATING LEASE Vancouver Office Virginia Office Nevada Office Pilot Plant Total $ $ $ $ $ Balance, October 31, 2020 18,123 – 12,211 350,593 380,927 Additions 91,237 260,649 – – 351,886 Lease payments (47,931 ) (5,137 ) (9,457 ) (139,037 ) (201,562 ) Interest expense 3,076 3,019 219 19,005 25,319 Prior period adjustment – – (3,065 ) – (3,065 ) Foreign exchange effect 2,099 4,081 92 24,548 30,820 Balance, October 31, 2021 66,604 262,612 – 255,109 584,325 Operating lease liability, beginning 66,604 262,612 – 255,109 584,325 Lease payments (24,187 ) – – (69,057 ) (93,244 ) Interest expense 1,958 9,230 – 6,711 17,899 Foreign exchange effect – (2,728 ) – (7,513 ) (10,241 ) Balance, April 30, 2022 44,375 269,114 – 185,250 498,739 Operating lease liability, ending 44,375 269,114 – 185,250 498,739 Which consist of: Current lease obligation 44,375 71,092 – 129,125 244,592 Non-current lease obligation – 198,022 – 56,125 254,147 Balance, April 30, 2022 44,375 269,114 – 185,250 498,739 | SCHEDULE OF OPERATING LEASE Vancouver Office Virginia Office Nevada Office Pilot Plant Total $ $ $ $ $ Balance, October 31, 2019 – – – – – Initial adoption of ASU 2016-02 60,418 – 23,131 – 83,549 Additions – – – 354,263 354,263 Lease payments (43,627 ) – (14,990 ) (10,831 ) (69,448 ) Interest expenses 2,477 – 1,005 3,551 7,033 Foreign exchange effect (1,145 ) – 3,065 3,610 5,530 Balance, October 31, 2020 18,123 – 12,211 350,593 380,927 Additions 91,237 260,649 – – 351,886 Lease payments (47,931 ) (5,137 ) (9,457 ) (139,037 ) (201,562 ) Interest expenses 3,076 3,019 219 19,005 25,319 Prior period adjustment – – (3,065 ) – (3,065 ) Foreign exchange effect 2,099 4,081 92 24,548 30,820 Balance, October 31, 2021 66,604 262,612 – 255,109 584,325 Which consist of: Current lease obligation 46,270 16,328 – 129,447 192,045 Non-current lease obligation 20,334 246,284 – 125,662 392,280 Balance, October 31, 2021 66,604 262,612 – 255,109 584,325 |
MINERAL PROPERTY COSTS (Tables)
MINERAL PROPERTY COSTS (Tables) | 12 Months Ended |
Oct. 31, 2021 | |
Extractive Industries [Abstract] | |
SCHEDULE OF MINERAL PROPERTY COSTS | SCHEDULE OF MINERAL PROPERTY COSTS Beaverdell Property Silverado Property Tami Mosi Total $ $ $ $ Balance, October 31, 2019 1 1 93,452 93,454 Sale of mineral property (1 ) – – (1 ) Balance, October 31, 2020 and 2021 – 1 93,452 93,453 Sale of mineral property - – – - Balance, October 31, 2020 and 2021 – 1 93,452 93,453 |
RELATED PARTY TRANSACTIONS (Tab
RELATED PARTY TRANSACTIONS (Tables) | 6 Months Ended | 12 Months Ended |
Apr. 30, 2022 | Oct. 31, 2021 | |
Related Party Transactions [Abstract] | ||
SCHEDULE OF DEPOSITS HELD BY RELATED PARTY | SCHEDULE OF DEPOSITS HELD BY RELATED PARTY Related Party A [i] Related Party B [ii] Total $ $ $ Balance, October 31, 2020 – – – Advances 987,912 2,292,912 3,280,824 Costs and expenses (696,431 ) (2,097,931 ) (2,794,362 ) Balance, October 31, 2021 291,481 194,981 486,462 Deposits held by related parties, beginning 291,481 194,981 486,462 Advances 330,930 1,225,118 1,556,048 Costs and expenses (249,872 ) (1,420,829 ) (1,670,701 ) Foreign exchange effect 16,218 730 16,948 Balance, April 30, 2022 388,757 – 388,757 Deposits held by related parties, beginning 388,757 – 388,757 [i] Related Party A is a company controlled by a director and officer. [ii] Related Party B is a company controlled by an officer. | SCHEDULE OF DEPOSITS HELD BY RELATED PARTY Related Party A [i] Related Party B [ii] Total $ $ $ Balance, October 31, 2020 – – – Advances 987,912 2,292,912 3,280,824 Costs and expenses (696,431 ) (2,097,931 ) (2,794,362 ) Balance, October 31, 2021 291,481 194,981 486,462 Advances 330,930 1,225,118 1,556,048 Costs and expenses (249,872 ) (1,420,829 ) (1,670,701 ) Foreign exchange effect 16,218 730 16,948 Balance, April 30, 2022 388,757 – 388,757 [i] Related Party A is a company controlled by a director and officer. [ii] Related Party B is a company controlled by an officer. |
SCHEDULE OF DUE TO RELATED PARTIES | SCHEDULE OF DUE TO RELATED PARTIES April 30, 2022 October 31, $ $ Wages payable to directors and officers 357,500 357,500 Benefits payable to directors and officers 730,810 539,209 Fees and expenses payable to directors and officers 164,970 127,878 Interest due to a shareholder – 2,230 Total 1,253,280 1,026,817 | SCHEDULE OF DUE TO RELATED PARTIES October 31, 2021 October 31, 2020 $ $ Wages payable to directors and officers 357,500 161,922 Benefits payable to directors and officers 539,209 – Fees and expenses payable to directors and officers 127,878 682,068 Interests due to a shareholder 2,230 – Total 1,026,817 843,990 |
CONVERTIBLE DEBENTURE AND DER_2
CONVERTIBLE DEBENTURE AND DERIVATIVE LIABILITY (Tables) | 6 Months Ended | 12 Months Ended |
Apr. 30, 2022 | Oct. 31, 2021 | |
Debt Disclosure [Abstract] | ||
SCHEDULE OF OPTION PRICING MODEL | The inputs used in the Black-Scholes Option Pricing Model are as follows: SCHEDULE OF OPTION PRICING MODEL April 22, November 1, October 31, June 15, July 27, 2022 2021 2021 2021 2020 Risk free rate of interest 2.65 % 1.07 % 1.08 % 0.31 % 0.26 % Expected life in years 0.23 0.70 1.11 1.50 0.74 Conversion exercise price CA$ 0.12 CA$ 0.12 $ 0.10 $ 0.10 CA$ 0.15 Underlying share price of the Company CA$ 0.36 CA$ 0.75 $ 0.59 $ 0.19 CA$ 0.13 Expected volatility 99.90 % 124.34 % 107.62 % 87.17 % 82.54 % Expected dividend rate Nil Nil Nil Nil Nil | The inputs used in the Black-Scholes Option Pricing Model are as follows: SCHEDULE OF OPTION PRICING MODEL October 31, June 15, July 27, 2021 2021 2020 Risk free rate of interest 1.08 % 0.31 % 0.26 % Expected life in years 1.11 1.50 0.74 Conversion exercise price $ 0.10 $ 0.10 CA$ 0.15 Underlying share price of the Company CA$ 0.73 CA$ 0.23 CA$ 0.13 Expected volatility 107.62 % 87.17 % 82.54 % Expected dividend rate Nil Nil Nil |
SCHEDULE OF DERIVATIVE INSTRUMENTS | SCHEDULE OF DERIVATIVE INSTRUMENTS July 2020 Convertible Debenture July 2021 Convertible Debenture June 2021 Convertible Debenture April 2022 Convertible Debenture Total $ $ $ $ $ Debt Host Liability Balance, October 31, 2020 96,318 – – – 96,318 Fair value of debt host liability recognized – – 1 – 1 Accretion and interest expense 23,587 63 43 – 23,693 Conversion (125,560 ) – – – (125,560 ) Foreign currency translation 5,655 – – – 5,655 Balance, October 31, 2021 – 63 44 – 107 Effects of functional currency change – – 1,500,000 – 1,500,000 Fair value at inception – – – 2,000,000 2,000,000 Accretion and interest expense – 28,050 5,610 17,159 50,819 Conversion – (28,031 ) (600,000 ) – (628,031 ) Foreign currency translation – (82 ) – – (82 ) Balance, April 30, 2022 – – 905,654 2,017,159 2,922,813 Embedded Derivative Liability Balance, October 31, 2020 20,123 – – – 20,123 Fair value of embedded derivative liability recognized – – 1,646,600 – 1,646,600 Fair value adjustment (16,058 ) – 5,717,328 – 5,701,270 Conversion (5,247 ) – – – (5,247 ) Foreign currency translation 1,182 – 85,772 – 86,954 Balance, October 31, 2021 – – 7,449,700 – 7,449,700 Effects of functional currency change – 421,094 (7,449,700 ) – (7,028,606 ) Fair value adjustment – (259,447 ) – – (259,447 ) Conversion – (158,169 ) – – (158,169 ) Foreign currency translation – (3,478 ) – – (3,478 ) Balance, April 30, 2022 – – – – – Debt Discount Balance, October 31, 2021 – – – – – Effects of functional currency change – – (1,500,000 ) – (1,500,000 ) Inception – – – (240,000 ) (240,000 ) Amortization – – 600,769 2 600,771 Balance, April 30, 2022 – – (899,231 ) (239,998 ) (1,139,229 ) Combined Value of Convertible Debenture Balance, October 31, 2020 116,441 – – – 116,441 Balance, October 31, 2021 – 63 7,449,744 7,449,744 7,449,807 Balance, April 30, 2022 – – 6,423 1,777,161 1,783,584 | SCHEDULE OF DERIVATIVE INSTRUMENTS July 2020 Convertible Debenture June 2021 Convertible Debenture July 2021 Convertible Debenture Total $ $ $ $ Debt Host Liability Balance, October 31, 2019 – – – – Value of debt host liability recognized 87,083 – – 87,083 Accretion and interest expense 8,751 – – 8,751 Foreign currency translation 484 – – 484 Fair value of embedded derivative liability recognized Fair value adjustment Conversion Effects of change in functional currency Balance, October 31, 2020 96,318 – – 96,318 Value of debt host liability recognized – 1 – 1 Accretion and interest expense 23,587 43 63 23,693 Conversion (125,560 ) – – (125,560 ) Foreign currency translation 5,655 – – 5,655 Balance, October 31, 2021 – 44 63 107 Embedded Derivative Liability Balance, October 31, 2019 – – – – Fair value of embedded derivative liability recognized 25,041 – – 25,041 Fair value adjustment (4,979 ) – – (4,979 ) Foreign currency translation 61 – – 61 Balance, October 31, 2020 20,123 – – 20,123 Fair value of embedded derivative liability recognized – 1,646,600 – 1,646,600 Fair value adjustment (16,058 ) 5,717,328 – 5,701,270 Conversion (5,247 ) – – (5,247 ) Foreign currency translation 1,182 85,772 – 86,954 Balance, October 31, 2021 – 7,449,700 – 7,449,700 Combined Value of Convertible Debenture Balance, October 31, 2019 – – – – Conversion – – – – Amortization Balance, October 31, 2020 116,441 – – 116,441 Conversion – – – – Balance, October 31, 2021 – 7,449,744 63 7,449,807 WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated |
SHARE CAPITAL (Tables)
SHARE CAPITAL (Tables) | 6 Months Ended | 12 Months Ended |
Apr. 30, 2022 | Oct. 31, 2021 | |
Equity [Abstract] | ||
SUMMARY OF CHANGES IN COMMON SHARE PURCHASE WARRANTS | A summary of the changes in the Company’s common share purchase warrants during the six months ended April 30, 2022 are as follows: SUMMARY OF CHANGES IN COMMON SHARE PURCHASE WARRANTS Expiry Date Exercise Price Weighted Average Life (Years) October 31, 2021 Granted Exercised Expired/ Cancelled April 30, 2022 Expiry Date Exercise Price Weighted Average Life (Years) October 31, 2021 Granted Exercised Expired/ Cancelled April 30, 2022 November 22, 2021 CA$ 0.19 – 4,160,021 – (4,080,573 ) (79,448 ) – January 17, 2022 CA$ 0.19 – 7,267,914 – (5,959,396 ) (1,308,518 ) – January 31, 2022 CA$ 0.19 – 5,382,303 – (4,341,906 ) (1,040,397 ) – February 21, 2022 CA$ 0.05 – 1,505,200 – (200,000 ) (1,305,200 ) – March 24, 2022 CA$ 0.19 – 6,341,872 – (4,515,139 ) (1,826,733 ) – March 27, 2022 CA$ 0.05 – 982,025 – (882,025 ) (100,000 ) – April 27, 2022 CA$ 0.19 – 791,395 – (791,395 ) – – May 9, 2022 CA$ 0.05 0.02 1,813,725 – (1,000,000 ) – 813,725 May 30, 2022 CA$ 0.19 0.08 5,223,420 – (276,675 ) – 4,946,745 June 17, 2022 CA$ 0.19 0.13 17,703,506 – (1,393,077 ) – 16,310,429 July 18, 2022 CA$ 0.30 0.22 4,350,000 – (60,960 ) – 4,289,040 August 14, 2022 CA$ 0.05 0.29 200,000 – (200,000 ) – – February 13, 2023 CA$ 0.65 0.79 3,827,601 – – – 3,827,601 April 22, 2024 CA$ 0.20 1.98 – 933,333 – – 933,333 Subtotal 59,548,982 933,333 (23,701,146 ) (5,660,296 ) 31,120,873 Weighted average exercise price CA$ 0.22 CA$ 0.20 CA$ 0.18 CA$ 0.16 CA$ 0.26 November 27, 2022 US$ 0.75 0.58 – 1,375,499 – – 1,375,499 June 10, 2026 US$ 0.13 4.12 – 3,000,000 – – 1,500,000 June 10, 2026 US$ 0.19 4.12 – 3,000,000 – – 1,500,000 Subtotal – 7,375,499 – – 4,375,499 Weighted average exercise price – US$ 0.27 – – US$ 0.27 Total 59,548,982 8,308,832 (23,701,146 ) (5,660,296 ) 38,496,372 A summary of the changes in the Company’s common share purchase warrants during the six months ended April 30, 2021 are as follows: Expiry Date Exercise Price Weighted Average Life (Years) October 31, 2020 Granted Exercised Expired/ Cancelled April 30, 2021 August 31, 2021 * CA$ 0.21 0.34 3,643,791 – – – 3,643,791 November 22, 2021 CA$ 0.19 0.56 – 5,599,171 – – 5,599,171 January 17, 2022 CA$ 0.19 0.71 – 7,337,914 – – 7,337,914 January 31, 2022 CA$ 0.19 0.75 – 5,382,303 – – 5,382,303 February 21, 2022 CA$ 0.05 0.81 1,505,200 – – – 1,505,200 March 24, 2022 CA$ 0.19 0.90 – 6,554,172 – – 6,554,172 March 27, 2022 CA$ 0.05 0.91 1,482,025 – – – 1,482,025 April 27, 2022 CA$ 0.19 0.99 – 851,395 – – 851,395 May 9, 2022 CA$ 0.05 1.02 2,368,626 – – – 2,368,626 August 14, 2022 CA$ 0.05 1.29 1,110,000 – (400,000 ) – 710,000 Total 10,109,642 25,724,955 (400,000 ) – 35,434,597 Weighted average exercise price CA$ 0.11 CA$ 0.19 CA$ 0.05 – CA$ 0.17 * The Company received approval of the TSX-V on January 13, 2021 and amended the expiry date of 3,643,791 extending the expiry date from January 17, 2021 to August 31, 2021 0.30 | A summary of the changes in the Company’s common share purchase warrants during the year ended October 31, 2021 are as follows: SUMMARY OF CHANGES IN COMMON SHARE PURCHASE WARRANTS Expiry Date Exercise Price (CA$) Weighted Average Life (Years) October 31, Granted Exercised Expired/ Cancelled October 31, 2021 August 31, 2021* 0.21 – 3,643,791 - (3,118,618 ) (525,173 ) – November 22, 2021 0.19 0.14 – 5,599,171 (1,439,150 ) – 4,160,021 January 17, 2022 0.19 0.29 – 7,337,914 (70,000 ) – 7,267,914 January 31, 2022 0.19 0.33 – 5,382,303 – – 5,382,303 February 21, 2022 0.05 0.39 1,505,200 – – – 1,505,200 March 24, 2022 0.19 0.48 – 6,554,172 (212,300 ) – 6,341,872 March 27, 2022 0.05 0.49 1,482,025 – (500,000 ) – 982,025 April 27, 2022 0.19 0.57 – 851,395 (60,000 ) – 791,395 May 9, 2022 0.05 0.61 2,368,626 – (554,901 ) – 1,813,725 May 30, 2022 0.19 0.66 – 5,223,420 – – 5,223,420 June 17, 2022 0.19 0.71 – 17,853,506 (150,000 ) – 17,703,506 July 18, 2022 0.30 0.79 – 4,350,000 – – 4,350,000 August 14, 2022 0.05 0.87 1,110,000 – (910,000 ) – 200,000 February 13, 2023 0.65 1.37 – 3,827,601 – – 3,827,601 Total 10,109,642 56,979,482 (7,014,969 ) (525,173 ) 59,548,982 Weighted average exercise price CA$ 0.11 CA$ 0.23 CA$ 0.16 CA$ 0.21 CA$ 0.22 * The Company received approval of the TSX-V on January 13, 2021 and amended the expiry date of 3,643,791 warrants, extending the expiry date from January 17, 2021 to August 31, 2021, subject to acceleration if the closing price of the Company’s shares exceeds CA$ 0.30 per common share for at least 10 consecutive trading days. A summary of the changes in the Company’s common share purchase warrants during the year ended October 31, 2020 are as follows: Expiry Date Exercise Price Weighted Average Life (Years) October 31, 2019 Granted Exercised Expired/ Cancelled October 31, 2020 January 17, 2021 0.21 – – 3,643,791 – – 3,643,791 February 21, 2022 0.05 2.31 1,505,200 – – – 1,505,200 March 27, 2022 0.05 2.41 3,426,025 – (1,944,000 ) – 1,482,025 May 9, 2022 0.05 2.52 5,088,626 – (2,720,000 ) – 2,368,626 August 14, 2022 0.05 2.79 1,310,000 – (200,000 ) – 1,110,000 May 7, 2020* 0.07 – 3,100,000 – (3,000,000 ) (100,000 ) – October 4, 2020* 0.08 – 5,016,000 – (3,425,000 ) (1,591,000 ) – November 30, 2020* 0.08 – 6,169,926 – (3,091,383 ) (3,078,543 ) – January 23, 2021* 0.08 – 6,388,435 – (3,409,160 ) (2,979,275 ) – March 29, 2021* 0.08 – 8,188,046 – (4,496,710 ) (3,691,336 ) – May 13, 2021* 0.08 – 31,404,738 – (18,050,408 ) (13,354,330 ) – Total 71,596,996 3,643,791 (40,336,661 ) (24,794,484 ) 10,109,642 Weighted average exercise price CA$ 0.07 CA$ 0.21 CA$ 0.08 CA$ 0.08 CA$ 0.11 * On December 20, 2019, the Company exercised its right to call, subject to acceleration provisions, all outstanding warrants set to expire between May 7, 2020 and May 13, 2021. The expiry was amended to January 19, 2020. This expiry date was then extended to February 19, 2020. Any unexercised warrants were voided and of no value after February 19, 2020. |
SCHEDULE OF ASSUMPTIONS USED | SCHEDULE OF ASSUMPTIONS USED 2022 2021 Risk free rate of interest 1.34 2.59 0.20 1.07 Expected life of options 5 2 5 Exercise price of options CA$ 0.40 0.58 CA$ 0.13 0.70 Expected annualized volatility 134.93 136.08 130.88 140.05 Expected dividend rate Nil Nil | SCHEDULE OF ASSUMPTIONS USED 2021 2020 Risk free rate of interest 0.20 1.07 % 0.43 1.51 % Expected life of options 2 5 5 Exercise price of options CA$ 0.13 0.70 CA$ 0.11 0.16 Expected annualized volatility 130.88 140.05 % 120.13 188.46 % Expected dividend rate Nil Nil |
SCHEDULE OF STOCK OPTIONS ACTIVITY | A summary of the changes in the Company’s stock options during the six months ended April 30, 2022 are as follows: SCHEDULE OF STOCK OPTIONS ACTIVITY Expiry Date Exercise Price Weighted Average Life (Years) Outstanding as at October 31, 2021 Granted Exercised Expired/ Cancelled Outstanding as at April 30, 2022 Vested as at April 30, 2022 March 27, 2022 0.05 – 1,500,000 – (750,000 ) (750,000 ) – – December 30, 2022 0.13 0.67 6,000,000 – – (150,000 ) 5,850,000 5,850,000 August 12, 2023 0.05 1.28 2,290,000 – – (750,000 ) 1,540,000 1,540,000 December 3, 2023 0.05 1.59 6,450,000 – – (1,000,000 ) 5,450,000 5,450,000 May 22, 2024 0.12 2.06 7,900,000 – – (850,000 ) 7,050,000 7,050,000 November 3, 2024 0.15 2.52 700,000 – – – 700,000 700,000 November 24, 2024 0.16 2.57 320,000 – – (300,000 ) 20,000 20,000 March 26, 2025 0.11 2.91 100,000 – – – 100,000 100,000 April 23, 2025 0.12 2.98 3,350,000 – – (250,000 ) 3,100,000 3,100,000 December 30, 2025 0.13 3.67 9,500,000 – – – 9,500,000 9,500,000 August 30, 2026 0.70 4.34 21,700,000 – – (200,000 ) 21,500,000 21,350,000 October 1, 2026 0.50 4.42 1,450,000 – – – 1,450,000 1,450,000 December 3, 2026 0.58 4.60 – 250,000 – – 250,000 250,000 March 7, 2027 0.40 4.85 – 500,000 – – 500,000 500,000 April 8, 2027 0.40 4.94 – 500,000 – – 500,000 500,000 Total 61,260,000 1,250,000 (750,000 ) (4,250,000 ) 57,510,000 57,360,000 Weighted average exercise price CA$ 0.33 CA$ 0.44 CA$ 0.05 CA$ 0.11 CA$ 0.34 CA$ 0.33 Aggregate intrinsic value $ 19,994,025 $ (2,149,050 ) $ (2,102,148 ) Weighted average remaining life 3.46 3.15 3.15 A summary of the changes in the Company’s stock options during the six months ended April 30, 2021 are as follows: Expiry Date Exercise Price Weighted Average Life (Years) Outstanding as at October 31, 2020 Granted Exercised Expired/ Cancelled Outstanding as at April 30, 2021 Vested as at April 30, 2021 February 11, 2021 0.05 0.03 800,000 – – (800,000 ) – – August 16, 2021 0.05 0.54 600,000 – – – 600,000 600,000 March 27, 2022 0.05 1.15 1,750,000 – – – 1,750,000 1,750,000 August 26, 2022 0.13 – 500,000 – – (500,000 ) – – December 30, 2022 0.13 1.91 – 6,150,000 – (6,150,000 ) – – April 19, 2023 0.05 2.21 800,000 – – – 800,000 800,000 August 12, 2023 0.05 2.53 3,120,000 – (100,000 ) – 3,020,000 3,020,000 December 3, 2023 0.05 2.84 7,000,000 – – – 7,000,000 7,000,000 May 22, 2024 0.12 3.31 7,950,000 – – – 7,950,000 7,950,000 November 3, 2024 0.15 3.76 700,000 – – – 700,000 700,000 November 24, 2024 0.16 3.82 900,000 – – – 900,000 900,000 March 26, 2025 0.11 4.15 300,000 – – – 300,000 300,000 April 23, 2025 0.12 4.23 4,000,000 – – (300,000 ) 3,700,000 3,700,000 December 30, 2025 0.13 4.92 – 9,500,000 – (9,500,000 ) – – Total 28,420,000 15,650,000 (100,000 ) (17,250,000 ) 26,720,000 26,720,000 Weighted average exercise price CA$ 0.09 CA$ 0.13 CA$ 0.05 CA$ 0.13 CA$ 0.09 CA$ 0.09 Aggregate intrinsic value $ 801,922 $ 597,721 $ 597,721 Weighted average remaining life 3.18 2.78 2.78 | A summary of the changes in the Company’s stock options during the year ended October 31, 2021 are as follows: SCHEDULE OF STOCK OPTIONS ACTIVITY Expiry Date Exercise Price Weighted Average Life (Years) Outstanding as at October 31, 2020 Granted Exercised Expired/ Cancelled Outstanding as at October 31, 2021 Vested as at October 31, 2021 February 11, 2021 0.05 – 800,000 – – (800,000 ) – – August 16, 2021 0.05 – 600,000 – (600,000 ) – – – March 27, 2022 0.05 0.40 1,750,000 – (250,000 ) – 1,500,000 1,500,000 August 26, 2022 0.13 – 500,000 – – (500,000 ) – – December 30, 2022 0.13 1.16 – 6,150,000 (100,000 ) (50,000 ) 6,000,000 5,837,500 April 19, 2023 0.05 – 800,000 – – (800,000 ) – – August 12, 2023 0.05 1.78 3,120,000 – (600,000 ) (230,000 ) 2,290,000 2,290,000 December 3, 2023 0.05 2.09 7,000,000 – (550,000 ) – 6,450,000 6,450,000 May 22, 2024 0.12 2.56 7,950,000 – – (50,000 ) 7,900,000 7,900,000 November 3, 2024 0.15 3.01 700,000 – – – 700,000 700,000 November 24, 2024 0.16 3.07 900,000 – (30,000 ) (550,000 ) 320,000 320,000 March 26, 2025 0.11 3.40 300,000 – (200,000 ) – 100,000 100,000 April 23, 2025 0.12 3.48 4,000,000 – (300,000 ) (350,000 ) 3,350,000 3,350,000 December 30, 2025 0.13 4.17 – 9,500,000 – – 9,500,000 9,500,000 August 30, 2026 0.70 4.83 – 21,700,000 – – 21,700,000 21,400,000 October 1, 2026 0.50 4.92 – 1,450,000 – – 1,450,000 1,450,000 Total 28,420,000 38,800,000 (2,630,000 ) (3,330,000 ) 61,260,000 60,797,500 Weighted average exercise price CA$0.09 CA$0.46 CA$0.07 CA$0.09 CA$0.33 CA$0.32 Aggregate intrinsic value $ 19,994,025 $ 19,908,026 Weighted average remaining life 3.46 3.46 Expiry Date Exercise Price Weighted Average Life (Years) Outstanding as at October 31, 2019 Granted Exercised Expired/ Cancelled Outstanding as at October 31, 2020 Vested as at October 31, 2020 May 31, 2020 0.08 – 400,000 – (400,000 ) – – – June 3, 2020 0.05 – 550,000 – – (550,000 ) – – February 11, 2021 0.05 0.53 1,300,000 – – (500,000 ) 800,000 800,000 August 16, 2021 0.05 1.04 1,200,000 – – (600,000 ) 600,000 600,000 March 27, 2022 0.05 1.65 2,000,000 – – (250,000 ) 1,750,000 1,750,000 August 26, 2022 0.13 – – 500,000 – – 500,000 – April 19, 2023 0.05 2.72 800,000 – – – 800,000 800,000 August 12, 2023 0.05 3.03 3,780,000 – (100,000 ) (560,000 ) 3,120,000 3,120,000 December 3, 2023 0.05 3.35 9,600,000 – – (2,600,000 ) 7,000,000 7,000,000 May 22, 2024 0.12 3.81 10,000,000 – – (2,050,000 ) 7,950,000 7,950,000 November 3, 2024 0.15 4.27 – 700,000 – – 700,000 700,000 November 24, 2024 0.16 4.32 – 900,000 – – 900,000 775,000 March 26, 2025 0.11 4.66 – 300,000 – – 300,000 300,000 April 23, 2025 0.12 4.73 – 4,200,000 – (200,000 ) 4,000,000 3,625,000 Total 29,630,000 6,600,000 (500,000 ) (7,310,000 ) 28,420,000 27,420,000 Weighted average exercise price CA$0.07 CA$0.13 CA$0.07 CA$0.07 CA$0.09 CA$0.09 Aggregate intrinsic value $ 801,922 $ 866,441 Weighted average remaining life 3.18 3.18 |
SCHEDULE OF NONVESTED STOCK OPTIONS | A summary of the changes in the Company’s nonvested stock options during the six months ended April 30, 2022 are as follows: SCHEDULE OF NONVESTED STOCK OPTIONS Expiry Date Fair Value Per Share Weighted Average Life (Years) Nonvested as at October 31, 2021 Granted Vested Expired/ Cancelled Nonvested as at April 30, 2022 December 30, 2022 0.07 1.16 162,500 – (162,500 ) – – August 30, 2026 0.56 4.83 300,000 – (150,000 ) – 150,000 Total 462,500 – (312,500 ) – 150,000 Weighted average grant date fair value – per option CA$ 0.39 – CA$ 0.30 – CA$ 0.56 Weighted average grant date fair value – total $ 144,131 – $ 74,063 – $ 65,463 | A summary of the changes in the Company’s nonvested stock options during the year ended October 31, 2021 are as follows: SCHEDULE OF NONVESTED STOCK OPTIONS Expiry Date Fair Value Per Share Weighted Average Life (Years) Nonvested as at October 31, 2020 Granted Vested Expired/ Cancelled Nonvested as at October 31, 2021 December 30, 2022 0.07 1.16 – 650,000 487,500 – 162,500 August 30, 2026 0.56 4.83 – 300,000 – – 300,000 Total – 950,000 487,500 – 462,500 Weighted average grant date fair value – per option – CA$0.22 CA$0.07 – CA$0.39 Weighted average grant date fair value – total – $ 170,781 $ 26,650 – $ 144,131 |
FINANCIAL INSTRUMENTS AND FIN_2
FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Tables) | 6 Months Ended | 12 Months Ended |
Apr. 30, 2022 | Oct. 31, 2021 | |
Fair Value Disclosures [Abstract] | ||
SCHEDULE OF CLASSIFICATION OF FINANCIAL INSTRUMENTS | The Company’s classification of its financial instruments is as follows: SCHEDULE OF CLASSIFICATION OF FINANCIAL INSTRUMENTS Financial Instruments Measurement Method Associated Risk Fair Value at April 30, 2022 ($) Cash FVTPL Credit and currency 774,409 Other receivables Amortized cost Credit and currency 50,765 Subscription receivable Amortized cost Credit and currency 185,000 Deposits held by related parties Amortized cost Credit and currency 388,757 Accounts payable and accrued liabilities Amortized cost Currency 2,715,924 Due to related parties Amortized cost Currency 1,253,280 Convertible debenture, net Amortized cost Currency 1,783,584 Warrant liability FVTPL Currency 2,468,261 | The Company’s classification of its financial instruments is as follows: SCHEDULE OF CLASSIFICATION OF FINANCIAL INSTRUMENTS Financial Instruments Measurement Method Associated Risk Fair Value at October 31, 2021 ($) Cash FVTPL Credit and currency 462,360 Amounts receivable Amortized cost Credit and currency 151,485 Deposits held by related parties Amortized cost Credit and currency 486,462 Accounts payable and accrued liabilities Amortized cost Currency 1,989,316 Due to related parties Amortized cost Currency 1,026,817 Convertible debenture Amortized cost Currency 107 Convertible debenture - derivative liability FVTPL Currency 7,449,700 |
SCHEDULE OF FOREIGN CURRENCY RISK | SCHEDULE OF FOREIGN CURRENCY RISK April 30, 2022 CA$ Cash 208,683 Other receivables 64,930 Accounts payable and accrued liabilities (1,511,845 ) Due to related parties (765,409 ) Total (2,003,641 ) | SCHEDULE OF FOREIGN CURRENCY RISK October 31, 2021 $ Cash 186,627 Deposits held by related parties 486,462 Accounts payable and accrued liabilities (773,011 ) Due to related parties (467,500 ) Convertible debenture (1,500,000 ) Total (2,067,422 ) |
SEGMENTED INFORMATION (Tables)
SEGMENTED INFORMATION (Tables) | 6 Months Ended | 12 Months Ended |
Apr. 30, 2022 | Oct. 31, 2021 | |
Segment Reporting [Abstract] | ||
SCHEDULE OF ASSETS INFORMATION | SCHEDULE OF ASSETS INFORMATION April 30, 2022 October 31, 2021 $ $ Canada – property, plant and equipment 3,946,315 2,546,383 United States – property, plant and equipment 31,304 28,321 United States – mineral property costs 93,453 93,453 Property, plant and equipment net 4,071,072 2,668,157 Canada – other assets 392,853 1,554,827 United States – other assets 1,611,578 290,528 Other assets 2,004,431 1,845,355 Total Assets 6,075,503 4,513,512 | SCHEDULE OF ASSETS INFORMATION October 31, 2021 October 31, 2020 $ $ Canada – property, plant and equipment 2,546,383 79,436 United States – property, plant and equipment 28,321 – United States – mineral property costs 93,453 93,453 Asset 2,668,157 172,889 Canada – other assets 1,554,827 533,815 United States – other assets 290,528 2,059 1,845,355 535,874 Total Assets 4,513,512 708,763 |
INCOME TAX (Tables)
INCOME TAX (Tables) | 12 Months Ended |
Oct. 31, 2021 | |
Income Tax Disclosure [Abstract] | |
SCHEDULE OF EFFECTIVE TAX RATES RECONCILIATION | Significant items resulting in the difference between the Company’s income tax rate and the federal statutory rate are as follows: SCHEDULE OF EFFECTIVE TAX RATES RECONCILIATION 2021 2020 $ $ Loss for the year (23,549,612 ) (4,672,605 ) Effective statutory rate 33.02 % 31.21 % Expected income tax recovery at statutory rate (7,778,880 ) (1,458,320 ) Net adjustment for deductible and non-deductible amounts 2,636,262 250,196 Foreign exchange effect (9,867 ) (175,597 ) Valuation allowance 5,152,485 1,383,721 Deferred income tax provision (recovery) – – |
SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITY | The Company’s deferred tax assets and liabilities are as follows: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITY 2021 2020 $ $ Non-capital loss carry-forwards 5,340,578 2,600,561 Property and equipment (159,673 ) (123,561 ) Lease liability 180,812 103,789 Convertible debenture (509,985 ) – Convertible debenture – derivative liability 2,532,898 – Exploration and evaluation asset 359,700 - Share issue costs - 11,056 Valuation allowance (7,744,330 ) (2,591,845 ) Deferred income tax asset (liability) – – |
NATURE OF OPERATIONS AND GOIN_2
NATURE OF OPERATIONS AND GOING CONCERN (Details Narrative) - USD ($) | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Apr. 30, 2022 | Apr. 30, 2021 | Apr. 30, 2022 | Apr. 30, 2021 | Oct. 31, 2021 | Oct. 31, 2020 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||||||
Accumulated deficit | $ 65,894,907 | $ 65,894,907 | $ 52,129,621 | $ 28,580,009 | ||
Working capital deficit | 7,172,573 | 7,172,573 | 9,657,316 | 2,392,189 | ||
Comprehensive loss | (1,230,426) | $ 518,555 | 13,551,323 | $ 2,745,438 | 23,827,678 | 4,749,411 |
Cash | $ 4,000,000 | $ 4,000,000 | $ 21,600 |
SCHEDULE OF DEPRECIATION RATE (
SCHEDULE OF DEPRECIATION RATE (Details) | 12 Months Ended |
Oct. 31, 2021 | |
Computer Equipment [Member] | |
Property, Plant and Equipment [Line Items] | |
Depreciation rate | 55% declining balance |
Furniture and Fixtures [Member] | |
Property, Plant and Equipment [Line Items] | |
Depreciation rate | 20% declining balance |
Equipment [Member] | |
Property, Plant and Equipment [Line Items] | |
Depreciation rate | 20% declining balance |
Furnace [Member] | |
Property, Plant and Equipment [Line Items] | |
Depreciation rate | To be determined |
Leasehold Improvements [Member] | |
Property, Plant and Equipment [Line Items] | |
Depreciation rate | Term of lease |
Right of Use Assets [Member] | |
Property, Plant and Equipment [Line Items] | |
Depreciation rate | Term of lease |
SCHEDULE OF PROPERTY, PLANT AND
SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($) | 6 Months Ended | 12 Months Ended | ||
Apr. 30, 2022 | Apr. 30, 2021 | Oct. 31, 2021 | Oct. 31, 2020 | |
Property, Plant and Equipment [Line Items] | ||||
Cost, Beginning Balance | $ 2,647,378 | $ 107,257 | $ 107,257 | $ 89,963 |
Additions | 1,601,999 | 2,496,927 | 18,172 | |
Foreign exchange effect | (76,405) | 47,439 | (878) | |
Write-off of equipment | (4,245) | |||
Cost, Ending Balance | 4,172,972 | 2,647,378 | 107,257 | |
Accumulated Depreciation, Beginning Balance | 72,674 | 27,821 | 27,821 | 6,813 |
Depreciation expense | 123,961 | 8,645 | 44,148 | 20,871 |
Foreign exchange effect | (1,282) | 2,762 | 137 | |
Write-off of equipment | (2,057) | |||
Accumulated Depreciation, Ending Balance | 195,353 | 72,674 | 27,821 | |
Net book value | 3,977,619 | 2,574,704 | 79,436 | |
Computer Equipment [Member] | ||||
Property, Plant and Equipment [Line Items] | ||||
Cost, Beginning Balance | 109,629 | 32,318 | 32,318 | 22,632 |
Additions | 7,008 | 77,955 | 9,852 | |
Foreign exchange effect | 3,601 | (166) | ||
Write-off of equipment | (4,245) | |||
Cost, Ending Balance | 116,637 | 109,629 | 32,318 | |
Accumulated Depreciation, Beginning Balance | 27,821 | 14,677 | 14,677 | 3,184 |
Depreciation expense | 18,236 | 13,907 | 11,412 | |
Foreign exchange effect | 1,294 | 81 | ||
Write-off of equipment | (2,057) | |||
Accumulated Depreciation, Ending Balance | 46,057 | 27,821 | 14,677 | |
Net book value | 70,580 | 81,808 | 17,641 | |
Furniture and Fixtures [Member] | ||||
Property, Plant and Equipment [Line Items] | ||||
Cost, Beginning Balance | 53,542 | 38,916 | 38,916 | 33,584 |
Additions | 2,171 | 11,510 | 5,672 | |
Foreign exchange effect | (288) | 3,116 | (340) | |
Write-off of equipment | ||||
Cost, Ending Balance | 55,425 | 53,542 | 38,916 | |
Accumulated Depreciation, Beginning Balance | 16,514 | 8,326 | 8,326 | 1,679 |
Depreciation expense | 3,833 | 7,443 | 6,598 | |
Foreign exchange effect | (48) | 745 | 49 | |
Write-off of equipment | ||||
Accumulated Depreciation, Ending Balance | 20,299 | 16,514 | 8,326 | |
Net book value | 35,126 | 37,028 | 30,590 | |
Leasehold Improvements [Member] | ||||
Property, Plant and Equipment [Line Items] | ||||
Cost, Beginning Balance | 139,481 | 7,610 | 7,610 | 5,850 |
Additions | 107,014 | 129,257 | 1,810 | |
Foreign exchange effect | (5,306) | 2,614 | (50) | |
Write-off of equipment | ||||
Cost, Ending Balance | 241,189 | 139,481 | 7,610 | |
Accumulated Depreciation, Beginning Balance | 14,147 | 4,818 | 4,818 | 1,950 |
Depreciation expense | 15,217 | 8,827 | 2,861 | |
Foreign exchange effect | (404) | 502 | 7 | |
Write-off of equipment | ||||
Accumulated Depreciation, Ending Balance | 28,960 | 14,147 | 4,818 | |
Net book value | 212,229 | 125,334 | 2,792 | |
Furnace and Plant Equipment [Member] | ||||
Property, Plant and Equipment [Line Items] | ||||
Cost, Beginning Balance | 2,344,726 | 28,413 | 28,413 | 27,897 |
Additions | 1,456,591 | 2,278,205 | 838 | |
Foreign exchange effect | (70,509) | 38,108 | (322) | |
Write-off of equipment | ||||
Cost, Ending Balance | 3,730,808 | 2,344,726 | 28,413 | |
Accumulated Depreciation, Beginning Balance | 14,192 | |||
Depreciation expense | 83,755 | 13,971 | ||
Foreign exchange effect | (801) | 221 | ||
Write-off of equipment | ||||
Accumulated Depreciation, Ending Balance | 97,146 | 14,192 | ||
Net book value | 3,633,662 | 2,330,534 | 28,413 | |
Vehicles [Member] | ||||
Property, Plant and Equipment [Line Items] | ||||
Cost, Beginning Balance | ||||
Additions | 29,215 | |||
Foreign exchange effect | (302) | |||
Write-off of equipment | ||||
Cost, Ending Balance | 28,913 | |||
Accumulated Depreciation, Beginning Balance | ||||
Depreciation expense | 2,920 | |||
Foreign exchange effect | (29) | |||
Write-off of equipment | ||||
Accumulated Depreciation, Ending Balance | 2,891 | |||
Net book value | $ 26,022 |
SCHEDULE OF RIGHT-OF-USE ASSETS
SCHEDULE OF RIGHT-OF-USE ASSETS (Details) - USD ($) | 6 Months Ended | 12 Months Ended | ||
Apr. 30, 2022 | Apr. 30, 2021 | Oct. 31, 2021 | Oct. 31, 2020 | |
Operating lease right-of-use asset, cost, beginning balance | $ 858,798 | $ 440,506 | $ 440,506 | |
Initial adoption of ASU 2016-02 | 83,549 | |||
Additions | 379,084 | 354,263 | ||
Foreign exchange effect | (15,316) | 39,208 | 2,694 | |
Operating lease right-of-use asset, cost, ending balance | 843,482 | 858,798 | 440,506 | |
Operating lease right-of-use asset, accumulated depreciation, beginning balance | 260,223 | 66,519 | 66,519 | |
Depreciation expense | 118,366 | 88,348 | 185,754 | 65,835 |
Foreign exchange effect | (4,928) | 7,950 | 684 | |
Operating lease right-of-use asset, accumulated depreciation, ending balance | 373,661 | 260,223 | 66,519 | |
Operating lease right-of-use asset | 469,821 | 598,575 | 373,987 | |
Net book value | 469,821 | 598,575 | 373,987 | |
Vancouver Office [Member] | ||||
Operating lease right-of-use asset, cost, beginning balance | 156,881 | 59,701 | 59,701 | |
Initial adoption of ASU 2016-02 | 60,418 | |||
Additions | 91,237 | |||
Foreign exchange effect | 5,943 | (717) | ||
Operating lease right-of-use asset, cost, ending balance | 156,881 | 156,881 | 59,701 | |
Operating lease right-of-use asset, accumulated depreciation, beginning balance | 90,277 | 42,142 | 42,142 | |
Depreciation expense | 22,229 | 44,259 | 41,708 | |
Foreign exchange effect | 3,876 | 434 | ||
Operating lease right-of-use asset, accumulated depreciation, ending balance | 112,506 | 90,277 | 42,142 | |
Operating lease right-of-use asset | 44,375 | 66,604 | 17,559 | |
Net book value | 44,375 | 66,604 | 17,559 | |
Virginia Office [Member] | ||||
Operating lease right-of-use asset, cost, beginning balance | 292,391 | |||
Initial adoption of ASU 2016-02 | ||||
Additions | 287,847 | |||
Foreign exchange effect | (3,038) | 4,544 | ||
Operating lease right-of-use asset, cost, ending balance | 289,353 | 292,391 | ||
Operating lease right-of-use asset, accumulated depreciation, beginning balance | 15,529 | |||
Depreciation expense | 33,790 | 15,288 | ||
Foreign exchange effect | (162) | 241 | ||
Operating lease right-of-use asset, accumulated depreciation, ending balance | 49,157 | 15,529 | ||
Operating lease right-of-use asset | 240,196 | 276,862 | ||
Net book value | 240,196 | 276,862 | ||
Nevada Office [Member] | ||||
Operating lease right-of-use asset, cost, beginning balance | 24,580 | 22,856 | 22,856 | |
Initial adoption of ASU 2016-02 | 23,131 | |||
Additions | ||||
Foreign exchange effect | 1,724 | (275) | ||
Operating lease right-of-use asset, cost, ending balance | 24,580 | 24,580 | 22,856 | |
Operating lease right-of-use asset, accumulated depreciation, beginning balance | 24,580 | 14,434 | 14,434 | |
Depreciation expense | 8,915 | 14,286 | ||
Foreign exchange effect | 1,231 | 148 | ||
Operating lease right-of-use asset, accumulated depreciation, ending balance | 24,580 | 24,580 | 14,434 | |
Operating lease right-of-use asset | 8,422 | |||
Net book value | 8,422 | |||
Pilot Plant [Member] | ||||
Operating lease right-of-use asset, cost, beginning balance | 384,946 | 357,949 | 357,949 | |
Initial adoption of ASU 2016-02 | ||||
Additions | 354,263 | |||
Foreign exchange effect | (12,278) | 26,997 | 3,686 | |
Operating lease right-of-use asset, cost, ending balance | 372,668 | 384,946 | 357,949 | |
Operating lease right-of-use asset, accumulated depreciation, beginning balance | 129,837 | $ 9,943 | 9,943 | |
Depreciation expense | 62,347 | 117,292 | 9,841 | |
Foreign exchange effect | (4,766) | 2,602 | 102 | |
Operating lease right-of-use asset, accumulated depreciation, ending balance | 187,418 | 129,837 | 9,943 | |
Operating lease right-of-use asset | 185,250 | 255,109 | 348,006 | |
Net book value | $ 185,250 | $ 255,109 | $ 348,006 |
SCHEDULE OF OPERATING LEASE (De
SCHEDULE OF OPERATING LEASE (Details) - USD ($) | 6 Months Ended | 12 Months Ended | |
Apr. 30, 2022 | Oct. 31, 2021 | Oct. 31, 2020 | |
Operating lease liability, beginning | $ 584,325 | $ 380,927 | |
Initial adoption of ASU 2016-02 | 83,549 | ||
Additions | 351,886 | 354,263 | |
Lease payments | (93,244) | (201,562) | (69,448) |
Interest expense | 17,899 | 25,319 | 7,033 |
Foreign exchange effect | (10,241) | 30,820 | 5,530 |
Prior period adjustment | (3,065) | ||
Balance, April 30, 2022 | 498,739 | 584,325 | 380,927 |
Current lease obligation | 244,592 | 192,045 | 143,709 |
Non-current lease obligation | 254,147 | 392,280 | 237,218 |
Vancouver Office [Member] | |||
Operating lease liability, beginning | 66,604 | 18,123 | |
Initial adoption of ASU 2016-02 | 60,418 | ||
Additions | 91,237 | ||
Lease payments | (24,187) | (47,931) | (43,627) |
Interest expense | 1,958 | 3,076 | 2,477 |
Foreign exchange effect | 2,099 | (1,145) | |
Prior period adjustment | |||
Balance, April 30, 2022 | 44,375 | 66,604 | 18,123 |
Current lease obligation | 44,375 | 46,270 | |
Non-current lease obligation | 20,334 | ||
Virginia Office [Member] | |||
Operating lease liability, beginning | 262,612 | ||
Initial adoption of ASU 2016-02 | |||
Additions | 260,649 | ||
Lease payments | (5,137) | ||
Interest expense | 9,230 | 3,019 | |
Foreign exchange effect | (2,728) | 4,081 | |
Prior period adjustment | |||
Balance, April 30, 2022 | 269,114 | 262,612 | |
Current lease obligation | 71,092 | 16,328 | |
Non-current lease obligation | 198,022 | 246,284 | |
Nevada Office [Member] | |||
Operating lease liability, beginning | 12,211 | ||
Initial adoption of ASU 2016-02 | 23,131 | ||
Additions | |||
Lease payments | (9,457) | (14,990) | |
Interest expense | 219 | 1,005 | |
Foreign exchange effect | 92 | 3,065 | |
Prior period adjustment | (3,065) | ||
Balance, April 30, 2022 | 12,211 | ||
Current lease obligation | |||
Non-current lease obligation | |||
Pilot Plant [Member] | |||
Operating lease liability, beginning | 255,109 | 350,593 | |
Initial adoption of ASU 2016-02 | |||
Additions | 354,263 | ||
Lease payments | (69,057) | (139,037) | (10,831) |
Interest expense | 6,711 | 19,005 | 3,551 |
Foreign exchange effect | (7,513) | 24,548 | 3,610 |
Prior period adjustment | |||
Balance, April 30, 2022 | 185,250 | 255,109 | $ 350,593 |
Current lease obligation | 129,125 | 129,447 | |
Non-current lease obligation | $ 56,125 | $ 125,662 |
LEASE OBLIGATIONS (Details Narr
LEASE OBLIGATIONS (Details Narrative) - USD ($) | Apr. 30, 2022 | Oct. 31, 2021 | Oct. 31, 2020 | Nov. 02, 2019 | Oct. 31, 2019 |
Operating lease, liability | $ 498,739 | $ 584,325 | $ 380,927 | $ 83,549 | |
Lessee, operating lease, discount rate | 7% | ||||
British Columbia [Member] | |||||
Operating lease, liability | $ 91,237 | $ 354,263 | |||
Lessee, operating lease, discount rate | 7% | 6% | |||
McLean,Virginia [Member] | |||||
Operating lease, liability | $ 260,649 | ||||
Lessee, operating lease, discount rate | 7% |
SCHEDULE OF MINERAL PROPERTY CO
SCHEDULE OF MINERAL PROPERTY COSTS (Details) - USD ($) | 12 Months Ended | |
Oct. 31, 2021 | Oct. 31, 2020 | |
Balance, beginning | $ 93,453 | $ 93,454 |
Sale of mineral property | (1) | |
Balance, ending | 93,453 | 93,453 |
Beaverdell Property [Member] | ||
Balance, beginning | 1 | |
Sale of mineral property | (1) | |
Balance, ending | ||
Silverado Property [Member] | ||
Balance, beginning | 1 | 1 |
Sale of mineral property | ||
Balance, ending | 1 | 1 |
Tami Mosi Property [Member] | ||
Balance, beginning | 93,452 | 93,452 |
Sale of mineral property | ||
Balance, ending | $ 93,452 | $ 93,452 |
MINERAL PROPERTY COSTS (Details
MINERAL PROPERTY COSTS (Details Narrative) | 12 Months Ended | |||
Oct. 31, 2021 USD ($) a | Oct. 31, 2020 USD ($) | Oct. 31, 2020 CAD ($) | Apr. 30, 2022 USD ($) a ha | |
Reserve Quantities [Line Items] | ||||
Mineral properties, net | $ 93,453 | $ 93,453 | $ 93,453 | |
Silverado Property [Member] | ||||
Reserve Quantities [Line Items] | ||||
Ownership percentage | 100% | |||
Carrying value of property | $ 1 | |||
Area of land | ha | 120 | |||
Tami Mosi Property [Member] | ||||
Reserve Quantities [Line Items] | ||||
Ownership percentage | 100% | |||
Royalty percentage | 2% | |||
Mineral properties, net | $ 93,452 | |||
Tami Mosi Property [Member] | White Pine County [Member] | ||||
Reserve Quantities [Line Items] | ||||
Area of land | a | 1,637 | |||
Tami Mosi Property [Member] | Moor Mining District [Member] | ||||
Reserve Quantities [Line Items] | ||||
Area of land | a | 10 | |||
Beaverdell Property [Member] | ||||
Reserve Quantities [Line Items] | ||||
Ownership percentage | 100% | |||
Sale of stock ownership interest percentage | 100% | 100% | ||
Aggregate proceeds from sale of property amount | $ 37,157 | $ 50,000 | ||
Recognized gain on sale of property | 37,156 | |||
Carrying value of property | $ 1 | |||
Silverado Property [Member] | ||||
Reserve Quantities [Line Items] | ||||
Ownership percentage | 100% | |||
Carrying value of property | $ 1 | |||
Tami Mosi Property [Member] | ||||
Reserve Quantities [Line Items] | ||||
Ownership percentage | 2% | |||
Sale of stock ownership interest percentage | 100% | |||
Area of land | a | 1,637 |
SCHEDULE OF DEPOSITS HELD BY RE
SCHEDULE OF DEPOSITS HELD BY RELATED PARTY (Details) - USD ($) | 6 Months Ended | 12 Months Ended | |
Apr. 30, 2022 | Oct. 31, 2021 | ||
Related Party Transaction [Line Items] | |||
Deposits held by related parties, beginning | $ 486,462 | ||
Advances | 1,556,048 | 3,280,824 | |
Costs and expenses | (1,670,701) | (2,794,362) | |
Foreign exchange effect | 16,948 | ||
Deposits held by related parties, beginning | 388,757 | 486,462 | |
Related Party A [Member] | |||
Related Party Transaction [Line Items] | |||
Deposits held by related parties, beginning | [1] | 291,481 | |
Advances | [1] | 330,930 | 987,912 |
Costs and expenses | [1] | (249,872) | (696,431) |
Foreign exchange effect | [1] | 16,218 | |
Deposits held by related parties, beginning | [1] | 388,757 | 291,481 |
Related Party B [Member] | |||
Related Party Transaction [Line Items] | |||
Deposits held by related parties, beginning | [2] | 194,981 | |
Advances | [2] | 1,225,118 | 2,292,912 |
Costs and expenses | [2] | (1,420,829) | (2,097,931) |
Foreign exchange effect | [2] | 730 | |
Deposits held by related parties, beginning | [2] | $ 194,981 | |
[1]Related Party A is a company controlled by a director and officer.[2]Related Party B is a company controlled by an officer. |
SCHEDULE OF DUE TO RELATED PART
SCHEDULE OF DUE TO RELATED PARTIES (Details) - USD ($) | Apr. 30, 2022 | Oct. 31, 2021 | Oct. 31, 2020 |
Related Party Transactions [Abstract] | |||
Wages payable to directors and officers | $ 357,500 | $ 357,500 | $ 161,922 |
Benefits payable to directors and officers | 730,810 | 539,209 | |
Fees and expenses payable to directors and officers | 164,970 | 127,878 | 682,068 |
Interest due to a shareholder | 2,230 | ||
Total | $ 1,253,280 | $ 1,026,817 | $ 843,990 |
RELATED PARTY TRANSACTIONS (Det
RELATED PARTY TRANSACTIONS (Details Narrative) | 1 Months Ended | 6 Months Ended | 12 Months Ended | ||||||||||
Nov. 03, 2021 USD ($) shares | Sep. 12, 2018 | Aug. 28, 2018 USD ($) | Jun. 30, 2021 USD ($) | Jun. 30, 2021 CAD ($) | Apr. 30, 2022 USD ($) | Apr. 30, 2022 CAD ($) | Apr. 30, 2021 USD ($) | Oct. 31, 2021 USD ($) | Oct. 31, 2021 CAD ($) | Oct. 31, 2020 USD ($) | Oct. 31, 2020 CAD ($) | Nov. 03, 2021 CAD ($) $ / shares | |
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] | |||||||||||||
Director and officer aggregate amount | $ 987,912 | ||||||||||||
Costs and expenses related party | 696,431 | ||||||||||||
Related party transaction remaining balance | 291,481 | ||||||||||||
Deposit held related parties | 486,462 | ||||||||||||
Due to related parties | 1,026,817 | $ 843,990 | |||||||||||
Stock based compensation | $ 3,100,000 | 2,900,000 | |||||||||||
Salaries management and consulting fees | 3,020,102 | 1,785,032 | |||||||||||
Consulting fees | 95,390 | $ 120,000 | 35,771 | $ 45,000 | |||||||||
Director and officer | 20,000 | ||||||||||||
Due to related parties | 1,253,280 | 1,026,817 | 843,990 | ||||||||||
Number of common stock issued | 546,697 | $ 2,024,442 | 6,841,169 | 376,997 | |||||||||
Officer [Member] | |||||||||||||
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] | |||||||||||||
Director and officer aggregate amount | 2,292,912 | ||||||||||||
Costs and expenses related party | 2,097,931 | ||||||||||||
Related party transaction remaining balance | 194,981 | ||||||||||||
Stock based compensation | 160,700 | ||||||||||||
Directors and Officers [Member] | |||||||||||||
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] | |||||||||||||
Salaries management and consulting fees | 1,626,279 | ||||||||||||
Directors officers and related parties stock based compensation | $ 10,248,013 | $ 300,211 | |||||||||||
Directors and Officers [Member] | Sublease Agreement [Member] | |||||||||||||
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] | |||||||||||||
Lease description | lease term from April 1, 2021 to March 31, 2023 | lease term from April 1, 2021 to March 31, 2023 | |||||||||||
Payments for rent | $ 7,656 | $ 9,794 | |||||||||||
Management [Member] | |||||||||||||
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] | |||||||||||||
Consulting fees | 27,630 | $ 35,000 | |||||||||||
Executive Officer [Member] | |||||||||||||
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] | |||||||||||||
Consulting fees | $ 30,000 | ||||||||||||
Director Andr Officer [Member] | Related Party Agreement [Member] | |||||||||||||
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] | |||||||||||||
Equity method investment, ownership percentage | 5% | ||||||||||||
Number of common stock issued | $ 5,000,000 | ||||||||||||
Number of common stock issued, shares | shares | 9,163,425 | ||||||||||||
Share price | $ / shares | $ 0.65 | ||||||||||||
Fair value of share issue | $ 4,796,832 | $ 5,956,226 |
CONTINGENT LIABILITIES AND CO_2
CONTINGENT LIABILITIES AND COMMITMENTS (Details Narrative) | 1 Months Ended | 6 Months Ended | 12 Months Ended | |||||||||||||||||||||||||||||
Mar. 04, 2022 USD ($) | Feb. 08, 2021 USD ($) shares | Feb. 08, 2021 CAD ($) shares | Dec. 31, 2020 USD ($) | Dec. 31, 2020 CAD ($) | Dec. 30, 2020 USD ($) | Dec. 30, 2020 CAD ($) | Sep. 29, 2020 USD ($) | Sep. 30, 2021 USD ($) | Jun. 30, 2021 USD ($) | Jun. 30, 2021 CAD ($) | Apr. 30, 2022 USD ($) $ / shares shares | Apr. 30, 2022 CAD ($) | Apr. 30, 2021 USD ($) shares | Oct. 31, 2021 USD ($) $ / shares shares | Oct. 31, 2021 CAD ($) | Oct. 31, 2020 USD ($) $ / shares shares | Oct. 31, 2020 CAD ($) | Apr. 22, 2022 CAD ($) shares | Nov. 03, 2021 USD ($) shares | Nov. 03, 2021 CAD ($) $ / shares shares | Aug. 11, 2021 $ / shares | Jun. 07, 2021 USD ($) shares | Jun. 07, 2021 CAD ($) shares | May 18, 2021 shares | Apr. 19, 2021 USD ($) | Mar. 11, 2021 CAD ($) | Jan. 13, 2021 $ / shares | Sep. 12, 2018 | Aug. 28, 2018 USD ($) | Nov. 01, 2016 USD ($) | Nov. 01, 2016 CAD ($) $ / shares | |
Loss Contingencies [Line Items] | ||||||||||||||||||||||||||||||||
Loss Contingency, Damages Sought, Value | $ 3,900,000 | $ 4,900,000 | $ 3,400,000 | $ 4,200,000 | ||||||||||||||||||||||||||||
Payment termination amount | $ 76,588 | $ 102,001 | ||||||||||||||||||||||||||||||
Debt instrument, face amount | $ 100,000 | |||||||||||||||||||||||||||||||
Commitment of cash or arrangments amount | $ 1,800 | |||||||||||||||||||||||||||||||
Commitment of cash or arrangments amount cash | $ 2,500 | |||||||||||||||||||||||||||||||
Number of shares issued price per share | $ / shares | $ 0.65 | $ 0.65 | $ 0.05 | |||||||||||||||||||||||||||||
Cash | $ 4,000,000 | $ 21,600 | ||||||||||||||||||||||||||||||
Outstanding amount payable | 53,491 | |||||||||||||||||||||||||||||||
Sublease Income | $ 7,909 | $ 9,794 | $ 16,727 | $ 20,715 | ||||||||||||||||||||||||||||
Payments for (Proceeds from) Tenant Allowance | $ 41,010 | $ 41,010 | ||||||||||||||||||||||||||||||
Percentage of issued and outstanding common shares | 5% | |||||||||||||||||||||||||||||||
Common stock outstanding | $ 5,000,000 | |||||||||||||||||||||||||||||||
Common stock shares issued | shares | 434,866,801 | 392,943,398 | 323,419,527 | 933,333 | 9,163,425 | 9,163,425 | 1,538,461 | 1,538,461 | 1,360,959 | |||||||||||||||||||||||
Common share price per share | (per share) | $ 0.001 | $ 0.001 | $ 0.001 | $ 0.65 | $ 0.30 | |||||||||||||||||||||||||||
Fair value of equivalents | $ 4,796,832 | $ 5,956,226 | $ 305,832 | $ 369,231 | $ 5,956,226 | |||||||||||||||||||||||||||
Lodestar Management Group L L C [Member] | ||||||||||||||||||||||||||||||||
Loss Contingencies [Line Items] | ||||||||||||||||||||||||||||||||
Debt instrument, face amount | $ 32,716 | $ 53,491 | ||||||||||||||||||||||||||||||
Commitment of cash or arrangments amount | $ 1,800 | $ 2,500 | ||||||||||||||||||||||||||||||
Number of shares issued price per share | $ / shares | $ 0.05 | |||||||||||||||||||||||||||||||
Issuance of share based minimum requirement | 1,800 | $ 2,500 | ||||||||||||||||||||||||||||||
Cash | $ 30,624 | |||||||||||||||||||||||||||||||
Number of shares issued | shares | ||||||||||||||||||||||||||||||||
Lampert Agreement [Member] | ||||||||||||||||||||||||||||||||
Loss Contingencies [Line Items] | ||||||||||||||||||||||||||||||||
Debt instrument, face amount | $ 367,227 | |||||||||||||||||||||||||||||||
Percentage of interest rate owned | 9% | |||||||||||||||||||||||||||||||
Lease Agreement [Member] | ||||||||||||||||||||||||||||||||
Loss Contingencies [Line Items] | ||||||||||||||||||||||||||||||||
Loss Contingency, Damages Sought, Value | $ 120,000 | |||||||||||||||||||||||||||||||
Sublease Income | $ 9,113 | |||||||||||||||||||||||||||||||
Lessee, Operating Lease, Description | lease term from September 14, 2021 to February 28, 2025 | lease term from October 1, 2020 to September 30, 2023 | lease term from October 1, 2020 to September 30, 2023 | |||||||||||||||||||||||||||||
Payments for Rent | $ 9,113 | $ 16,194 | $ 20,715 | |||||||||||||||||||||||||||||
Sublease Agreement [Member] | Directors and Officers [Member] | ||||||||||||||||||||||||||||||||
Loss Contingencies [Line Items] | ||||||||||||||||||||||||||||||||
Lessee, Operating Lease, Description | lease term from April 1, 2021 to March 31, 2023 | lease term from April 1, 2021 to March 31, 2023 | ||||||||||||||||||||||||||||||
Payments for Rent | $ 7,656 | $ 9,794 | ||||||||||||||||||||||||||||||
Maximum [Member] | ||||||||||||||||||||||||||||||||
Loss Contingencies [Line Items] | ||||||||||||||||||||||||||||||||
Loss Contingency, Damages Sought, Value | $ 2,500,000 | |||||||||||||||||||||||||||||||
Warrant to purchase connon stock shares | shares | 33,000,000 | 33,000,000 | ||||||||||||||||||||||||||||||
Issuance of share based minimum requirement | $ 1,800 | $ 2,500 |
PROMISSORY NOTE (Details Narrat
PROMISSORY NOTE (Details Narrative) | 12 Months Ended | |||||
Oct. 31, 2021 USD ($) | Oct. 31, 2020 USD ($) | Oct. 31, 2020 CAD ($) | Oct. 31, 2019 USD ($) | Oct. 31, 2019 CAD ($) | Apr. 22, 2022 CAD ($) | |
Related party loan | $ 112,895 | $ 150,000 | ||||
Percentage of unsecured loan interest | 18% | 18% | ||||
Interest and debt expense | $ 1,639 | $ 16,655 | ||||
Outstanding notes payable | $ 100,000 | |||||
Promissory Note [Member] | ||||||
Related party loan | 44,588 | $ 60,000 | $ 112,895 | $ 150,000 | ||
Percentage of unsecured loan interest | 18% | 18% | ||||
Interest and debt expense | 1,639 | 16,655 | ||||
Repayments of debt | 65,761 | 101,066 | ||||
Outstanding notes payable | 60,567 | |||||
Additional increase in promissory note loan | $ 157,483 | $ 210,000 | ||||
Maturity date | Sep. 24, 2021 | Sep. 24, 2021 | ||||
Minimum [Member] | ||||||
Additional increase in promissory note loan | $ 44,588 | $ 60,000 | ||||
Maximum [Member] | ||||||
Additional increase in promissory note loan | $ 157,483 | $ 210,000 |
PROVISION FOR FLOW THROUGH SH_2
PROVISION FOR FLOW THROUGH SHARE ISSUANCES (Details Narrative) - USD ($) | Apr. 30, 2022 | Oct. 31, 2021 | Oct. 31, 2020 |
Provision For Flow Through Share Issuances | |||
Provision for tax and related obligations | $ 225,833 | $ 233,285 | $ 216,924 |
SCHEDULE OF OPTION PRICING MODE
SCHEDULE OF OPTION PRICING MODEL (Details) | 6 Months Ended | 12 Months Ended | ||||
Apr. 30, 2022 $ / shares | Apr. 30, 2021 | Oct. 31, 2021 $ / shares | Oct. 31, 2020 | Apr. 30, 2022 $ / shares | Oct. 31, 2021 $ / shares | |
Short-Term Debt [Line Items] | ||||||
Expected life in years | 5 years | 5 years | ||||
Expected dividend rate | ||||||
October 31, 2021 [Member] | ||||||
Short-Term Debt [Line Items] | ||||||
Risk free rate of interest | 1.08% | 1.08% | ||||
Expected life in years | 1 year 1 month 9 days | 1 year 1 month 9 days | ||||
Conversion exercise price | $ 0.10 | $ 0.10 | ||||
Underlying share price of the Company | (per share) | $ 0.59 | $ 0.73 | ||||
Expected volatility | 107.62% | 107.62% | ||||
Expected dividend rate | ||||||
June 15, 2021 [Member] | ||||||
Short-Term Debt [Line Items] | ||||||
Risk free rate of interest | 0.31% | 0.31% | ||||
Expected life in years | 1 year 6 months | 1 year 6 months | ||||
Conversion exercise price | $ 0.10 | $ 0.10 | ||||
Underlying share price of the Company | (per share) | $ 0.19 | 0.23 | ||||
Expected volatility | 87.17% | 87.17% | ||||
Expected dividend rate | ||||||
July 27, 2020 [Member] | ||||||
Short-Term Debt [Line Items] | ||||||
Risk free rate of interest | 0.26% | 0.26% | ||||
Expected life in years | 8 months 26 days | |||||
Conversion exercise price | 0.15 | |||||
Underlying share price of the Company | $ 0.13 | |||||
Expected volatility | 82.54% | |||||
Expected dividend rate | ||||||
April 22, 2022 [Member] | ||||||
Short-Term Debt [Line Items] | ||||||
Risk free rate of interest | 2.65% | |||||
Expected life in years | 2 months 23 days | |||||
Conversion exercise price | $ 0.12 | |||||
Underlying share price of the Company | 0.36 | |||||
Expected volatility | 99.90% | |||||
Expected dividend rate | ||||||
November 1, 2021 [Member] | ||||||
Short-Term Debt [Line Items] | ||||||
Risk free rate of interest | 1.07% | |||||
Expected life in years | 8 months 12 days | |||||
Conversion exercise price | 0.12 | |||||
Underlying share price of the Company | 0.75 | |||||
Expected volatility | 124.34% | |||||
Expected dividend rate | ||||||
July Twenty Seven Two Thousand Twenty [Member] | ||||||
Short-Term Debt [Line Items] | ||||||
Expected life in years | 8 months 26 days | |||||
Conversion exercise price | 0.15 | |||||
Underlying share price of the Company | $ 0.13 | |||||
Expected volatility | 82.54% | |||||
Expected dividend rate |
SCHEDULE OF DERIVATIVE INSTRUME
SCHEDULE OF DERIVATIVE INSTRUMENTS (Details) - USD ($) | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Apr. 30, 2022 | Apr. 30, 2021 | Apr. 30, 2022 | Apr. 30, 2021 | Oct. 31, 2021 | Oct. 31, 2020 | |
Short-Term Debt [Line Items] | ||||||
Accretion and interest expense | $ 326,868 | $ 17,760 | $ 649,148 | $ 36,334 | $ 74,319 | $ 60,638 |
Foreign currency translation | 49,183 | (114,645) | 213,963 | (191,049) | (278,066) | (76,806) |
Fair value of embedded derivative liability recognized | 25,041 | |||||
Fair value adjustment | 4,858,644 | $ 31,190 | (6,701,147) | 16,656 | (5,701,270) | 4,979 |
Amortization | 600,771 | |||||
Debt Host Liability [Member] | ||||||
Short-Term Debt [Line Items] | ||||||
Balance, beginning | 107 | 96,318 | 96,318 | |||
Value of debt host liability recognized | 1 | 87,083 | ||||
Accretion and interest expense | 50,819 | 23,693 | 8,751 | |||
Foreign currency translation | (82) | 5,655 | 484 | |||
Conversion | (628,031) | (125,560) | ||||
Effects of functional currency change | 1,500,000 | |||||
Balance, ending | 2,922,813 | 2,922,813 | 107 | 96,318 | ||
Value of debt host liability recognized | 1 | |||||
Inception | 2,000,000 | |||||
Debt Host Liability [Member] | July 2020 Convertible Debenture [Member] | ||||||
Short-Term Debt [Line Items] | ||||||
Balance, beginning | 96,318 | 96,318 | ||||
Value of debt host liability recognized | 87,083 | |||||
Accretion and interest expense | 23,587 | 8,751 | ||||
Foreign currency translation | 5,655 | 484 | ||||
Conversion | (125,560) | |||||
Effects of functional currency change | ||||||
Balance, ending | 96,318 | |||||
Value of debt host liability recognized | ||||||
Inception | ||||||
Debt Host Liability [Member] | June 2021 Convertible Debenture [Member] | ||||||
Short-Term Debt [Line Items] | ||||||
Balance, beginning | 44 | |||||
Value of debt host liability recognized | 1 | |||||
Accretion and interest expense | 5,610 | 43 | ||||
Foreign currency translation | ||||||
Conversion | (600,000) | |||||
Effects of functional currency change | 1,500,000 | |||||
Balance, ending | 905,654 | 905,654 | 44 | |||
Value of debt host liability recognized | 1 | |||||
Inception | ||||||
Debt Host Liability [Member] | July 2021 Convertible Debenture [Member] | ||||||
Short-Term Debt [Line Items] | ||||||
Balance, beginning | 63 | |||||
Value of debt host liability recognized | ||||||
Accretion and interest expense | 28,050 | 63 | ||||
Foreign currency translation | (82) | |||||
Conversion | (28,031) | |||||
Effects of functional currency change | ||||||
Balance, ending | 63 | |||||
Value of debt host liability recognized | ||||||
Inception | ||||||
Debt Host Liability [Member] | April Two Thousand Twenty Two Convertible Debenture [Member] | ||||||
Short-Term Debt [Line Items] | ||||||
Balance, beginning | ||||||
Accretion and interest expense | 17,159 | |||||
Foreign currency translation | ||||||
Conversion | ||||||
Effects of functional currency change | ||||||
Balance, ending | 2,017,159 | 2,017,159 | ||||
Value of debt host liability recognized | ||||||
Inception | 2,000,000 | |||||
Embedded Derivative Liability [Member] | ||||||
Short-Term Debt [Line Items] | ||||||
Balance, beginning | 7,449,700 | 20,123 | 20,123 | |||
Foreign currency translation | (3,478) | 86,954 | 61 | |||
Fair value of embedded derivative liability recognized | 1,646,600 | 25,041 | ||||
Fair value adjustment | (259,447) | 5,701,270 | (4,979) | |||
Conversion | (158,169) | (5,247) | ||||
Effects of functional currency change | (7,028,606) | |||||
Balance, ending | 7,449,700 | 20,123 | ||||
Embedded Derivative Liability [Member] | July 2020 Convertible Debenture [Member] | ||||||
Short-Term Debt [Line Items] | ||||||
Balance, beginning | 20,123 | 20,123 | ||||
Foreign currency translation | 1,182 | 61 | ||||
Fair value of embedded derivative liability recognized | 25,041 | |||||
Fair value adjustment | (16,058) | (4,979) | ||||
Conversion | (5,247) | |||||
Effects of functional currency change | ||||||
Balance, ending | 20,123 | |||||
Embedded Derivative Liability [Member] | June 2021 Convertible Debenture [Member] | ||||||
Short-Term Debt [Line Items] | ||||||
Balance, beginning | 7,449,700 | |||||
Foreign currency translation | 85,772 | |||||
Fair value of embedded derivative liability recognized | 1,646,600 | |||||
Fair value adjustment | 5,717,328 | |||||
Conversion | ||||||
Effects of functional currency change | (7,449,700) | |||||
Balance, ending | 7,449,700 | |||||
Embedded Derivative Liability [Member] | July 2021 Convertible Debenture [Member] | ||||||
Short-Term Debt [Line Items] | ||||||
Balance, beginning | ||||||
Foreign currency translation | (3,478) | |||||
Fair value of embedded derivative liability recognized | ||||||
Fair value adjustment | (259,447) | |||||
Conversion | (158,169) | |||||
Effects of functional currency change | 421,094 | |||||
Balance, ending | ||||||
Embedded Derivative Liability [Member] | April Two Thousand Twenty Two Convertible Debenture [Member] | ||||||
Short-Term Debt [Line Items] | ||||||
Balance, beginning | ||||||
Foreign currency translation | ||||||
Fair value of embedded derivative liability recognized | ||||||
Fair value adjustment | ||||||
Conversion | ||||||
Effects of functional currency change | ||||||
Balance, ending | ||||||
Combined Value of Convertible Debenture [Member] | ||||||
Short-Term Debt [Line Items] | ||||||
Balance, beginning | 7,449,807 | 116,441 | 116,441 | |||
Balance, ending | 1,783,584 | 1,783,584 | 7,449,807 | 116,441 | ||
Balance, beginning | 7,449,807 | 116,441 | 116,441 | |||
Conversion | ||||||
Convertible Debt | 7,449,807 | 116,441 | ||||
Balance, ending | (7,449,807) | (116,441) | ||||
Combined Value of Convertible Debenture [Member] | July 2020 Convertible Debenture [Member] | ||||||
Short-Term Debt [Line Items] | ||||||
Balance, beginning | 116,441 | 116,441 | ||||
Balance, ending | 116,441 | |||||
Balance, beginning | 116,441 | 116,441 | ||||
Conversion | ||||||
Convertible Debt | 116,441 | |||||
Balance, ending | (116,441) | |||||
Combined Value of Convertible Debenture [Member] | June 2021 Convertible Debenture [Member] | ||||||
Short-Term Debt [Line Items] | ||||||
Balance, beginning | 7,449,744 | |||||
Balance, ending | 6,423 | 6,423 | 7,449,744 | |||
Balance, beginning | 7,449,744 | |||||
Conversion | ||||||
Convertible Debt | 7,449,744 | |||||
Balance, ending | (7,449,744) | |||||
Combined Value of Convertible Debenture [Member] | July 2021 Convertible Debenture [Member] | ||||||
Short-Term Debt [Line Items] | ||||||
Balance, beginning | 63 | |||||
Balance, ending | 63 | |||||
Balance, beginning | 63 | |||||
Conversion | ||||||
Convertible Debt | 63 | |||||
Balance, ending | (63) | |||||
Combined Value of Convertible Debenture [Member] | April Two Thousand Twenty Two Convertible Debenture [Member] | ||||||
Short-Term Debt [Line Items] | ||||||
Balance, beginning | 7,449,744 | |||||
Balance, ending | 1,777,161 | 1,777,161 | 7,449,744 | |||
Debt Discount [Member] | ||||||
Short-Term Debt [Line Items] | ||||||
Effects of functional currency change | (1,500,000) | |||||
Balance, beginning | ||||||
Amortization | 600,771 | |||||
Convertible Debt | 1,139,229 | 1,139,229 | ||||
Inception | (240,000) | |||||
Balance, ending | (1,139,229) | (1,139,229) | ||||
Debt Discount [Member] | July 2020 Convertible Debenture [Member] | ||||||
Short-Term Debt [Line Items] | ||||||
Effects of functional currency change | ||||||
Balance, beginning | ||||||
Amortization | ||||||
Convertible Debt | ||||||
Inception | ||||||
Balance, ending | ||||||
Debt Discount [Member] | June 2021 Convertible Debenture [Member] | ||||||
Short-Term Debt [Line Items] | ||||||
Effects of functional currency change | (1,500,000) | |||||
Balance, beginning | ||||||
Amortization | 600,769 | |||||
Convertible Debt | 899,231 | 899,231 | ||||
Inception | ||||||
Balance, ending | (899,231) | (899,231) | ||||
Debt Discount [Member] | July 2021 Convertible Debenture [Member] | ||||||
Short-Term Debt [Line Items] | ||||||
Effects of functional currency change | ||||||
Balance, beginning | ||||||
Amortization | ||||||
Convertible Debt | ||||||
Inception | ||||||
Balance, ending | ||||||
Debt Discount [Member] | April Two Thousand Twenty Two Convertible Debenture [Member] | ||||||
Short-Term Debt [Line Items] | ||||||
Effects of functional currency change | ||||||
Balance, beginning | ||||||
Amortization | 2 | |||||
Convertible Debt | 239,998 | 239,998 | ||||
Inception | (240,000) | |||||
Balance, ending | $ (239,998) | $ (239,998) |
CONVERTIBLE DEBENTURE AND DER_3
CONVERTIBLE DEBENTURE AND DERIVATIVE LIABILITY (Details Narrative) | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||||||||||||||||||||||||||||
Jun. 08, 2022 $ / shares shares | Apr. 22, 2022 CAD ($) $ / shares shares | Apr. 14, 2022 USD ($) $ / shares shares | Nov. 03, 2021 $ / shares shares | Oct. 31, 2021 USD ($) $ / shares shares | Oct. 31, 2021 CAD ($) | Jul. 30, 2021 | Jul. 30, 2021 USD ($) | Jul. 30, 2021 CAD ($) | Jun. 15, 2021 USD ($) shares | May 18, 2021 USD ($) shares | Feb. 10, 2022 $ / shares shares | Apr. 30, 2022 USD ($) $ / shares shares | Apr. 30, 2022 CAD ($) shares | Apr. 30, 2021 USD ($) shares | Oct. 31, 2021 USD ($) $ / shares shares | Oct. 31, 2020 USD ($) shares | Jun. 13, 2022 $ / shares shares | Apr. 30, 2022 CAD ($) shares | Nov. 03, 2021 $ / shares shares | Nov. 02, 2021 USD ($) | Oct. 31, 2021 CAD ($) $ / shares shares | Aug. 11, 2021 $ / shares | Jul. 15, 2021 USD ($) | Jul. 15, 2021 CAD ($) $ / shares | Jun. 15, 2021 CAD ($) | Jun. 07, 2021 $ / shares shares | Jul. 27, 2020 USD ($) | Jul. 27, 2020 CAD ($) $ / shares | Feb. 19, 2020 $ / shares | Oct. 31, 2019 | Nov. 01, 2016 $ / shares | |
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||
Debt instrument, face amount | $ 100,000 | |||||||||||||||||||||||||||||||
Debt instrument, interest rate percentage | 18% | |||||||||||||||||||||||||||||||
Debt host liability share, face value | $ / shares | $ 0.65 | $ 0.65 | $ 0.05 | |||||||||||||||||||||||||||||
Common stock, shares issued | shares | 933,333 | 9,163,425 | 392,943,398 | 1,360,959 | 434,866,801 | 392,943,398 | 323,419,527 | 434,866,801 | 9,163,425 | 392,943,398 | 1,538,461 | |||||||||||||||||||||
Conversion of stock, shares issued | shares | 263,973 | |||||||||||||||||||||||||||||||
Common stock, value issued | $ 29,842,167 | $ 39,096,950 | $ 29,842,167 | $ 21,322,022 | ||||||||||||||||||||||||||||
Warrants exercisable price | $ / shares | $ 0.20 | $ 0.05 | $ 0.08 | |||||||||||||||||||||||||||||
Interest expense | 70,521 | |||||||||||||||||||||||||||||||
Debt conversion, description | one-half of one Class A common stock purchase warrant, with each whole warrant being exercisable at a price of $0.13 until June 10, 2026, and (iii) one-half of one Class B common stock purchase warrant, with each whole warrant being exercisable at a price of $0.19 until June 10, 2026 (collectively, the “Class A and B Warrants”). In addition, the conversion price for accrued interest is the greater of (i) $0.10 and (ii) the minimum conversion price permitted by the TSX-V at the time of conversion. | |||||||||||||||||||||||||||||||
Debt instrument, fair value | 87,083 | $ 87,083 | ||||||||||||||||||||||||||||||
Embedded derivative liability | 25,041 | |||||||||||||||||||||||||||||||
Fair value of embedded derivative liability | 20,123 | |||||||||||||||||||||||||||||||
Contractual interest | 70,521 | |||||||||||||||||||||||||||||||
Penalty cash | 21,600 | 4,000,000 | 21,600 | |||||||||||||||||||||||||||||
Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature | 240,000 | $ 79,542 | ||||||||||||||||||||||||||||||
Amortization of debt discount premium | 600,771 | |||||||||||||||||||||||||||||||
Warrants [Member] | ||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||
Loss on recognition of debt liability | 7,060,790 | |||||||||||||||||||||||||||||||
Derivative Liability | 2,465,603 | $ 26,956,177 | ||||||||||||||||||||||||||||||
[custom:ExerciseOfCommonSharePurchaseWarrants] | 4,482,962 | |||||||||||||||||||||||||||||||
Broker Warrants [Member] | ||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||
Derivative Liability | $ 2,658 | $ 76,811 | ||||||||||||||||||||||||||||||
Common Stock [Member] | ||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||
Debt host liability share, face value | $ / shares | $ 0.65 | $ 0.24 | ||||||||||||||||||||||||||||||
Number of shares issued | shares | 1,375,499 | 1,375,499 | 25,724,955 | 56,979,482 | 3,643,791 | |||||||||||||||||||||||||||
Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature | ||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Common Stock [Member] | ||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||
Debt host liability share, face value | $ / shares | $ 0.19 | $ 0.19 | $ 0.65 | |||||||||||||||||||||||||||||
Number of shares issued | shares | 9,163,425 | 15,159,448 | ||||||||||||||||||||||||||||||
Number of warrants exercisable | shares | 3,793,331 | |||||||||||||||||||||||||||||||
July 2020 Convertible Debenture [Member] | ||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||
Debt instrument, face amount | $ 112,124 | $ 150,000 | ||||||||||||||||||||||||||||||
Debt instrument, interest rate percentage | 12% | 12% | ||||||||||||||||||||||||||||||
Debt host liability share, face value | $ / shares | $ 0.15 | |||||||||||||||||||||||||||||||
Common stock, shares issued | shares | 1,360,959 | |||||||||||||||||||||||||||||||
Conversion of stock, shares issued | shares | 263,973 | |||||||||||||||||||||||||||||||
Common stock, value issued | $ 26,286 | |||||||||||||||||||||||||||||||
Number of shares issued | shares | 1,360,959 | |||||||||||||||||||||||||||||||
Debt instrument, fair value | 87,083 | $ 96,318 | ||||||||||||||||||||||||||||||
Embedded derivative liability | 25,041 | |||||||||||||||||||||||||||||||
Effective interest rate percentage | 37% | 37% | ||||||||||||||||||||||||||||||
July 2021 Convertible Debenture [Member] | ||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||
Debt instrument, face amount | 79,542 | 79,542 | $ 100,000 | $ 79,542 | $ 100,000 | |||||||||||||||||||||||||||
Debt instrument, interest rate percentage | 12% | 12% | ||||||||||||||||||||||||||||||
Conversion of stock, shares issued | shares | 933,333 | |||||||||||||||||||||||||||||||
Debt instrument, conversion price | $ / shares | $ 0.12 | |||||||||||||||||||||||||||||||
Warrants exercisable price | $ / shares | $ 0.20 | |||||||||||||||||||||||||||||||
Interest expense | 5,802 | $ 7,299 | ||||||||||||||||||||||||||||||
Debt instrument interest rate description | effective interest rate of 1,878% | |||||||||||||||||||||||||||||||
Convertible debenture face value | $ 79,542 | $ 100,000 | 79,542 | $ 100,000 | ||||||||||||||||||||||||||||
Fair value of embedded derivative liability | 421,095 | $ 529,400 | ||||||||||||||||||||||||||||||
Effective interest rate percentage | 594% | |||||||||||||||||||||||||||||||
Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature | $ 341,553 | $ 429,400 | ||||||||||||||||||||||||||||||
June 2021 Convertible Debenture [Member] | ||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||
Debt instrument, face amount | $ 1,500,000 | $ 1,500,000 | $ 1,500,000 | $ 1,500,000 | ||||||||||||||||||||||||||||
Debt instrument, interest rate percentage | 12% | 12% | ||||||||||||||||||||||||||||||
Debt host liability share, face value | $ / shares | $ 1 | $ 1 | $ 1 | |||||||||||||||||||||||||||||
Debt instrument interest rate description | effective interest rate of 1,240 | effective interest rate of 1,240 | ||||||||||||||||||||||||||||||
Debt instrument maturity date | Dec. 10, 2022 | |||||||||||||||||||||||||||||||
Conversion of convertiable debenture | shares | 15,000,000 | |||||||||||||||||||||||||||||||
Debt conversion, description | (i) one share of the Company’ common stock, (ii) one-half of one Class A common stock purchase warrant, with each whole warrant being exercisable at a price of $0.13 until June 10, 2026, and (iii) one-half of one Class B common stock purchase warrant, with each whole warrant being exercisable at a price of $0.19 until June 10, 2026 (collectively, the “Class A and B Warrants”). In addition, the conversion price for accrued interest is the greater of (i) $0.10 and (ii) the minimum conversion price permitted by the TSX-V at the time of conversion | (i) one share of the Company’ common stock, (ii) one-half of one Class A common stock purchase warrant, with each whole warrant being exercisable at a price of $0.13 until June 10, 2026, and (iii) one-half of one Class B common stock purchase warrant, with each whole warrant being exercisable at a price of $0.19 until June 10, 2026 (collectively, the “Class A and B Warrants”). In addition, the conversion price for accrued interest is the greater of (i) $0.10 and (ii) the minimum conversion price permitted by the TSX-V at the time of conversion | ||||||||||||||||||||||||||||||
Number of shares issued | shares | 6,000,000 | 6,000,000 | ||||||||||||||||||||||||||||||
Debt instrument, fair value | $ 1,500,000 | |||||||||||||||||||||||||||||||
Embedded derivative liability | 1,646,600 | $ 1,646,600 | ||||||||||||||||||||||||||||||
Fair value of embedded derivative liability | $ 7,449,700 | 7,449,700 | ||||||||||||||||||||||||||||||
Convertible debt combined value | $ 7,449,744 | 7,449,744 | ||||||||||||||||||||||||||||||
Loss on recognition of debt liability | 146,601 | $ 146,601 | ||||||||||||||||||||||||||||||
Convertible debenture effective interest rate | 1,448 | 1,448 | 1,448 | |||||||||||||||||||||||||||||
Contractual interest | 140,942 | |||||||||||||||||||||||||||||||
Amortization of debt discount premium | 600,769 | |||||||||||||||||||||||||||||||
Debt discount carry value | $ 899,231 | |||||||||||||||||||||||||||||||
June 2021 Convertible Debenture [Member] | Convertible Debenture [Member] | ||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||
Debt instrument, fair value | $ 44 | $ 44 | ||||||||||||||||||||||||||||||
June 2021 Convertible Debenture [Member] | Common Class A [Member] | ||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||
Warrants exercisable price | $ / shares | $ 0.13 | |||||||||||||||||||||||||||||||
Number of warrants exercisable | shares | 3,000,000 | 3,000,000 | ||||||||||||||||||||||||||||||
June 2021 Convertible Debenture [Member] | Common Class B [Member] | ||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||
Warrants exercisable price | $ / shares | $ 0.19 | |||||||||||||||||||||||||||||||
Number of warrants exercisable | shares | 3,000,000 | 3,000,000 | ||||||||||||||||||||||||||||||
June 2021 Convertible Debenture [Member] | Common Stock [Member] | ||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||
Number of shares issued | shares | 6,000,000 | 6,000,000 | ||||||||||||||||||||||||||||||
June 2021 Convertible Debenture [Member] | Subsequent Event [Member] | ||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||
Number of shares issued | shares | 1,000,000 | 3,000,000 | ||||||||||||||||||||||||||||||
June 2021 Convertible Debenture [Member] | Subsequent Event [Member] | Common Class A [Member] | ||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||
Warrants exercisable price | $ / shares | $ 0.13 | $ 0.13 | ||||||||||||||||||||||||||||||
Number of warrants exercisable | shares | 500,000 | 1,500,000 | 1,500,000 | |||||||||||||||||||||||||||||
June 2021 Convertible Debenture [Member] | Subsequent Event [Member] | Common Class B [Member] | ||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||
Warrants exercisable price | $ / shares | $ 0.19 | $ 0.19 | ||||||||||||||||||||||||||||||
Number of warrants exercisable | shares | 500,000 | 1,500,000 | 1,500,000 | |||||||||||||||||||||||||||||
June 2021 Convertible Debenture [Member] | Subsequent Event [Member] | Common Stock [Member] | ||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||
Number of shares issued | shares | 1,000,000 | 3,000,000 | ||||||||||||||||||||||||||||||
July 2020 Convertible Debenture [Member] | ||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||
Convertible debt combined value | $ 116,441 | |||||||||||||||||||||||||||||||
April Two Thousand Twenty Two Convertible Debenture [Member] | ||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||
Debt instrument, face amount | $ 2,000,000 | |||||||||||||||||||||||||||||||
Debt instrument, interest rate percentage | 15% | |||||||||||||||||||||||||||||||
Interest expense | $ 2 | |||||||||||||||||||||||||||||||
Convertible debenture face value | $ 240,000 | |||||||||||||||||||||||||||||||
Debt instrument maturity date | Oct. 14, 2023 | |||||||||||||||||||||||||||||||
Effective interest rate percentage | 22% | 22% | ||||||||||||||||||||||||||||||
Contractual interest | $ 13,151 | |||||||||||||||||||||||||||||||
Penalty cash | $ 20,000 | |||||||||||||||||||||||||||||||
Debt discount carry value | $ 239,998 | |||||||||||||||||||||||||||||||
April Two Thousand Twenty Two Convertible Debenture [Member] | Common Stock [Member] | ||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||
Warrants exercisable price | $ / shares | $ 0.40 | |||||||||||||||||||||||||||||||
Number of shares issued | shares | 6,666,667 |
SUMMARY OF CHANGES IN COMMON SH
SUMMARY OF CHANGES IN COMMON SHARE PURCHASE WARRANTS (Details) | 6 Months Ended | 12 Months Ended | ||||||||||||||||
Apr. 30, 2022 $ / shares shares | Apr. 30, 2022 $ / shares $ / shares shares | Apr. 30, 2021 $ / shares $ / shares shares | Apr. 30, 2021 $ / shares shares | Oct. 31, 2021 $ / shares $ / shares shares | Oct. 31, 2021 $ / shares shares | Oct. 31, 2020 $ / shares $ / shares shares | Oct. 31, 2020 $ / shares shares | Apr. 30, 2022 $ / shares | Apr. 22, 2022 $ / shares | Feb. 19, 2020 $ / shares | ||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Exercise price | $ / shares | $ 0.05 | $ 0.05 | $ 0.20 | $ 0.08 | ||||||||||||||
Beginning balance | 59,548,982 | 59,548,982 | 10,109,642 | 10,109,642 | 10,109,642 | 10,109,642 | 71,596,996 | 71,596,996 | ||||||||||
Granted | 56,979,482 | 56,979,482 | 3,643,791 | 3,643,791 | ||||||||||||||
Exercised | (7,014,969) | (7,014,969) | (40,336,661) | (40,336,661) | ||||||||||||||
Expired/Cancelled | (525,173) | (525,173) | (24,794,484) | (24,794,484) | ||||||||||||||
Ending balance | 59,548,982 | 59,548,982 | 10,109,642 | 10,109,642 | ||||||||||||||
Weighted average exercise price, beginning | (per share) | $ 0.22 | $ 0.11 | $ 0.11 | $ 0.11 | $ 0.11 | $ 0.07 | ||||||||||||
Weighted average exercise price, granted | (per share) | 0.23 | 0.21 | ||||||||||||||||
Weighted average exercise price, exercised | (per share) | 0.16 | 0.08 | ||||||||||||||||
Weighted average exercise price, expired/cancelled | (per share) | 0.21 | 0.08 | ||||||||||||||||
Weighted average exercise price, ending | (per share) | $ 0.22 | $ 0.11 | $ 0.11 | |||||||||||||||
Purchase Warrant One [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Beginning balance | 59,548,982 | 59,548,982 | ||||||||||||||||
Granted | 933,333 | 933,333 | ||||||||||||||||
Exercised | (23,701,146) | (23,701,146) | ||||||||||||||||
Expired/Cancelled | (5,660,296) | (5,660,296) | ||||||||||||||||
Ending balance | 31,120,873 | 31,120,873 | 59,548,982 | 59,548,982 | ||||||||||||||
Weighted average exercise price, beginning | $ / shares | $ 0.22 | |||||||||||||||||
Weighted average exercise price, granted | $ / shares | 0.20 | |||||||||||||||||
Weighted average exercise price, exercised | $ / shares | 0.18 | |||||||||||||||||
Weighted average exercise price, expired/cancelled | $ / shares | 0.16 | |||||||||||||||||
Weighted average exercise price, ending | $ / shares | $ 0.26 | $ 0.22 | ||||||||||||||||
Purchase Warrant Two [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Beginning balance | ||||||||||||||||||
Granted | 7,375,499 | 7,375,499 | ||||||||||||||||
Exercised | ||||||||||||||||||
Expired/Cancelled | ||||||||||||||||||
Ending balance | 4,375,499 | 4,375,499 | ||||||||||||||||
Weighted average exercise price, beginning | $ / shares | ||||||||||||||||||
Weighted average exercise price, granted | $ / shares | 0.27 | |||||||||||||||||
Weighted average exercise price, exercised | $ / shares | ||||||||||||||||||
Weighted average exercise price, expired/cancelled | $ / shares | ||||||||||||||||||
Weighted average exercise price, ending | $ / shares | $ 0.27 | |||||||||||||||||
Purchase Warrant [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Beginning balance | 59,548,982 | 59,548,982 | 10,109,642 | 10,109,642 | 10,109,642 | 10,109,642 | ||||||||||||
Granted | 8,308,832 | 8,308,832 | 25,724,955 | 25,724,955 | ||||||||||||||
Exercised | (23,701,146) | (23,701,146) | (400,000) | (400,000) | ||||||||||||||
Expired/Cancelled | (5,660,296) | (5,660,296) | ||||||||||||||||
Ending balance | 38,496,372 | 38,496,372 | 35,434,597 | 35,434,597 | 59,548,982 | 59,548,982 | 10,109,642 | 10,109,642 | ||||||||||
Weighted average exercise price, beginning | $ / shares | $ 0.11 | $ 0.11 | ||||||||||||||||
Weighted average exercise price, granted | $ / shares | 0.19 | |||||||||||||||||
Weighted average exercise price, exercised | $ / shares | 0.05 | |||||||||||||||||
Weighted average exercise price, expired/cancelled | $ / shares | ||||||||||||||||||
Weighted average exercise price, ending | $ / shares | 0.17 | $ 0.11 | ||||||||||||||||
August 31, 2021 [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Exercise price | $ / shares | $ 0.21 | [1] | $ 0.21 | [1] | $ 0.21 | [2] | $ 0.21 | [2] | ||||||||||
Weighted Average Life (Years) | 4 months 2 days | 4 months 2 days | 0 years | [2] | 0 years | [2] | ||||||||||||
Beginning balance | [2] | 3,643,791 | 3,643,791 | 3,643,791 | 3,643,791 | |||||||||||||
Granted | [2] | [2] | ||||||||||||||||
Exercised | (3,118,618) | [2] | (3,118,618) | [2] | ||||||||||||||
Expired/Cancelled | (525,173) | [2] | (525,173) | [2] | ||||||||||||||
Ending balance | 3,643,791 | 3,643,791 | [2] | [2] | 3,643,791 | [2] | 3,643,791 | [2] | ||||||||||
Expiry Date | [1] | Aug. 31, 2021 | Aug. 31, 2021 | |||||||||||||||
November 22, 2021 [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Exercise price | $ / shares | $ 0.19 | [1] | $ 0.19 | [1] | $ 0.19 | $ 0.19 | $ 0.19 | |||||||||||
Weighted Average Life (Years) | 6 months 21 days | 6 months 21 days | 1 month 20 days | 1 month 20 days | ||||||||||||||
Beginning balance | 4,160,021 | 4,160,021 | ||||||||||||||||
Granted | 5,599,171 | 5,599,171 | 5,599,171 | 5,599,171 | ||||||||||||||
Exercised | (4,080,573) | (4,080,573) | (1,439,150) | (1,439,150) | ||||||||||||||
Expired/Cancelled | (79,448) | (79,448) | ||||||||||||||||
Ending balance | 5,599,171 | 5,599,171 | 4,160,021 | 4,160,021 | ||||||||||||||
Expiry Date | Nov. 22, 2021 | Nov. 22, 2021 | Nov. 22, 2021 | Nov. 22, 2021 | ||||||||||||||
January 17, 2022 [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Exercise price | $ / shares | $ 0.19 | [1] | $ 0.19 | [1] | $ 0.19 | $ 0.19 | 0.19 | |||||||||||
Weighted Average Life (Years) | 8 months 15 days | 8 months 15 days | 3 months 14 days | 3 months 14 days | ||||||||||||||
Beginning balance | 7,267,914 | 7,267,914 | ||||||||||||||||
Granted | 7,337,914 | 7,337,914 | 7,337,914 | 7,337,914 | ||||||||||||||
Exercised | (5,959,396) | (5,959,396) | (70,000) | (70,000) | ||||||||||||||
Expired/Cancelled | (1,308,518) | (1,308,518) | ||||||||||||||||
Ending balance | 7,337,914 | 7,337,914 | 7,267,914 | 7,267,914 | ||||||||||||||
Expiry Date | Jan. 17, 2022 | Jan. 17, 2022 | Jan. 17, 2022 | Jan. 17, 2022 | ||||||||||||||
January 31, 2022 [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Exercise price | $ / shares | $ 0.19 | [1] | $ 0.19 | [1] | $ 0.19 | $ 0.19 | 0.19 | |||||||||||
Weighted Average Life (Years) | 9 months | 9 months | 3 months 29 days | 3 months 29 days | ||||||||||||||
Beginning balance | 5,382,303 | 5,382,303 | ||||||||||||||||
Granted | 5,382,303 | 5,382,303 | 5,382,303 | 5,382,303 | ||||||||||||||
Exercised | (4,341,906) | (4,341,906) | ||||||||||||||||
Expired/Cancelled | (1,040,397) | (1,040,397) | ||||||||||||||||
Ending balance | 5,382,303 | 5,382,303 | 5,382,303 | 5,382,303 | ||||||||||||||
Expiry Date | Jan. 31, 2022 | Jan. 31, 2022 | Jan. 31, 2022 | Jan. 31, 2022 | ||||||||||||||
February 21, 2022 [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Exercise price | $ / shares | $ 0.05 | [1] | $ 0.05 | [1] | $ 0.05 | $ 0.05 | $ 0.05 | $ 0.05 | 0.05 | |||||||||
Weighted Average Life (Years) | 9 months 21 days | 9 months 21 days | 4 months 20 days | 4 months 20 days | 2 years 3 months 21 days | 2 years 3 months 21 days | ||||||||||||
Beginning balance | 1,505,200 | 1,505,200 | 1,505,200 | 1,505,200 | 1,505,200 | 1,505,200 | 1,505,200 | 1,505,200 | ||||||||||
Granted | ||||||||||||||||||
Exercised | (200,000) | (200,000) | ||||||||||||||||
Expired/Cancelled | (1,305,200) | (1,305,200) | ||||||||||||||||
Ending balance | 1,505,200 | 1,505,200 | 1,505,200 | 1,505,200 | 1,505,200 | 1,505,200 | ||||||||||||
Expiry Date | Feb. 21, 2022 | Feb. 21, 2022 | Feb. 21, 2022 | Feb. 21, 2022 | ||||||||||||||
March 24, 2022 [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Exercise price | $ / shares | $ 0.19 | [1] | $ 0.19 | [1] | $ 0.19 | $ 0.19 | 0.19 | |||||||||||
Weighted Average Life (Years) | 10 months 24 days | 10 months 24 days | 5 months 23 days | 5 months 23 days | ||||||||||||||
Beginning balance | 6,341,872 | 6,341,872 | ||||||||||||||||
Granted | 6,554,172 | 6,554,172 | 6,554,172 | 6,554,172 | ||||||||||||||
Exercised | (4,515,139) | (4,515,139) | (212,300) | (212,300) | ||||||||||||||
Expired/Cancelled | (1,826,733) | (1,826,733) | ||||||||||||||||
Ending balance | 6,554,172 | 6,554,172 | 6,341,872 | 6,341,872 | ||||||||||||||
Expiry Date | Mar. 24, 2022 | Mar. 24, 2022 | Mar. 24, 2022 | Mar. 24, 2022 | ||||||||||||||
March 27, 2022 [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Exercise price | $ / shares | $ 0.05 | [1] | $ 0.05 | [1] | $ 0.05 | $ 0.05 | $ 0.05 | $ 0.05 | 0.05 | |||||||||
Weighted Average Life (Years) | 10 months 28 days | 10 months 28 days | 5 months 26 days | 5 months 26 days | 2 years 4 months 28 days | 2 years 4 months 28 days | ||||||||||||
Beginning balance | 982,025 | 982,025 | 1,482,025 | 1,482,025 | 1,482,025 | 1,482,025 | 3,426,025 | 3,426,025 | ||||||||||
Granted | ||||||||||||||||||
Exercised | (882,025) | (882,025) | (500,000) | (500,000) | (1,944,000) | (1,944,000) | ||||||||||||
Expired/Cancelled | (100,000) | (100,000) | ||||||||||||||||
Ending balance | 1,482,025 | 1,482,025 | 982,025 | 982,025 | 1,482,025 | 1,482,025 | ||||||||||||
Expiry Date | Mar. 27, 2022 | Mar. 27, 2022 | Mar. 27, 2022 | Mar. 27, 2022 | ||||||||||||||
April 27, 2022 [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Exercise price | $ / shares | $ 0.19 | [1] | $ 0.19 | [1] | $ 0.19 | $ 0.19 | 0.19 | |||||||||||
Weighted Average Life (Years) | 11 months 26 days | 11 months 26 days | 6 months 25 days | 6 months 25 days | ||||||||||||||
Beginning balance | 791,395 | 791,395 | ||||||||||||||||
Granted | 851,395 | 851,395 | 851,395 | 851,395 | ||||||||||||||
Exercised | (791,395) | (791,395) | (60,000) | (60,000) | ||||||||||||||
Expired/Cancelled | ||||||||||||||||||
Ending balance | 851,395 | 851,395 | 791,395 | 791,395 | ||||||||||||||
Expiry Date | Apr. 27, 2022 | Apr. 27, 2022 | Apr. 27, 2022 | Apr. 27, 2022 | ||||||||||||||
May 9, 2022 [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Exercise price | $ / shares | $ 0.05 | [1] | $ 0.05 | [1] | $ 0.05 | $ 0.05 | $ 0.05 | $ 0.05 | $ 0.05 | |||||||||
Weighted Average Life (Years) | 7 days | 7 days | 1 year 7 days | 1 year 7 days | 7 months 9 days | 7 months 9 days | 2 years 6 months 7 days | 2 years 6 months 7 days | 7 days | |||||||||
Beginning balance | 1,813,725 | 1,813,725 | 2,368,626 | 2,368,626 | 2,368,626 | 2,368,626 | 5,088,626 | 5,088,626 | ||||||||||
Granted | ||||||||||||||||||
Exercised | (1,000,000) | (1,000,000) | (554,901) | (554,901) | (2,720,000) | (2,720,000) | ||||||||||||
Expired/Cancelled | ||||||||||||||||||
Ending balance | 813,725 | 813,725 | 2,368,626 | 2,368,626 | 1,813,725 | 1,813,725 | 2,368,626 | 2,368,626 | ||||||||||
Expiry Date | May 09, 2022 | May 09, 2022 | May 09, 2022 | May 09, 2022 | ||||||||||||||
May 30, 2022 [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Exercise price | $ / shares | $ 0.19 | $ 0.19 | $ 0.19 | |||||||||||||||
Weighted Average Life (Years) | 29 days | 29 days | 7 months 28 days | 7 months 28 days | 29 days | |||||||||||||
Beginning balance | 5,223,420 | 5,223,420 | ||||||||||||||||
Granted | 5,223,420 | 5,223,420 | ||||||||||||||||
Exercised | (276,675) | (276,675) | ||||||||||||||||
Expired/Cancelled | ||||||||||||||||||
Ending balance | 4,946,745 | 4,946,745 | 5,223,420 | 5,223,420 | ||||||||||||||
Expiry Date | May 30, 2022 | May 30, 2022 | ||||||||||||||||
June 17, 2022 [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Exercise price | $ / shares | $ 0.19 | $ 0.19 | $ 0.19 | |||||||||||||||
Weighted Average Life (Years) | 1 month 17 days | 1 month 17 days | 8 months 15 days | 8 months 15 days | 1 month 17 days | |||||||||||||
Beginning balance | 17,703,506 | 17,703,506 | ||||||||||||||||
Granted | 17,853,506 | 17,853,506 | ||||||||||||||||
Exercised | (1,393,077) | (1,393,077) | (150,000) | (150,000) | ||||||||||||||
Expired/Cancelled | ||||||||||||||||||
Ending balance | 16,310,429 | 16,310,429 | 17,703,506 | 17,703,506 | ||||||||||||||
Expiry Date | Jun. 17, 2022 | Jun. 17, 2022 | ||||||||||||||||
June 18, 2022 [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Exercise price | $ / shares | $ 0.30 | $ 0.30 | ||||||||||||||||
Weighted Average Life (Years) | 9 months 14 days | 9 months 14 days | ||||||||||||||||
Beginning balance | 4,350,000 | 4,350,000 | ||||||||||||||||
Granted | 4,350,000 | 4,350,000 | ||||||||||||||||
Exercised | ||||||||||||||||||
Expired/Cancelled | ||||||||||||||||||
Ending balance | 4,350,000 | 4,350,000 | ||||||||||||||||
August 14, 2022 [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Exercise price | $ / shares | $ 0.05 | [1] | $ 0.05 | [1] | $ 0.05 | $ 0.05 | $ 0.05 | $ 0.05 | $ 0.05 | |||||||||
Weighted Average Life (Years) | 3 months 14 days | 3 months 14 days | 1 year 3 months 14 days | 1 year 3 months 14 days | 10 months 13 days | 10 months 13 days | 2 years 9 months 14 days | 2 years 9 months 14 days | 3 months 14 days | |||||||||
Beginning balance | 200,000 | 200,000 | 1,110,000 | 1,110,000 | 1,110,000 | 1,110,000 | 1,310,000 | 1,310,000 | ||||||||||
Granted | ||||||||||||||||||
Exercised | (200,000) | (200,000) | (400,000) | (400,000) | (910,000) | (910,000) | (200,000) | (200,000) | ||||||||||
Expired/Cancelled | ||||||||||||||||||
Ending balance | 710,000 | 710,000 | 200,000 | 200,000 | 1,110,000 | 1,110,000 | ||||||||||||
Expiry Date | Aug. 14, 2022 | Aug. 14, 2022 | Aug. 14, 2022 | Aug. 14, 2022 | ||||||||||||||
February 13, 2023 [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Exercise price | $ / shares | $ 0.65 | $ 0.65 | $ 0.65 | |||||||||||||||
Weighted Average Life (Years) | 9 months 14 days | 9 months 14 days | 1 year 4 months 13 days | 1 year 4 months 13 days | 9 months 14 days | |||||||||||||
Beginning balance | 3,827,601 | 3,827,601 | ||||||||||||||||
Granted | 3,827,601 | 3,827,601 | ||||||||||||||||
Exercised | ||||||||||||||||||
Expired/Cancelled | ||||||||||||||||||
Ending balance | 3,827,601 | 3,827,601 | 3,827,601 | 3,827,601 | ||||||||||||||
Expiry Date | Feb. 13, 2023 | Feb. 13, 2023 | ||||||||||||||||
January 17, 2021 [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Exercise price | $ / shares | $ 0.21 | $ 0.21 | ||||||||||||||||
Weighted Average Life (Years) | 0 years | 0 years | ||||||||||||||||
Beginning balance | 3,643,791 | 3,643,791 | 3,643,791 | 3,643,791 | ||||||||||||||
Granted | 3,643,791 | 3,643,791 | ||||||||||||||||
Exercised | ||||||||||||||||||
Expired/Cancelled | ||||||||||||||||||
Ending balance | 3,643,791 | 3,643,791 | ||||||||||||||||
May 7 2020 [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Exercise price | $ / shares | [3] | $ 0.07 | $ 0.07 | |||||||||||||||
Weighted Average Life (Years) | [3] | 0 years | 0 years | |||||||||||||||
Beginning balance | [3] | 3,100,000 | 3,100,000 | |||||||||||||||
Granted | [3] | |||||||||||||||||
Exercised | [3] | (3,000,000) | (3,000,000) | |||||||||||||||
Expired/Cancelled | [3] | (100,000) | (100,000) | |||||||||||||||
Ending balance | [3] | |||||||||||||||||
October 4, 2020 [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Exercise price | $ / shares | [3] | $ 0.08 | $ 0.08 | |||||||||||||||
Weighted Average Life (Years) | [3] | 0 years | 0 years | |||||||||||||||
Beginning balance | [3] | 5,016,000 | 5,016,000 | |||||||||||||||
Granted | [3] | |||||||||||||||||
Exercised | [3] | (3,425,000) | (3,425,000) | |||||||||||||||
Expired/Cancelled | [3] | (1,591,000) | (1,591,000) | |||||||||||||||
Ending balance | [3] | |||||||||||||||||
November 30, 2020 [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Exercise price | $ / shares | [3] | $ 0.08 | $ 0.08 | |||||||||||||||
Weighted Average Life (Years) | [3] | 0 years | 0 years | |||||||||||||||
Beginning balance | [3] | 6,169,926 | 6,169,926 | |||||||||||||||
Granted | [3] | |||||||||||||||||
Exercised | [3] | (3,091,383) | (3,091,383) | |||||||||||||||
Expired/Cancelled | [3] | (3,078,543) | (3,078,543) | |||||||||||||||
Ending balance | [3] | |||||||||||||||||
January 23, 2021 [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Exercise price | $ / shares | [3] | $ 0.08 | $ 0.08 | |||||||||||||||
Weighted Average Life (Years) | [3] | 0 years | 0 years | |||||||||||||||
Beginning balance | [3] | 6,388,435 | 6,388,435 | |||||||||||||||
Granted | [3] | |||||||||||||||||
Exercised | [3] | (3,409,160) | (3,409,160) | |||||||||||||||
Expired/Cancelled | [3] | (2,979,275) | (2,979,275) | |||||||||||||||
Ending balance | [3] | |||||||||||||||||
March 29, 2021 [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Exercise price | $ / shares | [3] | $ 0.08 | $ 0.08 | |||||||||||||||
Weighted Average Life (Years) | [3] | 0 years | 0 years | |||||||||||||||
Beginning balance | [3] | 8,188,046 | 8,188,046 | |||||||||||||||
Granted | [3] | |||||||||||||||||
Exercised | [3] | (4,496,710) | (4,496,710) | |||||||||||||||
Expired/Cancelled | [3] | (3,691,336) | (3,691,336) | |||||||||||||||
Ending balance | [3] | |||||||||||||||||
May 13, 2021 [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Exercise price | $ / shares | [3] | $ 0.08 | $ 0.08 | |||||||||||||||
Weighted Average Life (Years) | [3] | 0 years | 0 years | |||||||||||||||
Beginning balance | [3] | 31,404,738 | 31,404,738 | |||||||||||||||
Granted | [3] | |||||||||||||||||
Exercised | [3] | (18,050,408) | (18,050,408) | |||||||||||||||
Expired/Cancelled | [3] | (13,354,330) | (13,354,330) | |||||||||||||||
Ending balance | [3] | |||||||||||||||||
July Eighteen Two Thousand Twenty Two [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Exercise price | $ / shares | $ 0.30 | |||||||||||||||||
Weighted Average Life (Years) | 2 months 19 days | 2 months 19 days | 2 months 19 days | |||||||||||||||
Beginning balance | 4,350,000 | 4,350,000 | ||||||||||||||||
Granted | ||||||||||||||||||
Exercised | (60,960) | (60,960) | ||||||||||||||||
Expired/Cancelled | ||||||||||||||||||
Ending balance | 4,289,040 | 4,289,040 | 4,350,000 | 4,350,000 | ||||||||||||||
Expiry Date | Jul. 18, 2022 | Jul. 18, 2022 | ||||||||||||||||
April Twenty Two Two Thousand Twenty Four [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Exercise price | $ / shares | $ 0.20 | |||||||||||||||||
Weighted Average Life (Years) | 1 year 11 months 23 days | 1 year 11 months 23 days | 1 year 11 months 23 days | |||||||||||||||
Beginning balance | ||||||||||||||||||
Granted | 933,333 | 933,333 | ||||||||||||||||
Exercised | ||||||||||||||||||
Expired/Cancelled | ||||||||||||||||||
Ending balance | 933,333 | 933,333 | ||||||||||||||||
Expiry Date | Apr. 22, 2024 | Apr. 22, 2024 | ||||||||||||||||
November Twenty Seven Two Thousand Twenty Two [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Exercise price | $ / shares | $ 0.75 | $ 0.75 | ||||||||||||||||
Weighted Average Life (Years) | 6 months 29 days | 6 months 29 days | 6 months 29 days | |||||||||||||||
Beginning balance | ||||||||||||||||||
Granted | 1,375,499 | 1,375,499 | ||||||||||||||||
Exercised | ||||||||||||||||||
Expired/Cancelled | ||||||||||||||||||
Ending balance | 1,375,499 | 1,375,499 | ||||||||||||||||
Expiry Date | Nov. 27, 2022 | Nov. 27, 2022 | ||||||||||||||||
June Ten Two Thousand Twenty Six [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Exercise price | $ / shares | $ 0.13 | $ 0.13 | ||||||||||||||||
Weighted Average Life (Years) | 4 years 1 month 13 days | 4 years 1 month 13 days | 4 years 1 month 13 days | |||||||||||||||
Beginning balance | ||||||||||||||||||
Granted | 3,000,000 | 3,000,000 | ||||||||||||||||
Exercised | ||||||||||||||||||
Expired/Cancelled | ||||||||||||||||||
Ending balance | 1,500,000 | 1,500,000 | ||||||||||||||||
Expiry Date | Jun. 10, 2026 | Jun. 10, 2026 | ||||||||||||||||
June Ten Two Thousand Twenty Six One [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Exercise price | $ / shares | $ 0.19 | $ 0.19 | ||||||||||||||||
Weighted Average Life (Years) | 4 years 1 month 13 days | 4 years 1 month 13 days | 4 years 1 month 13 days | |||||||||||||||
Beginning balance | ||||||||||||||||||
Granted | 3,000,000 | 3,000,000 | ||||||||||||||||
Exercised | ||||||||||||||||||
Expired/Cancelled | ||||||||||||||||||
Ending balance | 1,500,000 | 1,500,000 | ||||||||||||||||
Expiry Date | Jun. 10, 2026 | Jun. 10, 2026 | ||||||||||||||||
[1]The Company received approval of the TSX-V on January 13, 2021 and amended the expiry date of 3,643,791 extending the expiry date from January 17, 2021 to August 31, 2021 0.30 3,643,791 |
SUMMARY OF CHANGES IN COMMON _2
SUMMARY OF CHANGES IN COMMON SHARE PURCHASE WARRANTS (Details) (Parenthetical) | Jan. 13, 2021 Days $ / shares shares | Apr. 30, 2022 $ / shares | Nov. 03, 2021 $ / shares | Oct. 31, 2021 $ / shares | Oct. 31, 2020 $ / shares |
Equity [Abstract] | |||||
Class of warrant or right outstanding | shares | 3,643,791 | ||||
Common stock par or stated value per share | (per share) | $ 0.30 | $ 0.001 | $ 0.65 | $ 0.001 | $ 0.001 |
Number of minimum consecutive trading days | Days | 10 | ||||
Maturity date, description | extending the expiry date from January 17, 2021 to August 31, 2021 |
SCHEDULE OF ASSUMPTIONS USED (D
SCHEDULE OF ASSUMPTIONS USED (Details) - $ / shares | 6 Months Ended | 12 Months Ended | ||
Apr. 30, 2022 | Apr. 30, 2021 | Oct. 31, 2021 | Oct. 31, 2020 | |
Risk free rate of interest, minimum | 1.34% | 0.20% | 0.20% | 0.43% |
Risk free rate of interest, maximum | 2.59% | 1.07% | 1.07% | 1.51% |
Expected life of options | 5 years | 5 years | ||
Expected annualized volatility, minimum | 134.93% | 130.88% | 130.88% | 120.13% |
Expected annualized volatility, maximum | 136.08% | 140.05% | 140.05% | 188.46% |
Expected dividend rate | ||||
Minimum [Member] | ||||
Expected life of options | 2 years | 2 years | ||
Exercise price of options | $ 0.40 | $ 0.13 | $ 0.13 | $ 0.11 |
Maximum [Member] | ||||
Expected life of options | 5 years | 5 years | ||
Exercise price of options | $ 0.58 | $ 0.70 | $ 0.70 | $ 0.16 |
SCHEDULE OF STOCK OPTIONS ACTIV
SCHEDULE OF STOCK OPTIONS ACTIVITY (Details) | 6 Months Ended | 12 Months Ended | ||||||
Apr. 30, 2022 USD ($) shares | Apr. 30, 2022 USD ($) $ / shares shares | Apr. 30, 2021 USD ($) shares | Apr. 30, 2021 USD ($) $ / shares shares | Oct. 31, 2021 USD ($) shares | Oct. 31, 2021 USD ($) $ / shares shares | Oct. 31, 2020 USD ($) shares | Oct. 31, 2020 USD ($) $ / shares shares | |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||||
Total outstanding, beginning balance | 61,260,000 | 28,420,000 | 28,420,000 | 29,630,000 | ||||
Total granted | 1,250,000 | 15,650,000 | 38,800,000 | 6,600,000 | ||||
Exercised | 750,000 | 100,000 | (2,630,000) | (500,000) | ||||
Total expired, cancelled | (4,250,000) | (17,250,000) | (3,330,000) | (7,310,000) | ||||
Total outstanding, ending balance | 57,510,000 | 26,720,000 | 61,260,000 | 28,420,000 | ||||
Options vested | 57,360,000 | 57,360,000 | 26,720,000 | 26,720,000 | 60,797,500 | 60,797,500 | 27,420,000 | 27,420,000 |
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | 4,250,000 | 17,250,000 | 3,330,000 | 7,310,000 | ||||
Weighted average remaining life, outstanding | 3 years 1 month 24 days | 2 years 9 months 10 days | 3 years 5 months 15 days | 3 years 2 months 4 days | ||||
Weighted average exercise price, beginning balance | $ / shares | $ 0.33 | $ 0.09 | $ 0.09 | $ 0.07 | ||||
Weighted average exercise price, granted | $ / shares | 0.44 | 0.13 | 0.46 | 0.13 | ||||
Weighted average exercise price, exercised | $ / shares | 0.05 | 0.05 | 0.07 | 0.07 | ||||
Weighted average exercise price, expired/cancelled | $ / shares | 0.11 | 0.13 | 0.09 | 0.07 | ||||
Weighted average exercise price, ending balance | $ / shares | 0.34 | 0.09 | 0.33 | 0.09 | ||||
Weighted average exercise price, vested | $ / shares | $ 0.33 | $ 0.09 | $ 0.32 | $ 0.09 | ||||
Aggregate intrinsic value, outstanding | $ | $ 2,149,050 | $ 2,149,050 | $ 597,721 | $ 597,721 | $ 19,994,025 | $ 19,994,025 | $ 801,922 | $ 801,922 |
Aggregate intrinsic value, vested | $ | $ 2,102,148 | $ 2,102,148 | $ 597,721 | $ 597,721 | $ 19,908,026 | $ 19,908,026 | $ 866,441 | $ 866,441 |
Weighted average remaining life, vested | 3 years 1 month 24 days | 2 years 9 months 10 days | 3 years 5 months 15 days | 3 years 2 months 4 days | ||||
Total vested | 57,360,000 | 26,720,000 | 60,797,500 | 27,420,000 | ||||
Total exercised | (750,000) | (100,000) | 2,630,000 | 500,000 | ||||
Weighted average exercise price, ending balance | $ / shares | ||||||||
Aggregate intrinsic value, outstanding | $ | $ 19,994,025 | $ 801,922 | $ 801,922 | |||||
Aggregate intrinsic value, outstanding | $ | (2,149,050) | (597,721) | (19,994,025) | $ (801,922) | ||||
Aggregate intrinsic value, vested | $ | $ (2,102,148) | $ (597,721) | (19,908,026) | (866,441) | ||||
Weighted average remaining life, outstanding | 3 years 5 months 15 days | 3 years 2 months 4 days | ||||||
Aggregate intrinsic value, outstanding | $ | $ 2,149,050 | $ 597,721 | 19,994,025 | 801,922 | ||||
Aggregate intrinsic value, vested | $ | $ 2,102,148 | $ 597,721 | $ 19,908,026 | $ 866,441 | ||||
March 27, 2022 [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||||
Expiry Date | Mar. 27, 2022 | Mar. 27, 2022 | ||||||
Option One [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||||
Expiry Date | Mar. 27, 2022 | Feb. 11, 2021 | Feb. 11, 2021 | May 31, 2020 | ||||
Exercise Price | $ / shares | ||||||||
Total outstanding, beginning balance | 1,500,000 | 800,000 | 800,000 | |||||
Total granted | ||||||||
Exercised | (750,000) | |||||||
Total expired, cancelled | (750,000) | (800,000) | ||||||
Total outstanding, ending balance | 1,500,000 | 800,000 | ||||||
Options vested | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | 750,000 | 800,000 | ||||||
Weighted average remaining life, outstanding | 10 days | |||||||
Share Price | $ / shares | $ 0.05 | $ 0.05 | ||||||
Total vested | ||||||||
Total exercised | 750,000 | |||||||
Option One [Member] | February 11, 2021 [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||||
Exercise Price | $ / shares | ||||||||
Total outstanding, beginning balance | 800,000 | 800,000 | ||||||
Total granted | ||||||||
Exercised | ||||||||
Total expired, cancelled | (800,000) | |||||||
Total outstanding, ending balance | 800,000 | |||||||
Options vested | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | 800,000 | |||||||
Share Price | $ / shares | $ 0.05 | |||||||
Total vested | ||||||||
Total exercised | ||||||||
Option Two [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||||
Expiry Date | Dec. 30, 2022 | Aug. 16, 2021 | Aug. 16, 2021 | Jun. 03, 2020 | ||||
Exercise Price | $ / shares | ||||||||
Total outstanding, beginning balance | 6,000,000 | 600,000 | 600,000 | |||||
Total granted | ||||||||
Exercised | ||||||||
Total expired, cancelled | (150,000) | |||||||
Total outstanding, ending balance | 5,850,000 | 600,000 | 6,000,000 | 600,000 | ||||
Options vested | 5,850,000 | 5,850,000 | 600,000 | 600,000 | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | 150,000 | |||||||
Weighted average remaining life, outstanding | 8 months 1 day | 6 months 14 days | ||||||
Share Price | $ / shares | $ 0.13 | $ 0.05 | ||||||
Total vested | 5,850,000 | 600,000 | ||||||
Total exercised | ||||||||
Option Two [Member] | August 16, 2021 [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||||
Exercise Price | $ / shares | ||||||||
Total outstanding, beginning balance | 600,000 | 600,000 | ||||||
Total granted | ||||||||
Exercised | (600,000) | |||||||
Total expired, cancelled | ||||||||
Total outstanding, ending balance | 600,000 | |||||||
Options vested | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | ||||||||
Share Price | $ / shares | $ 0.05 | |||||||
Total vested | ||||||||
Total exercised | 600,000 | |||||||
Option Three [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||||
Expiry Date | Aug. 12, 2023 | Mar. 27, 2022 | Mar. 27, 2022 | Feb. 11, 2021 | ||||
Exercise Price | $ / shares | ||||||||
Total outstanding, beginning balance | 2,290,000 | 1,750,000 | 1,750,000 | |||||
Total granted | ||||||||
Exercised | ||||||||
Total expired, cancelled | (750,000) | |||||||
Total outstanding, ending balance | 1,540,000 | 1,750,000 | 2,290,000 | 1,750,000 | ||||
Options vested | 1,540,000 | 1,540,000 | 1,750,000 | 1,750,000 | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | 750,000 | |||||||
Weighted average remaining life, outstanding | 1 year 3 months 10 days | 1 year 1 month 24 days | ||||||
Share Price | $ / shares | $ 0.05 | $ 0.05 | ||||||
Total vested | 1,540,000 | 1,750,000 | ||||||
Total exercised | ||||||||
Option Three [Member] | March 27, 2022 [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||||
Exercise Price | $ / shares | ||||||||
Total outstanding, beginning balance | 1,500,000 | 1,750,000 | 1,750,000 | |||||
Total granted | ||||||||
Exercised | (250,000) | |||||||
Total expired, cancelled | ||||||||
Total outstanding, ending balance | 1,500,000 | 1,750,000 | ||||||
Options vested | 1,500,000 | 1,500,000 | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | ||||||||
Weighted average remaining life, outstanding | 4 months 24 days | |||||||
Share Price | $ / shares | $ 0.05 | |||||||
Total vested | 1,500,000 | |||||||
Total exercised | 250,000 | |||||||
Option Four [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||||
Expiry Date | Dec. 03, 2023 | Aug. 26, 2022 | Aug. 26, 2022 | Aug. 16, 2021 | ||||
Exercise Price | $ / shares | ||||||||
Total outstanding, beginning balance | 6,450,000 | 500,000 | 500,000 | |||||
Total granted | ||||||||
Exercised | ||||||||
Total expired, cancelled | (1,000,000) | (500,000) | ||||||
Total outstanding, ending balance | 5,450,000 | 6,450,000 | 500,000 | |||||
Options vested | 5,450,000 | 5,450,000 | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | 1,000,000 | 500,000 | ||||||
Weighted average remaining life, outstanding | 1 year 7 months 2 days | |||||||
Share Price | $ / shares | $ 0.05 | $ 0.13 | ||||||
Total vested | 5,450,000 | |||||||
Total exercised | ||||||||
Option Four [Member] | August 26, 2022 [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||||
Exercise Price | $ / shares | ||||||||
Total outstanding, beginning balance | 500,000 | 500,000 | ||||||
Total granted | ||||||||
Exercised | ||||||||
Total expired, cancelled | (500,000) | |||||||
Total outstanding, ending balance | 500,000 | |||||||
Options vested | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | 500,000 | |||||||
Share Price | $ / shares | $ 0.13 | |||||||
Total vested | ||||||||
Total exercised | ||||||||
Option Five [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||||
Expiry Date | May 22, 2024 | Dec. 30, 2022 | Dec. 30, 2022 | Mar. 27, 2022 | ||||
Exercise Price | $ / shares | ||||||||
Total outstanding, beginning balance | 7,900,000 | |||||||
Total granted | 6,150,000 | |||||||
Exercised | ||||||||
Total expired, cancelled | (850,000) | (6,150,000) | ||||||
Total outstanding, ending balance | 7,050,000 | 7,900,000 | ||||||
Options vested | 7,050,000 | 7,050,000 | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | 850,000 | 6,150,000 | ||||||
Weighted average remaining life, outstanding | 2 years 21 days | 1 year 10 months 28 days | ||||||
Share Price | $ / shares | $ 0.12 | $ 0.13 | ||||||
Total vested | 7,050,000 | |||||||
Total exercised | ||||||||
Option Five [Member] | December 30, 2022 [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||||
Exercise Price | $ / shares | ||||||||
Total outstanding, beginning balance | 6,000,000 | |||||||
Total granted | 6,150,000 | |||||||
Exercised | (100,000) | |||||||
Total expired, cancelled | (50,000) | |||||||
Total outstanding, ending balance | 6,000,000 | |||||||
Options vested | 5,837,500 | 5,837,500 | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | 50,000 | |||||||
Weighted average remaining life, outstanding | 1 year 1 month 28 days | |||||||
Share Price | $ / shares | $ 0.13 | |||||||
Total vested | 5,837,500 | |||||||
Total exercised | 100,000 | |||||||
Option Six [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||||
Expiry Date | Nov. 03, 2024 | Apr. 19, 2023 | Apr. 19, 2023 | Aug. 26, 2022 | ||||
Exercise Price | $ / shares | ||||||||
Total outstanding, beginning balance | 700,000 | 800,000 | 800,000 | |||||
Total granted | ||||||||
Exercised | ||||||||
Total expired, cancelled | ||||||||
Total outstanding, ending balance | 700,000 | 800,000 | 700,000 | 800,000 | ||||
Options vested | 700,000 | 700,000 | 800,000 | 800,000 | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | ||||||||
Weighted average remaining life, outstanding | 2 years 6 months 7 days | 2 years 2 months 15 days | ||||||
Share Price | $ / shares | $ 0.15 | $ 0.05 | ||||||
Total vested | 700,000 | 800,000 | ||||||
Total exercised | ||||||||
Option Six [Member] | April 19, 2023 [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||||
Exercise Price | $ / shares | ||||||||
Total outstanding, beginning balance | 800,000 | 800,000 | ||||||
Total granted | ||||||||
Exercised | ||||||||
Total expired, cancelled | (800,000) | |||||||
Total outstanding, ending balance | 800,000 | |||||||
Options vested | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | 800,000 | |||||||
Share Price | $ / shares | $ 0.05 | |||||||
Total vested | ||||||||
Total exercised | ||||||||
Option Seven [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||||
Expiry Date | Nov. 24, 2024 | Aug. 12, 2023 | Aug. 12, 2023 | Apr. 19, 2023 | ||||
Exercise Price | $ / shares | ||||||||
Total outstanding, beginning balance | 320,000 | 3,120,000 | 3,120,000 | |||||
Total granted | ||||||||
Exercised | (100,000) | |||||||
Total expired, cancelled | (300,000) | |||||||
Total outstanding, ending balance | 20,000 | 3,020,000 | 320,000 | 3,120,000 | ||||
Options vested | 20,000 | 20,000 | 3,020,000 | 3,020,000 | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | 300,000 | |||||||
Weighted average remaining life, outstanding | 2 years 6 months 25 days | 2 years 6 months 10 days | ||||||
Share Price | $ / shares | $ 0.16 | $ 0.05 | ||||||
Total vested | 20,000 | 3,020,000 | ||||||
Total exercised | 100,000 | |||||||
Option Seven [Member] | August 12, 2023 [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||||
Exercise Price | $ / shares | ||||||||
Total outstanding, beginning balance | 2,290,000 | 3,120,000 | 3,120,000 | |||||
Total granted | ||||||||
Exercised | (600,000) | |||||||
Total expired, cancelled | (230,000) | |||||||
Total outstanding, ending balance | 2,290,000 | 3,120,000 | ||||||
Options vested | 2,290,000 | 2,290,000 | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | 230,000 | |||||||
Weighted average remaining life, outstanding | 1 year 9 months 10 days | |||||||
Share Price | $ / shares | $ 0.05 | |||||||
Total vested | 2,290,000 | |||||||
Total exercised | 600,000 | |||||||
Option Eight [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||||
Expiry Date | Mar. 26, 2025 | Dec. 03, 2023 | Dec. 03, 2023 | Aug. 12, 2023 | ||||
Exercise Price | $ / shares | ||||||||
Total outstanding, beginning balance | 100,000 | 7,000,000 | 7,000,000 | |||||
Total granted | ||||||||
Exercised | ||||||||
Total expired, cancelled | ||||||||
Total outstanding, ending balance | 100,000 | 7,000,000 | 100,000 | 7,000,000 | ||||
Options vested | 100,000 | 100,000 | 7,000,000 | 7,000,000 | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | ||||||||
Weighted average remaining life, outstanding | 2 years 10 months 28 days | 2 years 10 months 2 days | ||||||
Share Price | $ / shares | $ 0.11 | $ 0.05 | ||||||
Total vested | 100,000 | 7,000,000 | ||||||
Total exercised | ||||||||
Option Eight [Member] | December 3, 2023 [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||||
Exercise Price | $ / shares | ||||||||
Total outstanding, beginning balance | 6,450,000 | 7,000,000 | 7,000,000 | |||||
Total granted | ||||||||
Exercised | (550,000) | |||||||
Total expired, cancelled | ||||||||
Total outstanding, ending balance | 6,450,000 | 7,000,000 | ||||||
Options vested | 6,450,000 | 6,450,000 | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | ||||||||
Weighted average remaining life, outstanding | 2 years 1 month 2 days | |||||||
Share Price | $ / shares | $ 0.05 | |||||||
Total vested | 6,450,000 | |||||||
Total exercised | 550,000 | |||||||
Option Nine [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||||
Expiry Date | Apr. 23, 2025 | May 22, 2024 | May 22, 2024 | Dec. 03, 2023 | ||||
Exercise Price | $ / shares | ||||||||
Total outstanding, beginning balance | 3,350,000 | 7,950,000 | 7,950,000 | |||||
Total granted | ||||||||
Exercised | ||||||||
Total expired, cancelled | (250,000) | |||||||
Total outstanding, ending balance | 3,100,000 | 7,950,000 | 3,350,000 | 7,950,000 | ||||
Options vested | 3,100,000 | 3,100,000 | 7,950,000 | 7,950,000 | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | 250,000 | |||||||
Weighted average remaining life, outstanding | 2 years 11 months 23 days | 3 years 3 months 21 days | ||||||
Share Price | $ / shares | $ 0.12 | $ 0.12 | ||||||
Total vested | 3,100,000 | 7,950,000 | ||||||
Total exercised | ||||||||
Option Nine [Member] | May 22, 2024 [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||||
Exercise Price | $ / shares | ||||||||
Total outstanding, beginning balance | 7,900,000 | 7,950,000 | 7,950,000 | |||||
Total granted | ||||||||
Exercised | ||||||||
Total expired, cancelled | (50,000) | |||||||
Total outstanding, ending balance | 7,900,000 | 7,950,000 | ||||||
Options vested | 7,900,000 | 7,900,000 | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | 50,000 | |||||||
Weighted average remaining life, outstanding | 2 years 6 months 21 days | |||||||
Share Price | $ / shares | $ 0.12 | |||||||
Total vested | 7,900,000 | |||||||
Total exercised | ||||||||
Option Ten [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||||
Expiry Date | Dec. 30, 2025 | Nov. 03, 2024 | Nov. 03, 2024 | May 22, 2024 | ||||
Exercise Price | $ / shares | ||||||||
Total outstanding, beginning balance | 9,500,000 | 700,000 | 700,000 | |||||
Total granted | ||||||||
Exercised | ||||||||
Total expired, cancelled | ||||||||
Total outstanding, ending balance | 9,500,000 | 700,000 | 9,500,000 | 700,000 | ||||
Options vested | 9,500,000 | 9,500,000 | 700,000 | 700,000 | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | ||||||||
Weighted average remaining life, outstanding | 3 years 8 months 1 day | 3 years 9 months 3 days | ||||||
Share Price | $ / shares | $ 0.13 | $ 0.15 | ||||||
Total vested | 9,500,000 | 700,000 | ||||||
Total exercised | ||||||||
Option Ten [Member] | November 3, 2024 [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||||
Exercise Price | $ / shares | ||||||||
Total outstanding, beginning balance | 700,000 | 700,000 | 700,000 | |||||
Total granted | ||||||||
Exercised | ||||||||
Total expired, cancelled | ||||||||
Total outstanding, ending balance | 700,000 | 700,000 | ||||||
Options vested | 700,000 | 700,000 | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | ||||||||
Weighted average remaining life, outstanding | 3 years 3 days | |||||||
Share Price | $ / shares | $ 0.15 | |||||||
Total vested | 700,000 | |||||||
Total exercised | ||||||||
Option Eleven [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||||
Expiry Date | Aug. 30, 2026 | Nov. 24, 2024 | Nov. 24, 2024 | Nov. 03, 2024 | ||||
Exercise Price | $ / shares | ||||||||
Total outstanding, beginning balance | 21,700,000 | 900,000 | 900,000 | |||||
Total granted | ||||||||
Exercised | ||||||||
Total expired, cancelled | (200,000) | |||||||
Total outstanding, ending balance | 21,500,000 | 900,000 | 21,700,000 | 900,000 | ||||
Options vested | 21,350,000 | 21,350,000 | 900,000 | 900,000 | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | 200,000 | |||||||
Weighted average remaining life, outstanding | 4 years 4 months 2 days | 3 years 9 months 25 days | ||||||
Share Price | $ / shares | $ 0.70 | $ 0.16 | ||||||
Total vested | 21,350,000 | 900,000 | ||||||
Total exercised | ||||||||
Option Eleven [Member] | November 24, 2024 [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||||
Exercise Price | $ / shares | ||||||||
Total outstanding, beginning balance | 320,000 | 900,000 | 900,000 | |||||
Total granted | ||||||||
Exercised | (30,000) | |||||||
Total expired, cancelled | (550,000) | |||||||
Total outstanding, ending balance | 320,000 | 900,000 | ||||||
Options vested | 320,000 | 320,000 | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | 550,000 | |||||||
Weighted average remaining life, outstanding | 3 years 25 days | |||||||
Share Price | $ / shares | $ 0.16 | |||||||
Total vested | 320,000 | |||||||
Total exercised | 30,000 | |||||||
Option Twelve [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||||
Expiry Date | Oct. 01, 2026 | Mar. 26, 2025 | Mar. 26, 2025 | Nov. 24, 2024 | ||||
Exercise Price | $ / shares | ||||||||
Total outstanding, beginning balance | 1,450,000 | 300,000 | 300,000 | |||||
Total granted | ||||||||
Exercised | ||||||||
Total expired, cancelled | ||||||||
Total outstanding, ending balance | 1,450,000 | 300,000 | 1,450,000 | 300,000 | ||||
Options vested | 1,450,000 | 1,450,000 | 300,000 | 300,000 | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | ||||||||
Weighted average remaining life, outstanding | 4 years 5 months 1 day | 4 years 1 month 24 days | ||||||
Share Price | $ / shares | $ 0.50 | $ 0.11 | ||||||
Total vested | 1,450,000 | 300,000 | ||||||
Total exercised | ||||||||
Option Twelve [Member] | March 26, 2025 [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||||
Exercise Price | $ / shares | ||||||||
Total outstanding, beginning balance | 100,000 | 300,000 | 300,000 | |||||
Total granted | ||||||||
Exercised | (200,000) | |||||||
Total expired, cancelled | ||||||||
Total outstanding, ending balance | 100,000 | 300,000 | ||||||
Options vested | 100,000 | 100,000 | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | ||||||||
Weighted average remaining life, outstanding | 3 years 4 months 24 days | |||||||
Share Price | $ / shares | $ 0.11 | |||||||
Total vested | 100,000 | |||||||
Total exercised | 200,000 | |||||||
Option Thirteen [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||||
Expiry Date | Dec. 03, 2026 | Apr. 23, 2025 | Apr. 23, 2025 | Mar. 26, 2025 | ||||
Exercise Price | $ / shares | ||||||||
Total outstanding, beginning balance | 4,000,000 | 4,000,000 | ||||||
Total granted | 250,000 | |||||||
Exercised | ||||||||
Total expired, cancelled | (300,000) | |||||||
Total outstanding, ending balance | 250,000 | 3,700,000 | 4,000,000 | |||||
Options vested | 250,000 | 250,000 | 3,700,000 | 3,700,000 | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | 300,000 | |||||||
Weighted average remaining life, outstanding | 4 years 7 months 6 days | 4 years 2 months 23 days | ||||||
Share Price | $ / shares | $ 0.58 | $ 0.12 | ||||||
Total vested | 250,000 | 3,700,000 | ||||||
Total exercised | ||||||||
Option Thirteen [Member] | April 23, 2025 [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||||
Exercise Price | $ / shares | ||||||||
Total outstanding, beginning balance | 3,350,000 | 4,000,000 | 4,000,000 | |||||
Total granted | ||||||||
Exercised | (300,000) | |||||||
Total expired, cancelled | (350,000) | |||||||
Total outstanding, ending balance | 3,350,000 | 4,000,000 | ||||||
Options vested | 3,350,000 | 3,350,000 | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | 350,000 | |||||||
Weighted average remaining life, outstanding | 3 years 5 months 23 days | |||||||
Share Price | $ / shares | $ 0.12 | |||||||
Total vested | 3,350,000 | |||||||
Total exercised | 300,000 | |||||||
Option Fourteen [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||||
Expiry Date | Mar. 07, 2027 | Dec. 30, 2025 | Dec. 30, 2025 | Apr. 23, 2025 | ||||
Exercise Price | $ / shares | ||||||||
Total outstanding, beginning balance | ||||||||
Total granted | 500,000 | 9,500,000 | ||||||
Exercised | ||||||||
Total expired, cancelled | (9,500,000) | |||||||
Total outstanding, ending balance | 500,000 | |||||||
Options vested | 500,000 | 500,000 | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | 9,500,000 | |||||||
Weighted average remaining life, outstanding | 4 years 10 months 6 days | 4 years 11 months 1 day | ||||||
Share Price | $ / shares | $ 0.40 | $ 0.13 | ||||||
Total vested | 500,000 | |||||||
Total exercised | ||||||||
Option Fourteen [Member] | December 30, 2025 [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||||
Exercise Price | $ / shares | ||||||||
Total outstanding, beginning balance | 9,500,000 | |||||||
Total granted | 9,500,000 | |||||||
Exercised | ||||||||
Total expired, cancelled | ||||||||
Total outstanding, ending balance | 9,500,000 | |||||||
Options vested | 9,500,000 | 9,500,000 | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | ||||||||
Weighted average remaining life, outstanding | 4 years 2 months 1 day | |||||||
Share Price | $ / shares | $ 0.13 | |||||||
Total vested | 9,500,000 | |||||||
Total exercised | ||||||||
Option Fifteen [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||||
Expiry Date | Apr. 08, 2027 | Aug. 30, 2026 | ||||||
Exercise Price | $ / shares | ||||||||
Total outstanding, beginning balance | ||||||||
Total granted | 500,000 | |||||||
Exercised | ||||||||
Total expired, cancelled | ||||||||
Total outstanding, ending balance | 500,000 | |||||||
Options vested | 500,000 | 500,000 | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | ||||||||
Weighted average remaining life, outstanding | 4 years 11 months 8 days | |||||||
Share Price | $ / shares | $ 0.40 | |||||||
Total vested | 500,000 | |||||||
Total exercised | ||||||||
Option Fifteen [Member] | August 30, 2026 [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||||
Exercise Price | $ / shares | ||||||||
Total outstanding, beginning balance | 21,700,000 | |||||||
Total granted | 21,700,000 | |||||||
Exercised | ||||||||
Total expired, cancelled | ||||||||
Total outstanding, ending balance | 21,700,000 | |||||||
Options vested | 21,400,000 | 21,400,000 | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | ||||||||
Weighted average remaining life, outstanding | 4 years 9 months 29 days | |||||||
Share Price | $ / shares | $ 0.70 | |||||||
Total vested | 21,400,000 | |||||||
Total exercised | ||||||||
Option Sixteen [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||||
Expiry Date | Oct. 01, 2026 | |||||||
Option Sixteen [Member] | October 1, 2026 [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||||
Exercise Price | $ / shares | ||||||||
Total outstanding, beginning balance | 1,450,000 | |||||||
Total granted | 1,450,000 | |||||||
Exercised | ||||||||
Total expired, cancelled | ||||||||
Total outstanding, ending balance | 1,450,000 | |||||||
Options vested | 1,450,000 | 1,450,000 | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | ||||||||
Weighted average remaining life, outstanding | 4 years 11 months 1 day | |||||||
Share Price | $ / shares | $ 0.50 | |||||||
Total vested | 1,450,000 | |||||||
Total exercised |
SCHEDULE OF NONVESTED STOCK OPT
SCHEDULE OF NONVESTED STOCK OPTIONS (Details) | 6 Months Ended | 12 Months Ended | |||
Apr. 30, 2022 USD ($) $ / shares shares | Apr. 30, 2022 $ / shares | Oct. 31, 2021 USD ($) $ / shares shares | Oct. 31, 2021 $ / shares | Oct. 31, 2020 $ / shares shares | |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||
Weighted average grant date fair value per option, granted | $ / shares | $ 0.22 | ||||
Total nonvested, beginning balance | 462,500 | 950,000 | |||
Total nonvested, granted | |||||
Total nonvested, vested | (312,500) | 487,500 | |||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares | |||||
Total nonvested, ending balance | 150,000 | 462,500 | 950,000 | ||
Total nonvested, expired, cancelled | |||||
Weighted average grant date fair value per option, beginning balance | $ / shares | 0.39 | ||||
Weighted average grant date fair value per option, vested | $ / shares | 0.30 | 0.07 | |||
Weighted average grant date fair value per option, expired, cancelled | $ / shares | |||||
Weighted average grant date fair value per option, ending balance | $ / shares | 0.56 | 0.39 | |||
Weighted average grant date fair value total, beginning balance | $ | $ 144,131 | ||||
Weighted average grant date fair value total, granted | $ | 170,781 | ||||
Weighted average grant date fair value total, vested | $ | $ 74,063 | $ 26,650 | |||
Weighted average grant date fair value total, expired, cancelled | $ / shares | |||||
Weighted average grant date fair value total, ending balance | $ | $ 65,463 | $ 144,131 | |||
December 30, 2022 [Member] | |||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||
Share Based Compensation Arrangement By Share Based Payment Award Non vested Expiration Date | Dec. 30, 2022 | ||||
Weighted average grant date fair value per option, granted | $ / shares | 0.07 | ||||
Total nonvested, beginning balance | 162,500 | ||||
Total nonvested, granted | 650,000 | ||||
Total nonvested, vested | 487,500 | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares | |||||
Total nonvested, ending balance | 162,500 | ||||
Weighted average life (years) | 1 year 1 month 28 days | ||||
Total nonvested, expired, cancelled | |||||
August 30, 2026 [Member] | |||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||
Share Based Compensation Arrangement By Share Based Payment Award Non vested Expiration Date | Aug. 30, 2026 | ||||
Weighted average grant date fair value per option, granted | $ / shares | $ 0.56 | ||||
Total nonvested, beginning balance | 300,000 | ||||
Total nonvested, granted | 300,000 | ||||
Total nonvested, vested | |||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares | |||||
Total nonvested, ending balance | 300,000 | ||||
Weighted average life (years) | 4 years 9 months 29 days | ||||
Total nonvested, expired, cancelled | |||||
Option One [Member] | |||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||
Share Based Compensation Arrangement By Share Based Payment Award Non vested Expiration Date | Dec. 30, 2022 | ||||
Weighted average grant date fair value per option, granted | $ / shares | 0.07 | ||||
Total nonvested, beginning balance | 162,500 | ||||
Total nonvested, granted | |||||
Total nonvested, vested | (162,500) | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares | |||||
Total nonvested, ending balance | 162,500 | ||||
Weighted average life (years) | 1 year 1 month 28 days | ||||
Total nonvested, expired, cancelled | |||||
Option Two [Member] | |||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||
Share Based Compensation Arrangement By Share Based Payment Award Non vested Expiration Date | Aug. 30, 2026 | ||||
Weighted average grant date fair value per option, granted | $ / shares | $ 0.56 | ||||
Total nonvested, beginning balance | 300,000 | ||||
Total nonvested, granted | |||||
Total nonvested, vested | (150,000) | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares | |||||
Total nonvested, ending balance | 150,000 | 300,000 | |||
Weighted average life (years) | 4 years 9 months 29 days | ||||
Total nonvested, expired, cancelled |
SHARE CAPITAL (Details Narrativ
SHARE CAPITAL (Details Narrative) | 1 Months Ended | 2 Months Ended | 3 Months Ended | 5 Months Ended | 6 Months Ended | 12 Months Ended | 24 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Apr. 30, 2022 USD ($) $ / shares $ / shares shares | Apr. 22, 2022 CAD ($) $ / shares shares | Apr. 08, 2022 $ / shares shares | Mar. 10, 2022 $ / shares shares | Mar. 07, 2022 $ / shares shares | Jan. 20, 2022 USD ($) $ / shares shares | Dec. 13, 2021 $ / shares shares | Dec. 03, 2021 $ / shares shares | Nov. 26, 2021 USD ($) $ / shares shares | Nov. 04, 2021 $ / shares $ / shares shares | Nov. 03, 2021 USD ($) $ / shares shares | Oct. 18, 2021 USD ($) | Oct. 01, 2021 $ / shares shares | Aug. 30, 2021 $ / shares shares | Aug. 11, 2021 USD ($) $ / shares shares | Aug. 11, 2021 CAD ($) shares | Jul. 16, 2021 USD ($) shares | Jul. 16, 2021 CAD ($) $ / shares shares | Jul. 16, 2021 USD ($) shares | Jul. 16, 2021 CAD ($) $ / shares shares | Jun. 17, 2021 USD ($) shares | Jun. 17, 2021 CAD ($) $ / shares shares | Jun. 07, 2021 USD ($) shares | May 28, 2021 USD ($) shares | May 28, 2021 CAD ($) $ / shares shares | May 18, 2021 USD ($) shares | May 05, 2021 CAD ($) $ / shares | Apr. 27, 2021 USD ($) shares | Apr. 27, 2021 CAD ($) $ / shares shares | Mar. 24, 2021 USD ($) shares | Mar. 24, 2021 CAD ($) $ / shares shares | Jan. 29, 2021 USD ($) shares | Jan. 29, 2021 CAD ($) $ / shares shares | Jan. 15, 2021 USD ($) shares | Jan. 15, 2021 CAD ($) shares | Dec. 30, 2020 $ / shares shares | Nov. 20, 2020 USD ($) shares | Nov. 20, 2020 CAD ($) $ / shares shares | Sep. 10, 2020 CAD ($) $ / shares shares | May 26, 2020 USD ($) shares | May 26, 2020 CAD ($) shares | Feb. 19, 2020 $ / shares shares | Jan. 17, 2020 USD ($) shares | Jan. 17, 2020 CAD ($) shares | Aug. 08, 2018 | Apr. 27, 2022 $ / shares shares | Jun. 17, 2021 USD ($) | Jan. 31, 2022 CAD ($) $ / shares shares | Apr. 30, 2022 USD ($) $ / shares shares | Apr. 30, 2022 CAD ($) $ / shares shares | Jan. 31, 2022 USD ($) shares | Jan. 31, 2022 CAD ($) $ / shares shares | Apr. 30, 2021 USD ($) shares | Apr. 27, 2021 USD ($) shares | Apr. 27, 2021 CAD ($) $ / shares shares | Apr. 30, 2022 USD ($) $ / shares shares | Apr. 30, 2022 CAD ($) $ / shares shares | Apr. 30, 2021 USD ($) shares | Apr. 30, 2021 USD ($) $ / shares shares | Oct. 31, 2021 USD ($) $ / shares shares | Oct. 31, 2021 CAD ($) $ / shares shares | Oct. 31, 2020 USD ($) $ / shares shares | Oct. 31, 2020 USD ($) $ / shares $ / shares shares | Oct. 31, 2022 $ / shares shares | Apr. 30, 2022 $ / shares | Nov. 03, 2021 CAD ($) $ / shares shares | Oct. 31, 2021 CAD ($) $ / shares shares | Aug. 11, 2021 $ / shares | Jul. 15, 2021 USD ($) | Jul. 15, 2021 CAD ($) $ / shares | Jun. 11, 2021 shares | Jun. 07, 2021 CAD ($) $ / shares shares | Apr. 30, 2021 $ / shares | Apr. 24, 2021 $ / shares | Mar. 11, 2021 CAD ($) | Feb. 08, 2021 shares | Jan. 15, 2021 $ / shares | Jan. 13, 2021 $ / shares | Oct. 31, 2020 CAD ($) $ / shares shares | Jul. 27, 2020 USD ($) | Jul. 27, 2020 CAD ($) $ / shares | Jan. 17, 2020 CAD ($) $ / shares | Aug. 29, 2018 USD ($) | Aug. 28, 2018 USD ($) | Nov. 01, 2016 $ / shares | |
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common voting shares | 1,000,000,000 | 1,000,000,000 | 1,000,000,000 | 1,000,000,000 | 1,000,000,000 | 1,000,000,000 | 1,000,000,000 | 1,000,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock, par value | (per share) | $ 0.001 | $ 0.001 | $ 0.001 | $ 0.001 | $ 0.001 | $ 0.001 | $ 0.65 | $ 0.30 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants expire date | Feb. 19, 2020 | Feb. 19, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock warrants exercised | 35,472,661 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise of warrants price per share | $ / shares | $ 0.20 | $ 0.08 | $ 0.05 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock warrants exercised | 4,864,000 | 4,864,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, price per share | $ / shares | $ 0.65 | $ 0.65 | $ 0.05 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock shares subscriptions | $ | $ 388,701 | $ 388,701 | $ 388,701 | $ 209,827 | $ 596,872 | $ 596,872 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock shares issued | 500,000 | 500,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from stock options erercised | $ 26,401 | $ 37,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from other equity | $ | $ 19,775 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock, shares issued | 434,866,801 | 933,333 | 9,163,425 | 1,538,461 | 1,360,959 | 434,866,801 | 434,866,801 | 392,943,398 | 323,419,527 | 323,419,527 | 9,163,425 | 392,943,398 | 1,538,461 | 323,419,527 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertiable common shares | 263,973 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of stock value | $ | $ 26,286 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value of assets | $ 4,796,832 | $ 305,832 | $ 5,956,226 | $ 369,231 | $ 5,956,226 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from stock warrants erercised | $ 887,520 | $ 1,120,130 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock warrants expired unexercised | 525,173 | 525,173 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options granted | 1,250,000 | 1,250,000 | 15,650,000 | 38,800,000 | 38,800,000 | 6,600,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock, value, issued | $ | $ 39,096,950 | $ 39,096,950 | $ 39,096,950 | $ 29,842,167 | $ 21,322,022 | $ 21,322,022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares available for grant | 5,892,368 | 5,892,368 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share based compensation | $ | $ 302,254 | $ (1,060,085) | $ 433,829 | $ 11,051,124 | $ 666,259 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock options granted | $ / shares | $ 0.22 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, beginning balance | 61,260,000 | 61,260,000 | 61,260,000 | 61,260,000 | 61,260,000 | 61,260,000 | 28,420,000 | 28,420,000 | 28,420,000 | 29,630,000 | 28,420,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period shares stock options exercised | 750,000 | 750,000 | 100,000 | (2,630,000) | (2,630,000) | (500,000) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | (4,250,000) | (4,250,000) | (17,250,000) | (3,330,000) | (3,330,000) | (7,310,000) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, ending balance | 57,510,000 | 57,510,000 | 57,510,000 | 26,720,000 | 57,510,000 | 57,510,000 | 26,720,000 | 61,260,000 | 61,260,000 | 28,420,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | 57,360,000 | 57,360,000 | 26,720,000 | 57,360,000 | 26,720,000 | 26,720,000 | 60,797,500 | 27,420,000 | 27,420,000 | 60,797,500 | 27,420,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 3 years 1 month 24 days | 3 years 1 month 24 days | 2 years 9 months 10 days | 3 years 5 months 15 days | 3 years 5 months 15 days | 3 years 2 months 4 days | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Weighted average exercise price, beginning balance | $ / shares | $ 0.33 | $ 0.33 | $ 0.33 | $ 0.33 | $ 0.09 | $ 0.09 | $ 0.07 | $ 0.09 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares | 0.44 | 0.13 | 0.46 | 0.13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | $ / shares | 0.05 | 0.05 | 0.07 | 0.07 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price | $ / shares | 0.11 | 0.13 | 0.09 | 0.07 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Weighted average exercise price, ending balance | $ / shares | $ 0.34 | $ 0.34 | 0.34 | 0.09 | 0.33 | 0.09 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Weighted average exercise price, vested | $ / shares | $ 0.33 | $ 0.33 | $ 0.33 | $ 0.09 | $ 0.32 | $ 0.09 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value | $ | $ 2,149,050 | $ 2,149,050 | $ 597,721 | $ 2,149,050 | $ 597,721 | $ 597,721 | $ 19,994,025 | $ 801,922 | $ 801,922 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value | $ | $ 2,102,148 | $ 2,102,148 | $ 597,721 | $ 2,102,148 | $ 597,721 | $ 597,721 | $ 19,908,026 | $ 866,441 | $ 866,441 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term | 3 years 1 month 24 days | 3 years 1 month 24 days | 2 years 9 months 10 days | 3 years 5 months 15 days | 3 years 5 months 15 days | 3 years 2 months 4 days | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Intrinsic value of options exercised | $ | $ 962,936 | $ 28,533 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ | $ 100,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Antidilutive securities excluded from computation of earnings per share amount | 96,006,372 | 96,006,372 | 120,808,982 | 120,808,982 | 38,529,642 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Conversion of Convertible Securities | 2,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of common stock | $ | $ 3,851,614 | $ 1,856,336 | $ 7,328,389 | $ 2,715,129 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | $ | $ 12,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unit placement assigned value | $ | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class A Warrants [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise of warrants price per share | $ / shares | $ 0.13 | $ 0.13 | $ 0.13 | $ 0.13 | $ 0.13 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 500,000 | 500,000 | 500,000 | 1,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class B Warrants [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise of warrants price per share | $ / shares | $ 0.19 | $ 0.19 | $ 0.19 | $ 0.19 | $ 0.19 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments of stock issuance costs | $ | $ 1,361 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 500,000 | 500,000 | 500,000 | 500,000 | 1,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equipment [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued pursuant to private placements [note 13[b]], shares | 1,538,461 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, price per share | $ / shares | $ 0.24 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value of assets | $ 305,832 | $ 369,231 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
July 2021 Convertible Debenture [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise of warrants price per share | $ / shares | $ 0.20 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertiable common shares | 933,333 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 79,542 | $ 100,000 | $ 79,542 | $ 100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
July 2020 Convertible Debenture [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued pursuant to private placements [note 13[b]], shares | 1,360,959 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, price per share | $ / shares | $ 0.15 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock, shares issued | 1,360,959 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertiable common shares | 263,973 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of stock value | $ | $ 26,286 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock, value, issued | $ | $ 26,286 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 112,124 | $ 150,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
June 2021 Convertible Debentures [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period, shares, conversion of units | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | 2,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Option One [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options granted | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock options granted | $ / shares | $ 0.07 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date | Mar. 27, 2022 | Mar. 27, 2022 | Feb. 11, 2021 | Feb. 11, 2021 | Feb. 11, 2021 | May 31, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share Price | $ / shares | $ 0.05 | $ 0.05 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, beginning balance | 1,500,000 | 1,500,000 | 1,500,000 | 1,500,000 | 1,500,000 | 1,500,000 | 800,000 | 800,000 | 800,000 | 800,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period shares stock options exercised | (750,000) | (750,000) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | (750,000) | (750,000) | (800,000) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, ending balance | 1,500,000 | 1,500,000 | 800,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 10 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Option Two [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options granted | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock options granted | $ / shares | $ 0.56 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date | Dec. 30, 2022 | Dec. 30, 2022 | Aug. 16, 2021 | Aug. 16, 2021 | Aug. 16, 2021 | Jun. 03, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share Price | $ / shares | 0.13 | 0.05 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, beginning balance | 6,000,000 | 6,000,000 | 6,000,000 | 6,000,000 | 6,000,000 | 6,000,000 | 600,000 | 600,000 | 600,000 | 600,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period shares stock options exercised | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | (150,000) | (150,000) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, ending balance | 5,850,000 | 5,850,000 | 5,850,000 | 600,000 | 5,850,000 | 5,850,000 | 600,000 | 6,000,000 | 6,000,000 | 600,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | 5,850,000 | 5,850,000 | 600,000 | 5,850,000 | 600,000 | 600,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 8 months 1 day | 8 months 1 day | 6 months 14 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Option Three [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options granted | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date | Aug. 12, 2023 | Aug. 12, 2023 | Mar. 27, 2022 | Mar. 27, 2022 | Mar. 27, 2022 | Feb. 11, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share Price | $ / shares | 0.05 | 0.05 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, beginning balance | 2,290,000 | 2,290,000 | 2,290,000 | 2,290,000 | 2,290,000 | 2,290,000 | 1,750,000 | 1,750,000 | 1,750,000 | 1,750,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period shares stock options exercised | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | (750,000) | (750,000) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, ending balance | 1,540,000 | 1,540,000 | 1,540,000 | 1,750,000 | 1,540,000 | 1,540,000 | 1,750,000 | 2,290,000 | 2,290,000 | 1,750,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | 1,540,000 | 1,540,000 | 1,750,000 | 1,540,000 | 1,750,000 | 1,750,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 1 year 3 months 10 days | 1 year 3 months 10 days | 1 year 1 month 24 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Option Four [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options granted | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date | Dec. 03, 2023 | Dec. 03, 2023 | Aug. 26, 2022 | Aug. 26, 2022 | Aug. 26, 2022 | Aug. 16, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share Price | $ / shares | 0.05 | 0.13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, beginning balance | 6,450,000 | 6,450,000 | 6,450,000 | 6,450,000 | 6,450,000 | 6,450,000 | 500,000 | 500,000 | 500,000 | 500,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period shares stock options exercised | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | (1,000,000) | (1,000,000) | (500,000) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, ending balance | 5,450,000 | 5,450,000 | 5,450,000 | 5,450,000 | 5,450,000 | 6,450,000 | 6,450,000 | 500,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | 5,450,000 | 5,450,000 | 5,450,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 1 year 7 months 2 days | 1 year 7 months 2 days | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Option Five [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options granted | 6,150,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date | May 22, 2024 | May 22, 2024 | Dec. 30, 2022 | Dec. 30, 2022 | Dec. 30, 2022 | Mar. 27, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share Price | $ / shares | 0.12 | 0.13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, beginning balance | 7,900,000 | 7,900,000 | 7,900,000 | 7,900,000 | 7,900,000 | 7,900,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period shares stock options exercised | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | (850,000) | (850,000) | (6,150,000) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, ending balance | 7,050,000 | 7,050,000 | 7,050,000 | 7,050,000 | 7,050,000 | 7,900,000 | 7,900,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | 7,050,000 | 7,050,000 | 7,050,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 2 years 21 days | 2 years 21 days | 1 year 10 months 28 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Option Six [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options granted | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date | Nov. 03, 2024 | Nov. 03, 2024 | Apr. 19, 2023 | Apr. 19, 2023 | Apr. 19, 2023 | Aug. 26, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share Price | $ / shares | 0.15 | 0.05 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, beginning balance | 700,000 | 700,000 | 700,000 | 700,000 | 700,000 | 700,000 | 800,000 | 800,000 | 800,000 | 800,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period shares stock options exercised | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, ending balance | 700,000 | 700,000 | 700,000 | 800,000 | 700,000 | 700,000 | 800,000 | 700,000 | 700,000 | 800,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | 700,000 | 700,000 | 800,000 | 700,000 | 800,000 | 800,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 2 years 6 months 7 days | 2 years 6 months 7 days | 2 years 2 months 15 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Option Seven [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options granted | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date | Nov. 24, 2024 | Nov. 24, 2024 | Aug. 12, 2023 | Aug. 12, 2023 | Aug. 12, 2023 | Apr. 19, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share Price | $ / shares | 0.16 | 0.05 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, beginning balance | 320,000 | 320,000 | 320,000 | 320,000 | 320,000 | 320,000 | 3,120,000 | 3,120,000 | 3,120,000 | 3,120,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period shares stock options exercised | (100,000) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | (300,000) | (300,000) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, ending balance | 20,000 | 20,000 | 20,000 | 3,020,000 | 20,000 | 20,000 | 3,020,000 | 320,000 | 320,000 | 3,120,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | 20,000 | 20,000 | 3,020,000 | 20,000 | 3,020,000 | 3,020,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 2 years 6 months 25 days | 2 years 6 months 25 days | 2 years 6 months 10 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Option Eight [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options granted | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date | Mar. 26, 2025 | Mar. 26, 2025 | Dec. 03, 2023 | Dec. 03, 2023 | Dec. 03, 2023 | Aug. 12, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share Price | $ / shares | 0.11 | 0.05 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, beginning balance | 100,000 | 100,000 | 100,000 | 100,000 | 100,000 | 100,000 | 7,000,000 | 7,000,000 | 7,000,000 | 7,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period shares stock options exercised | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, ending balance | 100,000 | 100,000 | 100,000 | 7,000,000 | 100,000 | 100,000 | 7,000,000 | 100,000 | 100,000 | 7,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | 100,000 | 100,000 | 7,000,000 | 100,000 | 7,000,000 | 7,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 2 years 10 months 28 days | 2 years 10 months 28 days | 2 years 10 months 2 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Option Nine [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options granted | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date | Apr. 23, 2025 | Apr. 23, 2025 | May 22, 2024 | May 22, 2024 | May 22, 2024 | Dec. 03, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share Price | $ / shares | 0.12 | 0.12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, beginning balance | 3,350,000 | 3,350,000 | 3,350,000 | 3,350,000 | 3,350,000 | 3,350,000 | 7,950,000 | 7,950,000 | 7,950,000 | 7,950,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period shares stock options exercised | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | (250,000) | (250,000) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, ending balance | 3,100,000 | 3,100,000 | 3,100,000 | 7,950,000 | 3,100,000 | 3,100,000 | 7,950,000 | 3,350,000 | 3,350,000 | 7,950,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | 3,100,000 | 3,100,000 | 7,950,000 | 3,100,000 | 7,950,000 | 7,950,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 2 years 11 months 23 days | 2 years 11 months 23 days | 3 years 3 months 21 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Option Ten [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options granted | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date | Dec. 30, 2025 | Dec. 30, 2025 | Nov. 03, 2024 | Nov. 03, 2024 | Nov. 03, 2024 | May 22, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share Price | $ / shares | 0.13 | 0.15 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, beginning balance | 9,500,000 | 9,500,000 | 9,500,000 | 9,500,000 | 9,500,000 | 9,500,000 | 700,000 | 700,000 | 700,000 | 700,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period shares stock options exercised | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, ending balance | 9,500,000 | 9,500,000 | 9,500,000 | 700,000 | 9,500,000 | 9,500,000 | 700,000 | 9,500,000 | 9,500,000 | 700,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | 9,500,000 | 9,500,000 | 700,000 | 9,500,000 | 700,000 | 700,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 3 years 8 months 1 day | 3 years 8 months 1 day | 3 years 9 months 3 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Option Eleven [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options granted | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date | Aug. 30, 2026 | Aug. 30, 2026 | Nov. 24, 2024 | Nov. 24, 2024 | Nov. 24, 2024 | Nov. 03, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share Price | $ / shares | 0.70 | 0.16 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, beginning balance | 21,700,000 | 21,700,000 | 21,700,000 | 21,700,000 | 21,700,000 | 21,700,000 | 900,000 | 900,000 | 900,000 | 900,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period shares stock options exercised | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | (200,000) | (200,000) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, ending balance | 21,500,000 | 21,500,000 | 21,500,000 | 900,000 | 21,500,000 | 21,500,000 | 900,000 | 21,700,000 | 21,700,000 | 900,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | 21,350,000 | 21,350,000 | 900,000 | 21,350,000 | 900,000 | 900,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 4 years 4 months 2 days | 4 years 4 months 2 days | 3 years 9 months 25 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Option Twelve [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options granted | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date | Oct. 01, 2026 | Oct. 01, 2026 | Mar. 26, 2025 | Mar. 26, 2025 | Mar. 26, 2025 | Nov. 24, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share Price | $ / shares | 0.50 | 0.11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, beginning balance | 1,450,000 | 1,450,000 | 1,450,000 | 1,450,000 | 1,450,000 | 1,450,000 | 300,000 | 300,000 | 300,000 | 300,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period shares stock options exercised | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, ending balance | 1,450,000 | 1,450,000 | 1,450,000 | 300,000 | 1,450,000 | 1,450,000 | 300,000 | 1,450,000 | 1,450,000 | 300,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | 1,450,000 | 1,450,000 | 300,000 | 1,450,000 | 300,000 | 300,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 4 years 5 months 1 day | 4 years 5 months 1 day | 4 years 1 month 24 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Option Thirteen [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options granted | 250,000 | 250,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date | Dec. 03, 2026 | Dec. 03, 2026 | Apr. 23, 2025 | Apr. 23, 2025 | Apr. 23, 2025 | Mar. 26, 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share Price | $ / shares | 0.58 | 0.12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, beginning balance | 4,000,000 | 4,000,000 | 4,000,000 | 4,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period shares stock options exercised | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | (300,000) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, ending balance | 250,000 | 250,000 | 250,000 | 3,700,000 | 250,000 | 250,000 | 3,700,000 | 4,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | 250,000 | 250,000 | 3,700,000 | 250,000 | 3,700,000 | 3,700,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 4 years 7 months 6 days | 4 years 7 months 6 days | 4 years 2 months 23 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Option Fourteen [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options granted | 500,000 | 500,000 | 9,500,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date | Mar. 07, 2027 | Mar. 07, 2027 | Dec. 30, 2025 | Dec. 30, 2025 | Dec. 30, 2025 | Apr. 23, 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share Price | $ / shares | 0.40 | $ 0.13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, beginning balance | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period shares stock options exercised | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | (9,500,000) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, ending balance | 500,000 | 500,000 | 500,000 | 500,000 | 500,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | 500,000 | 500,000 | 500,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 4 years 10 months 6 days | 4 years 10 months 6 days | 4 years 11 months 1 day | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity Option [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock options granted | $ / shares | $ 0.36 | $ 0.14 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
May 31, 2020 [Member] | Option One [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options granted | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share Price | $ / shares | $ 0.08 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, beginning balance | 400,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period shares stock options exercised | (400,000) | (400,000) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, ending balance | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
June Three Two Thousand Twenty [Member] | Option Two [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options granted | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share Price | $ / shares | $ 0.05 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, beginning balance | 550,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period shares stock options exercised | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | (550,000) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, ending balance | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
February 11, 2021 [Member] | Option Three [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options granted | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share Price | $ / shares | $ 0.05 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, beginning balance | 800,000 | 800,000 | 800,000 | 1,300,000 | 800,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period shares stock options exercised | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | (500,000) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, ending balance | 800,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | 800,000 | 800,000 | 800,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 6 months 10 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
August 16, 2021 [Member] | Option Four [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options granted | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share Price | $ / shares | $ 0.05 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, beginning balance | 600,000 | 600,000 | 600,000 | 1,200,000 | 600,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period shares stock options exercised | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | (600,000) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, ending balance | 600,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | 600,000 | 600,000 | 600,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 1 year 14 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
March 27, 2022 [Member] | Option Five [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options granted | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share Price | $ / shares | $ 0.05 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, beginning balance | 1,750,000 | 1,750,000 | 1,750,000 | 2,000,000 | 1,750,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period shares stock options exercised | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | (250,000) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, ending balance | 1,750,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | 1,750,000 | 1,750,000 | 1,750,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 1 year 7 months 24 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
August 26, 2022 [Member] | Option Six [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options granted | 500,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share Price | $ / shares | $ 0.13 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, beginning balance | 500,000 | 500,000 | 500,000 | 500,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period shares stock options exercised | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, ending balance | 500,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
April 19, 2023 [Member] | Option Seven [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options granted | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share Price | $ / shares | $ 0.05 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, beginning balance | 800,000 | 800,000 | 800,000 | 800,000 | 800,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period shares stock options exercised | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, ending balance | 800,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | 800,000 | 800,000 | 800,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 2 years 8 months 19 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
August 12, 2023 [Member] | Option Eight [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options granted | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share Price | $ / shares | $ 0.05 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, beginning balance | 3,120,000 | 3,120,000 | 3,120,000 | 3,780,000 | 3,120,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period shares stock options exercised | (100,000) | (100,000) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | (560,000) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, ending balance | 3,120,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | 3,120,000 | 3,120,000 | 3,120,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 3 years 10 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
December 3, 2023 [Member] | Option Nine [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options granted | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share Price | $ / shares | $ 0.05 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, beginning balance | 7,000,000 | 7,000,000 | 7,000,000 | 9,600,000 | 7,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period shares stock options exercised | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | (2,600,000) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, ending balance | 7,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | 7,000,000 | 7,000,000 | 7,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
December 3, 2023 [Member] | Option Ten [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 3 years 4 months 6 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
May 22, 2024 [Member] | Option Ten [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options granted | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share Price | $ / shares | $ 0.12 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, beginning balance | 7,950,000 | 7,950,000 | 7,950,000 | 10,000,000 | 7,950,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period shares stock options exercised | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | (2,050,000) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, ending balance | 7,950,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | 7,950,000 | 7,950,000 | 7,950,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 3 years 9 months 21 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
November 3, 2024 [Member] | Option Eleven [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options granted | 700,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share Price | $ / shares | $ 0.15 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, beginning balance | 700,000 | 700,000 | 700,000 | 700,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period shares stock options exercised | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, ending balance | 700,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | 700,000 | 700,000 | 700,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 4 years 3 months 7 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
November 24, 2024 [Member] | Option Twelve [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options granted | 900,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share Price | $ / shares | $ 0.16 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, beginning balance | 900,000 | 900,000 | 900,000 | 900,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period shares stock options exercised | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, ending balance | 900,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | 775,000 | 775,000 | 775,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 4 years 3 months 25 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
March 26, 2025 [Member] | Option Thirteen [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options granted | 300,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share Price | $ / shares | $ 0.11 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, beginning balance | 300,000 | 300,000 | 300,000 | 300,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period shares stock options exercised | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, ending balance | 300,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | 300,000 | 300,000 | 300,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 4 years 7 months 28 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
April 23, 2025 [Member] | Option Fourteen [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options granted | 4,200,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share Price | $ / shares | $ 0.12 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, beginning balance | 4,000,000 | 4,000,000 | 4,000,000 | 4,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period shares stock options exercised | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period | (200,000) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total outstanding, ending balance | 4,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | 3,625,000 | 3,625,000 | 3,625,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 4 years 8 months 23 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2017 Stock Option Plan [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options granted | 15,650,000 | 6,600,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Options exercisable price | $ / shares | $ 0.13 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock option granted terms | Stock options granted are subject to a maximum term of 5 years. All options granted shall vest immediately, except for those options granted to persons performing investor relations activities for the Company | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2017 Stock Option Plan [Member] | Exercisable at Five Years [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options exercisable | 9,500,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2017 Stock Option Plan [Member] | Exercisable at Two Years [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options exercisable | 6,150,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2021 Equity Incentive Plan [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options granted | 9,092,368 | 500,000 | 500,000 | 250,000 | 1,450,000 | 21,700,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maximum number of common shares available | 27,312,368 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options forfeited | 1,730,000 | 1,730,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Options exercisable price | $ / shares | $ 0.40 | $ 0.40 | $ 0.58 | $ 0.50 | $ 0.70 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Options exercisable period | 5 years | 5 years | 5 years | 5 years | 5 years | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares available for grant | 29,042,368 | 29,042,368 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity Option [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from stock options erercised | $ 29,715 | $ 37,500 | $ 140,734 | $ 175,800 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from other equity | $ | $ 22,203 | $ 121,932 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options granted | 750,000 | 750,000 | 2,630,000 | 2,630,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Options exercisable price | $ / shares | 0.05 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock options granted | $ / shares | $ 0.37 | $ 0.09 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maximum [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 33,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maximum [Member] | 2017 Stock Option Plan [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Percentage of authorized grant stock options | 20% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Options exercisable price | $ / shares | $ 0.16 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Options exercisable period | 5 years | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maximum [Member] | 2021 Equity Incentive Plan [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maximum number of common shares available | 33,292,368 | 33,292,368 | 33,292,368 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options forfeited | 29,042,368 | 29,042,368 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maximum [Member] | Director and Officers [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Percentage of ownership of common stock | 5% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock, value, issued | $ | $ 5,000,000 | $ 5,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maximum [Member] | Equity Option [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise of options price per share | $ / shares | $ 0.16 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Options exercisable price | $ / shares | $ 0.16 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Minimum [Member] | 2017 Stock Option Plan [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Options exercisable price | $ / shares | $ 0.11 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Options exercisable period | 2 years | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Minimum [Member] | 2021 Equity Incentive Plan [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maximum number of common shares available | 5,980,000 | 5,980,000 | 5,980,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options forfeited | 1,730,000 | 1,730,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Minimum [Member] | Equity Option [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise of options price per share | $ / shares | $ 0.05 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Options exercisable price | $ / shares | $ 0.05 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Non Brokered Private Placement [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued pursuant to private placements [note 13[b]], shares | 3,827,601 | 3,827,601 | 4,350,000 | 4,350,000 | 4,350,000 | 4,350,000 | 23,076,926 | 23,076,926 | 3,643,792 | 3,643,792 | 25,724,955 | 25,724,955 | 25,724,955 | 25,724,955 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, price per share | (per share) | $ 0.44 | $ 0.20 | $ 0.20 | $ 0.13 | $ 0.13 | $ 0.13 | $ 0.13 | 0.13 | $ 0.55 | $ 0.15 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of private placement | $ 1,683,336 | $ 2,105,180 | $ 690,860 | $ 870,000 | $ 690,860 | $ 870,000 | $ 3,000,000 | $ 416,719 | $ 546,569 | $ 2,442,531 | $ 2,621,314 | $ 3,344,244 | $ 2,621,314 | $ 3,344,244 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock shares subscriptions | 39,722 | $ 596,872 | $ 596,872 | $ 747,392 | $ 52,922 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Finders fees paid | $ | $ 41,275 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of shares, description | Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.65 (US$0.52) for a period of eighteen months from the date of closing. | Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.65 (US$0.52) for a period of eighteen months from the date of closing. | Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.30 for a period of one year from the date of closing | Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.30 for a period of one year from the date of closing | Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.30 for a period of one year from the date of closing. | Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.30 for a period of one year from the date of closing. | Each unit issued consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.19 for a period of one year from the date of closing of the respective financing tranche. | Each unit issued consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.19 for a period of one year from the date of closing of the respective financing tranche. | Each unit is comprised of one common share and one common share purchase warrant exercisable at CA$0.19 per common share for a period of one year. | Each unit issued consists of one common share and one common share purchase warrant entitling the holder to acquire a further common share at a price of CA$0.19 for a period of one year from the closing date of the respective financing tranche. | Each unit issued consists of one common share and one common share purchase warrant entitling the holder to acquire a further common share at a price of CA$0.19 for a period of one year from the closing date of the respective financing tranche. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments of stock issuance costs | $ | $ 124,923 | $ 48,319 | $ 48,319 | $ 154,336 | $ 195,614 | $ 195,614 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issuance costs | $ | $ 116,479 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Non Brokered Private Placement [Member] | Share-Based Payment Arrangement, Tranche One [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued pursuant to private placements [note 13[b]], shares | 5,223,420 | 5,223,420 | 5,599,171 | 5,599,171 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, price per share | $ / shares | $ 0.13 | $ 0.13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of private placement | $ 561,844 | $ 679,044 | $ 556,876 | $ 727,892 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Non Brokered Private Placement [Member] | Share-Based Payment Arrangement, Tranche Two [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued pursuant to private placements [note 13[b]], shares | 7,337,914 | 7,337,914 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, price per share | $ / shares | $ 0.13 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of private placement | $ 749,435 | $ 953,930 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock shares subscriptions | $ | $ 39,996 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Non Brokered Private Placement [Member] | Share-Based Payment Arrangement, Tranche Three [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued pursuant to private placements [note 13[b]], shares | 5,382,303 | 5,382,303 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, price per share | $ / shares | $ 0.13 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of private placement | $ 547,496 | $ 699,699 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Non Brokered Private Placement [Member] | Share Based Compensation Award Tranche Four [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued pursuant to private placements [note 13[b]], shares | 6,554,172 | 6,554,172 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, price per share | $ / shares | $ 0.13 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of private placement | $ 678,270 | $ 852,042 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Non Brokered Private Placement [Member] | Share Based Compensation Award Tranche Five and Final [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued pursuant to private placements [note 13[b]], shares | 851,395 | 851,395 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, price per share | $ / shares | $ 0.13 | $ 0.13 | $ 0.13 | $ 0.13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of private placement | $ 89,237 | $ 110,681 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Non Brokered Private Placement [Member] | Share Based Compensation Award Tranche Two And Final [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued pursuant to private placements [note 13[b]], shares | 17,853,506 | 17,853,506 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, price per share | $ / shares | $ 0.13 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of private placement | $ 1,880,687 | $ 2,320,956 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Non Brokered Private Placement [Member] | Maximum [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued pursuant to private placements [note 13[b]], shares | 53,846,154 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of private placement | $ | $ 3,000,000 | $ 7,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Non Brokered Private Placement One [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued pursuant to private placements [note 13[b]], shares | 23,076,926 | 23,076,926 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, price per share | $ / shares | 0.13 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of private placement | $ 2,442,531 | $ 3,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of shares, description | Each unit issued consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.19 for a period of one year from the date of closing of the respective financing tranche | Each unit issued consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.19 for a period of one year from the date of closing of the respective financing tranche | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments of stock issuance costs | $ | $ 154,336 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock warrants expired unexercised | 24,794,484 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from other equity | $ | $ 4,291 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock, shares issued | 7,014,969 | 7,014,969 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock warrants expired unexercised | 525,173 | 525,173 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from stock warrants erercised | $ 887,520 | $ 1,120,130 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants expired unexercised | 2,428,363 | 2,428,363 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Maximum [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise of warrants price per share | $ / shares | $ 0.21 | $ 0.21 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Minimum [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise of warrants price per share | $ / shares | $ 0.05 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued pursuant to private placements [note 13[b]], shares | 1,375,499 | 1,375,499 | 25,724,955 | 56,979,482 | 56,979,482 | 3,643,791 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, price per share | $ / shares | $ 0.65 | $ 0.24 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock shares issued | 750,000 | 750,000 | 100,000 | 2,630,000 | 2,630,000 | 500,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Conversion of Convertible Securities | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | 6,933,333 | 6,933,333 | 1,360,959 | 1,360,959 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of common stock | $ 2,899,295 | $ 2,293,946 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants expired unexercised | 15,389,448 | 15,389,448 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock [Member] | Non Brokered Private Placement One [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of shares, description | Each unit issued consists of one common share and one common share purchase warrant entitling the holder to acquire a further common share at a price of CA$0.19 for a period of one year from the closing date of the respective financing tranche | Each unit issued consists of one common share and one common share purchase warrant entitling the holder to acquire a further common share at a price of CA$0.19 for a period of one year from the closing date of the respective financing tranche | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock [Member] | Private Placement [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued pursuant to private placements [note 13[b]], shares | 1,375,499 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, price per share | $ / shares | $ 0.55 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of private placement | $ | $ 756,524 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments of stock issuance costs | $ | $ 26,656 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share Price | $ / shares | $ 0.75 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock One [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, price per share | $ / shares | $ 0.19 | $ 0.19 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 15,159,448 | 15,159,448 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of common stock | 2,279,136 | $ 2,880,295 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock Two [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, price per share | $ / shares | 0.05 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 200,000 | 200,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of common stock | $ 10,000 | $ 7,830 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock Three [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, price per share | $ / shares | $ 0.30 | $ 0.30 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 30,000 | 30,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of common stock | $ 6,981 | $ 9,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock Purchase Warrant [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued pursuant to private placements [note 13[b]], shares | 929,005 | 929,005 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, price per share | $ / shares | 0.19 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock warrants expired unexercised | 3,191,933 | 3,191,933 | 3,191,933 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of common stock | $ 929,005 | $ 1,177,755 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock broker warrants expired unexercised | 40,000 | 40,000 | 40,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock Purchase Warrant One [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued pursuant to private placements [note 13[b]], shares | 2,082,025 | 2,082,025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, price per share | $ / shares | 0.05 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of common stock | $ 81,354 | $ 104,101 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock Purchase Warrant Two [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued pursuant to private placements [note 13[b]], shares | 30,960 | 30,960 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, price per share | $ / shares | $ 0.30 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of common stock | $ 7,357 | $ 9,288 |
CAPITAL MANAGEMENT (Details Nar
CAPITAL MANAGEMENT (Details Narrative) - USD ($) | Apr. 30, 2022 | Oct. 31, 2021 | Apr. 30, 2021 | Oct. 31, 2020 | Oct. 31, 2019 |
Capital Management | |||||
Stockholders deficit | $ 2,870,118 | $ 6,770,038 | $ 2,929,921 | $ 2,079,903 | $ 1,269,030 |
SCHEDULE OF CLASSIFICATION OF F
SCHEDULE OF CLASSIFICATION OF FINANCIAL INSTRUMENTS (Details) - USD ($) | Apr. 30, 2022 | Oct. 31, 2021 |
Fair Value Disclosures [Abstract] | ||
Cash | $ 774,409 | $ 462,360 |
Amounts receivable | 151,485 | |
Deposits held by related parties | 388,757 | 486,462 |
Accounts payable and accrued liabilities | 2,715,924 | 1,989,316 |
Due to related parties | 1,253,280 | 1,026,817 |
Convertible debenture, net | 1,783,584 | 107 |
Convertible debenture and derivative liability | 7,449,700 | |
Other receivables | 50,765 | |
Subscription receivable | 185,000 | |
Warrant liability | $ 2,468,261 |
SCHEDULE OF FOREIGN CURRENCY RI
SCHEDULE OF FOREIGN CURRENCY RISK (Details) | Apr. 30, 2022 CAD ($) | Oct. 31, 2021 USD ($) |
Total | $ (2,003,641) | $ (2,067,422) |
Cash [Member] | ||
Total | 208,683 | 186,627 |
Deposits Held By Related Parties [Member] | ||
Total | 486,462 | |
Accounts Payable and Accrued Liabilities [Member] | ||
Total | (1,511,845) | (773,011) |
Due To Related Parties [Member] | ||
Total | (765,409) | (467,500) |
Convertible Debenture [Member] | ||
Total | $ (1,500,000) | |
Other Receivable [Member] | ||
Total | $ 64,930 |
FINANCIAL INSTRUMENTS AND FIN_3
FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Details Narrative) - USD ($) | 6 Months Ended | 12 Months Ended | |
Apr. 30, 2022 | Oct. 31, 2021 | Oct. 31, 2020 | |
Fair Value Disclosures [Abstract] | |||
Cash | $ 774,409 | $ 462,360 | $ 39,571 |
Short term investments | 0 | 0 | 0 |
Foreign currency risk rate | |||
Increase decrease in foreign currency transaction amount | 78,312 | 262,941 | |
Working capital deficit | $ 7,172,573 | $ 9,657,316 | $ 2,392,189 |
SCHEDULE OF ASSETS INFORMATION
SCHEDULE OF ASSETS INFORMATION (Details) - USD ($) | Apr. 30, 2022 | Oct. 31, 2021 | Oct. 31, 2020 |
Revenues from External Customers and Long-Lived Assets [Line Items] | |||
United States – property, plant and equipment | $ 3,977,619 | $ 2,574,704 | $ 79,436 |
United States – mineral property costs | 93,453 | 93,453 | 93,453 |
Property, plant and equipment net | 4,071,072 | 2,668,157 | 172,889 |
Other assets | 2,004,431 | 1,845,355 | 535,874 |
Total Assets | 6,075,503 | 4,513,512 | 708,763 |
CANADA | |||
Revenues from External Customers and Long-Lived Assets [Line Items] | |||
United States – property, plant and equipment | 3,946,315 | 2,546,383 | 79,436 |
Other assets | 392,853 | 1,554,827 | 533,815 |
UNITED STATES | |||
Revenues from External Customers and Long-Lived Assets [Line Items] | |||
United States – property, plant and equipment | 31,304 | 28,321 | |
United States – mineral property costs | 93,453 | 93,453 | 93,453 |
Other assets | $ 1,611,578 | $ 290,528 | $ 2,059 |
SCHEDULE OF EFFECTIVE TAX RATES
SCHEDULE OF EFFECTIVE TAX RATES RECONCILIATION (Details) - USD ($) | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Apr. 30, 2022 | Apr. 30, 2021 | Apr. 30, 2022 | Apr. 30, 2021 | Oct. 31, 2021 | Oct. 31, 2020 | |
Income Tax Disclosure [Abstract] | ||||||
Loss for the year | $ 1,181,243 | $ (403,910) | $ (13,765,286) | $ (2,554,388) | $ (23,549,612) | $ (4,672,605) |
Statutory rate | 33.02% | 31.21% | ||||
Expected income tax recovery at statutory rate | $ (7,778,880) | $ (1,458,320) | ||||
Net adjustment for deductible and non-deductible amounts | 2,636,262 | 250,196 | ||||
Foreign exchange effect | (9,867) | (175,597) | ||||
Valuation allowance | 5,152,485 | 1,383,721 | ||||
Deferred income tax provision (recovery) |
SCHEDULE OF DEFERRED TAX ASSETS
SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITY (Details) - USD ($) | Oct. 31, 2021 | Oct. 31, 2020 |
Income Tax Disclosure [Abstract] | ||
Non-capital loss carry-forwards | $ 5,340,578 | $ 2,600,561 |
Property and equipment | (159,673) | (123,561) |
Lease liability | 180,812 | 103,789 |
Convertible debenture | (509,985) | |
Convertible debenture – derivative liability | 2,532,898 | |
Exploration and evaluation asset | 359,700 | |
Share issue costs | 11,056 | |
Valuation allowance | (7,744,330) | (2,591,845) |
Deferred income tax asset (liability) |
INCOME TAX (Details Narrative)
INCOME TAX (Details Narrative) - USD ($) | Oct. 31, 2021 | Oct. 30, 2021 |
UNITED KINGDOM | ||
Net operating loss | $ 13,439,000 | $ 3,515,000 |
SUBSEQUENT EVENTS (Details Narr
SUBSEQUENT EVENTS (Details Narrative) | 1 Months Ended | 2 Months Ended | 3 Months Ended | 5 Months Ended | 6 Months Ended | 12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||
Jun. 08, 2022 $ / shares shares | Jun. 03, 2022 USD ($) $ / shares shares | May 09, 2022 USD ($) $ / shares shares | Apr. 30, 2022 USD ($) $ / shares shares | Apr. 08, 2022 $ / shares shares | Mar. 10, 2022 $ / shares shares | Mar. 07, 2022 $ / shares shares | Jan. 20, 2022 $ / shares shares | Dec. 13, 2021 $ / shares shares | Dec. 03, 2021 $ / shares shares | Nov. 26, 2021 USD ($) $ / shares shares | Nov. 04, 2021 $ / shares shares | Nov. 03, 2021 USD ($) $ / shares shares | Nov. 03, 2021 CAD ($) shares | Oct. 01, 2021 $ / shares shares | Aug. 30, 2021 $ / shares shares | Aug. 11, 2021 USD ($) $ / shares shares | Aug. 11, 2021 CAD ($) shares | Jul. 16, 2021 USD ($) shares | Jul. 16, 2021 CAD ($) $ / shares shares | Jul. 16, 2021 USD ($) shares | Jul. 16, 2021 CAD ($) $ / shares shares | Jun. 17, 2021 CAD ($) shares | May 28, 2021 USD ($) shares | May 28, 2021 CAD ($) $ / shares shares | May 05, 2021 CAD ($) $ / shares | Nov. 20, 2020 USD ($) shares | Nov. 20, 2020 CAD ($) $ / shares shares | Sep. 10, 2020 CAD ($) $ / shares shares | Jan. 17, 2020 USD ($) shares | Jan. 17, 2020 CAD ($) $ / shares shares | Jun. 13, 2022 CAD ($) $ / shares shares | Apr. 27, 2022 $ / shares shares | Jun. 17, 2021 USD ($) | Jan. 31, 2022 CAD ($) $ / shares shares | Feb. 10, 2022 CAD ($) $ / shares shares | Jan. 31, 2022 USD ($) | Jan. 31, 2022 CAD ($) $ / shares shares | Apr. 27, 2021 USD ($) shares | Apr. 27, 2021 CAD ($) $ / shares shares | Apr. 30, 2022 USD ($) $ / shares shares | Apr. 30, 2022 CAD ($) shares | Apr. 30, 2021 USD ($) shares | Oct. 31, 2021 USD ($) $ / shares shares | Oct. 31, 2020 USD ($) shares | Apr. 30, 2022 $ / shares | Apr. 22, 2022 $ / shares | Nov. 03, 2021 $ / shares shares | Oct. 31, 2021 $ / shares | Aug. 11, 2021 $ / shares | Jun. 07, 2021 $ / shares | Feb. 08, 2021 shares | Feb. 19, 2020 $ / shares | Aug. 28, 2018 USD ($) | Nov. 01, 2016 $ / shares | |
Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued price per share | $ / shares | $ 0.65 | $ 0.65 | $ 0.05 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of common stock | $ | $ 3,851,614 | $ 1,856,336 | $ 7,328,389 | $ 2,715,129 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Capital stock Authorized: 1 billion common stock at par value of $0.001 Issued and paid: 434,866,801 (2021 – 392,943,398) | $ | $ 39,096,950 | 39,096,950 | 29,842,167 | 21,322,022 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period, value | $ | $ 546,697 | $ 2,024,442 | $ 6,841,169 | $ 376,997 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period, conversion shares | 2,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercisable price | $ / shares | $ 0.20 | $ 0.05 | $ 0.08 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Incentive stock options granted | 1,250,000 | 1,250,000 | 15,650,000 | 38,800,000 | 6,600,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
2021 Equity Incentive Plan [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Incentive stock options granted | 9,092,368 | 500,000 | 500,000 | 250,000 | 1,450,000 | 21,700,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
Options exercisable price | $ / shares | $ 0.40 | $ 0.40 | $ 0.58 | $ 0.50 | $ 0.70 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Options exercisable term | 5 years | 5 years | 5 years | 5 years | 5 years | ||||||||||||||||||||||||||||||||||||||||||||||||||
Non Brokered Private Placement [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | 3,827,601 | 3,827,601 | 4,350,000 | 4,350,000 | 4,350,000 | 4,350,000 | 23,076,926 | 3,643,792 | 3,643,792 | 25,724,955 | 25,724,955 | 25,724,955 | 25,724,955 | ||||||||||||||||||||||||||||||||||||||||||
Number of shares issued price per share | (per share) | $ 0.44 | $ 0.20 | $ 0.20 | $ 0.13 | $ 0.13 | $ 0.15 | $ 0.13 | $ 0.13 | $ 0.55 | ||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Private Placement | $ 1,683,336 | $ 2,105,180 | $ 690,860 | $ 870,000 | $ 690,860 | $ 870,000 | $ 3,000,000 | $ 416,719 | $ 546,569 | $ 2,442,531 | $ 2,621,314 | $ 3,344,244 | $ 2,621,314 | $ 3,344,244 | |||||||||||||||||||||||||||||||||||||||||
[custom:IssuanceOfSharesDescription] | Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.65 (US$0.52) for a period of eighteen months from the date of closing. | Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.65 (US$0.52) for a period of eighteen months from the date of closing. | Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.30 for a period of one year from the date of closing | Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.30 for a period of one year from the date of closing | Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.30 for a period of one year from the date of closing. | Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.30 for a period of one year from the date of closing. | Each unit issued consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.19 for a period of one year from the date of closing of the respective financing tranche. | Each unit is comprised of one common share and one common share purchase warrant exercisable at CA$0.19 per common share for a period of one year. | Each unit issued consists of one common share and one common share purchase warrant entitling the holder to acquire a further common share at a price of CA$0.19 for a period of one year from the closing date of the respective financing tranche. | Each unit issued consists of one common share and one common share purchase warrant entitling the holder to acquire a further common share at a price of CA$0.19 for a period of one year from the closing date of the respective financing tranche. | |||||||||||||||||||||||||||||||||||||||||||||
Non Brokered Private Placement [Member] | Share-Based Payment Arrangement, Tranche One [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | 5,223,420 | 5,223,420 | 5,599,171 | 5,599,171 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued price per share | $ / shares | $ 0.13 | $ 0.13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Private Placement | $ 561,844 | $ 679,044 | $ 556,876 | $ 727,892 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Non Brokered Private Placement One [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | 23,076,926 | 23,076,926 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued price per share | $ / shares | 0.13 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Private Placement | $ 2,442,531 | $ 3,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
[custom:IssuanceOfSharesDescription] | Each unit issued consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.19 for a period of one year from the date of closing of the respective financing tranche | Each unit issued consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.19 for a period of one year from the date of closing of the respective financing tranche | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Class A Warrants [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of warrants exercisable | 500,000 | 500,000 | 500,000 | 1,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercisable price | $ / shares | $ 0.13 | $ 0.13 | $ 0.13 | $ 0.13 | $ 0.13 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Class B Warrants [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of warrants exercisable | 500,000 | 500,000 | 500,000 | 500,000 | 1,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercisable price | $ / shares | $ 0.19 | $ 0.19 | $ 0.19 | $ 0.19 | $ 0.19 | ||||||||||||||||||||||||||||||||||||||||||||||||||
June 2021 Convertible Debentures [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period, conversion units | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | 2,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
June 2021 Convertible Debenture [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | 6,000,000 | 6,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued price per share | $ / shares | $ 1 | $ 1 | $ 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
June 2021 Convertible Debenture [Member] | Common Class A [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of warrants exercisable | 3,000,000 | 3,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercisable price | $ / shares | $ 0.13 | $ 0.13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
June 2021 Convertible Debenture [Member] | Common Class B [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of warrants exercisable | 3,000,000 | 3,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercisable price | $ / shares | $ 0.19 | $ 0.19 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Maximum [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of warrants exercisable | 33,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maximum [Member] | Non Brokered Private Placement [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | 53,846,154 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Private Placement | $ | $ 3,000,000 | $ 7,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | 1,375,499 | 1,375,499 | 25,724,955 | 56,979,482 | 3,643,791 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued price per share | $ / shares | $ 0.65 | $ 0.24 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of common stock | $ 2,899,295 | $ 2,293,946 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants shares | 15,389,448 | 15,389,448 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period, value | $ | $ 756,524 | $ 2,621,314 | $ 7,438,041 | $ 416,719 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period, conversion shares | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | 6,933,333 | 6,933,333 | 1,360,959 | ||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock [Member] | Private Placement [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | 1,375,499 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued price per share | $ / shares | $ 0.55 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Private Placement | $ | $ 756,524 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share price | $ / shares | $ 0.75 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock [Member] | Non Brokered Private Placement One [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
[custom:IssuanceOfSharesDescription] | Each unit issued consists of one common share and one common share purchase warrant entitling the holder to acquire a further common share at a price of CA$0.19 for a period of one year from the closing date of the respective financing tranche | Each unit issued consists of one common share and one common share purchase warrant entitling the holder to acquire a further common share at a price of CA$0.19 for a period of one year from the closing date of the respective financing tranche | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock [Member] | June 2021 Convertible Debenture [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | 6,000,000 | 6,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock [Member] | Agreement [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock issued and outstanding percentage | 5% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock [Member] | Agreement [Member] | Maximum [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Capital stock Authorized: 1 billion common stock at par value of $0.001 Issued and paid: 434,866,801 (2021 – 392,943,398) | $ | $ 5,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock One [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued price per share | $ / shares | $ 0.19 | $ 0.19 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of common stock | 2,279,136 | $ 2,880,295 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of warrants exercisable | 15,159,448 | 15,159,448 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock Two [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued price per share | $ / shares | $ 0.05 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of common stock | $ 10,000 | $ 7,830 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of warrants exercisable | 200,000 | 200,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants shares | 2,428,363 | 2,428,363 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Maximum [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercisable price | $ / shares | $ 0.21 | $ 0.21 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock Three [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued price per share | $ / shares | $ 0.30 | $ 0.30 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of common stock | $ 6,981 | $ 9,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of warrants exercisable | 30,000 | 30,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | 2021 Equity Incentive Plan [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Incentive stock options granted | 250,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Options exercisable price | $ / shares | $ 0.58 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Options exercisable term | 5 years | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Non Brokered Private Placement [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | 2,467,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Private Placement | $ | $ 616,750 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Non Brokered Private Placement [Member] | Share-Based Payment Arrangement, Tranche One [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | 1,727,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued price per share | $ / shares | $ 0.25 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Private Placement | $ | $ 431,750 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Non Brokered Private Placement [Member] | Share Based Compensation Award Second And Final Tranche [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | 740,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued price per share | $ / shares | $ 0.25 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Private Placement | $ | $ 185,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Non Brokered Private Placement One [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
[custom:IssuanceOfSharesDescription] | Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of $0.45 for a period of one year from the date of closing | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Class A Warrants [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of warrants exercisable | 500,000 | 500,000 | 500,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercisable price | $ / shares | $ 0.13 | $ 0.13 | $ 0.13 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Class B Warrants [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of warrants exercisable | 500,000 | 500,000 | 500,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercisable price | $ / shares | $ 0.19 | $ 0.19 | $ 0.19 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | June 2021 Convertible Debentures [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period, conversion units | 1,000,000 | 1,000,000 | 1,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | June 2021 Convertible Debenture [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | 1,000,000 | 3,000,000 | 3,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | June 2021 Convertible Debenture [Member] | Common Class A [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of warrants exercisable | 500,000 | 1,500,000 | 1,500,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercisable price | $ / shares | $ 0.13 | $ 0.13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | June 2021 Convertible Debenture [Member] | Common Class B [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of warrants exercisable | 500,000 | 1,500,000 | 1,500,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercisable price | $ / shares | $ 0.19 | $ 0.19 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Common Stock [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | 9,163,425 | 9,163,425 | 15,159,448 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued price per share | $ / shares | $ 0.19 | $ 0.19 | $ 0.65 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of common stock | $ | $ 720,733 | $ 2,880,295 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period, value | $ 4,796,832 | $ 5,956,226 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period, conversion shares | 1,000,000 | 1,000,000 | 1,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of warrants exercisable | 3,793,331 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock broker warrants expired unexercised | 13,725 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Common Stock [Member] | Private Placement [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | 1,375,499 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued price per share | $ / shares | $ 0.55 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Private Placement | $ | $ 756,524 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share price | $ / shares | $ 0.75 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Common Stock [Member] | June 2021 Convertible Debenture [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | 1,000,000 | 3,000,000 | 3,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Common Stock One [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | 200,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued price per share | $ / shares | $ 0.05 | $ 0.05 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of common stock | $ | $ 40,000 | $ 10,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of warrants exercisable | 800,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Common Stock Two [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | 30,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued price per share | $ / shares | $ 0.05 | $ 0.30 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of common stock | $ | $ 15,000 | $ 9,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of warrants exercisable | 300,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Warrant [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants shares | 1,153,414 | 2,428,363 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Common Stock Three [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued price per share | $ / shares | $ 0.13 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of common stock | $ | $ 32,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of warrants exercisable | 250,000 |